inline xbrl viewer application relies heavily javascript need allow javascript to use this application inline viewer menu menu information save xbrl instance save xbrl zip file open html setting help section section additional search option include fact name include fact content include label include definition include dimension reference option include topic include sub topic include paragraph include publisher include section match case clear search submit search data data amount text only calculation only negative only additional item only tag tag all standard only custom only filter more filter selecting will take moment period measure axis explicit typed member explicit typed scale balance debit credit reset all filter link fact loading inline form tagged section search all search in internal section only search in external section only clear section search submit section search help getting started the inline xbrl viewer allows user to quickly easily review detail of the tagged information in inline document automatically placing top and bottom highlight border around tagged numeric fact and left and right border each block tagged fact hovering tagged fact will highlight shade all content related to the tagged fact and clicking on tagged fact will reveal tagging detail in the fact review window navigation search and filter option also provided to easily refine and identify specific type of tagged information fact review window the fact review window show the tagging detail for the currently selected fact highlighted solid blue border are four category of fact detail which viewed an value indicates there is available information for the item within the given category attribute all primary information applicable describing the tagged fact including period sign decimal dimensional detail ax and member scale measure and data type label detailed documentation definition for the tag used and label reference authoritative reference information applicable for the selected tag calculation balance and calculation hierarchy detail numeric non dimensioned item only searching there are two way to search the document fact and section to search information enter keyword in search box and select the magnifying glass icon to return matching result search operator and via and and or via or or are available to refine search fact the search fact box can be used to find tagged fact matching entered keywords by default tag name tag label and tagged content are included in search tagged fact matching the search criterion are shown with yellow colored default shading on the page and appear in the fact list select the button to the left of the magnifying glass icon to clear the search the content included in search can be increased to included tag definition dimension and authoritative reference by selecting the cog wheel icon to the left of the search box see setting for more information section the search section box can be used to filter the tagged section of the financial statement filter filter change the number of highlighted fact and item in the fact list by providing several way to review and pinpoint certain tagged information multiple filter can be used data filter filter option allow the user to refine the highlighted tagged fact by data type all display all tagged data default amount only numeric fact only text only textual fact only calculation only numeric fact participating in calculation only negative only negative numeric amount only additional item only tagged fact without corresponding html presentation hidden fact only tag filter these filter allow the user to refine the highlighted fact by tag type all display all tagged data default standard only fact with standard tag common taxonomy us_gaap ifrs dei custom only fact with extension custom tag unique to the entity document more filter additional filter allow user to further refine the highlighted fact period list of all used context year and reporting period measure list of all used unit of measure dollar applicable axis list of all used axis dimension applicable dimension applicable scale list of all used scaled option thousand million applicable balance debit credit applicable multiple filter work in conjunction with each other for example selecting the amount only data filter and custom only tag filter will highlight only numeric tagged fact using custom tag and list in the fact list active filter are displayed in the filter toolbar are selected active filter can be removed individually by unchecking or selecting all option for each filter or all at once via the reset all filter option fact list result on the toolbar select the count to the right of the word fact fact to reveal the fact list result navigable listing of all currently highlighted tagged fact the count represents the current number of fact by default all tagged fact are displayed in the fact list result the list content and count reflects the currently highlighted fact filter and search criterion refine the list to match the highlighted tagged fact navigation control are available to move the list well move the current view to the corresponding highlighted fact location automatically fact in the fact result list is selected will reveal the fact review window certain letter may appear to the right of an item in the fact result list to indicate certain property the letter appears for fact it indicates the fact is additional data hidden with potentially no corresponding html presentation if the letter appears the fact is tagged with custom tag if the letter appears the fact is tagged with dimensional information section the section toolbar item provides listing of the tagged section of the inline document section are divided three group document entity information financial statement note to the financial statement by expanding group and selecting section item in the listing inline xbrl viewer will navigate to that section when the tagged section feature is open the search section box will additionally filter the list of section to only section that match the entered criterion menu information the information menu item provides additional detail the current inline document and customizable viewer setting company and document basic company and document information tag fact and tag standard and custom information file file used additional item additional hidden data that tagged potentially corresponding location in the html save xbrl instance the save xbrl instance menu item allows an xbrl instance document xml that is extracted from the inline document to be saved locally for use by software supporting the xbrl format save xbrl zip the save xbrl zip menu item allows zip file zip that contains the provided xbrl instance document and related custom taxonomy file to be saved locally setting the setting menu item provides the ability to customize viewer feature tagged fact hover on display the hover fact review window for any tagged fact hide the hover fact review window for any tagged fact default may impact performance with certain web browser auto scrolling position this setting will have no effect on ie or safari top selecting fact from the section menu or the fact menu will automatically scroll that element to the top of the inline xbrl viewer window default center selecting fact from the section menu or the fact menu will automatically scroll that element to the middle of the inline xbrl viewer window highlight color use the save and reset button to save the selected setting or reset to default tagged data change the highlight color of the tagged fact border search result change the background color of tagged item matching the search result selected fact change the color of highlight border used to identify the currently selected fact tag shading hover change the color of the shading applied to tagged data on hover search option match case match the specific case of the entered search keyword include label extends search to include tag label include definition extends search to include tag definition include dimension extends search to include dimensional detail include reference extends search to include authoritative reference information optionally specify the reference part to include in the search topic subtopic section help this content version indicates the current build of the inline xbrl viewer application fact select page loading document false mrk mrk mrk mrk mrk gaap treasurystockmember gaap treasurystockmember gaap noncontrollinginterestmember gaap retainedearningsmember gaap noncontrollinginterestmember gaap noncontrollinginterestmember gaap retainedearningsmember gaap treasurystockmember gaap commonstockmember gaap noncontrollinginterestmember gaap retainedearningsmember gaap accumulatedothercomprehensiveincomemember gaap additionalpaidincapitalmember gaap treasurystockmember gaap accumulatedothercomprehensiveincomemember gaap additionalpaidincapitalmember gaap commonstockmember gaap retainedearningsmember gaap additionalpaidincapitalmember gaap noncontrollinginterestmember gaap accumulatedothercomprehensiveincomemember gaap commonstockmember gaap accumulatedothercomprehensiveincomemember gaap noncontrollinginterestmember gaap treasurystockmember gaap retainedearningsmember gaap additionalpaidincapitalmember gaap additionalpaidincapitalmember gaap accumulatedothercomprehensiveincomemember gaap retainedearningsmember gaap accumulatedothercomprehensiveincomemember gaap commonstockmember gaap treasurystockmember gaap noncontrollinginterestmember gaap retainedearningsmember gaap treasurystockmember gaap accumulatedothercomprehensiveincomemember gaap additionalpaidincapitalmember gaap additionalpaidincapitalmember mrk keytrudamember srt maximummember country gaap srt minimummember gaap nonusmember srt maximummember gaap buildingmember srt minimummember gaap machineryandequipmentmember srt minimummember gaap softwareandsoftwaredevelopmentcostsmember mrk enterprisewideresourceplanningsystemmember mrk enterprisewideresourceplanningsystemmember srt minimummember gaap buildingmember srt maximummember srt minimummember country mrk pharmaceuticalsegmentmember srt minimummember mrk enterprisewideresourceplanningsystemmember srt maximummember mrk enterprisewideresourceplanningsystemmember srt maximummember gaap machineryandequipmentmember srt minimummember srt maximummember gaap nonusmember srt maximummember gaap softwareandsoftwaredevelopmentcostsmember srt minimummember country mrk animalhealthsegmentmember mrk antelliqmember mrk antelliqmember gaap measurementinputdiscountratemember mrk valleesamember mrk valleesamember mrk valleesamember mrk immunedesignmember mrk pelotonmember mrk antelliqmember mrk rigontecmember mrk rigontecmember mrk pelotonmember mrk viralyticsmember mrk viralyticsmember mrk pelotonmember mrk commercialmilestonemember mrk samsungmember mrk pelotonmember mrk salesbasedmilestonesmember mrk arqulemember gaap subsequenteventmember mrk pelotonmember mrk pelotonmember mrk regulatorymilestonesmember mrk viralyticsmember mrk immunedesignmember mrk valleesamember srt minimummember mrk antelliqmember srt maximummember mrk antelliqmember mrk bayeragmember gaap researchanddevelopmentexpensemember gaap collaborativearrangementmember mrk bayeragmember gaap sellinggeneralandadministrativeexpensesmember gaap collaborativearrangementmember mrk bayeragmember gaap salesmember gaap collaborativearrangementmember mrk bayeragmember gaap sellinggeneralandadministrativeexpensesmember gaap collaborativearrangementmember mrk bayeragmember gaap sellinggeneralandadministrativeexpensesmember gaap collaborativearrangementmember mrk bayeragmember gaap othernoncurrentliabilitiesmember gaap collaborativearrangementmember mrk bayeragmember gaap salesmember gaap collaborativearrangementmember mrk bayeragmember gaap salesmember gaap collaborativearrangementmember mrk bayeragmember gaap researchanddevelopmentexpensemember gaap collaborativearrangementmember mrk bayeragmember gaap costofsalesmember gaap collaborativearrangementmember mrk bayeragmember gaap othercurrentassetsmember gaap collaborativearrangementmember mrk bayeragmember gaap researchanddevelopmentexpensemember gaap collaborativearrangementmember mrk bayeragmember gaap othercurrentassetsmember gaap collaborativearrangementmember mrk bayeragmember gaap costofsalesmember gaap collaborativearrangementmember mrk bayeragmember gaap costofsalesmember gaap collaborativearrangementmember mrk bayeragmember gaap othernoncurrentliabilitiesmember gaap collaborativearrangementmember mrk astrazenecamember mrk lynparzamember gaap subsequenteventmember mrk salesbasedmilestonesmember mrk astrazenecamember mrk lynparzamember mrk salesbasedmilestonesmember mrk bayeragmember mrk salesbasedmilestonesmember mrk eisaimember mrk lenvimamember mrk regulatorymilestonesmember mrk eisaimember mrk regulatorymilestonesmember mrk eisaimember mrk astrazenecamember mrk eisaimember mrk astrazenecamember mrk eisaimember mrk astrazenecamember mrk lynparzamember mrk regulatorymilestonesmember mrk astrazenecamember mrk lynparzamember mrk salesbasedmilestonesmember mrk eisaimember mrk lenvimamember mrk salesbasedmilestonesmember mrk adempasmember gaap otherintangibleassetsmember mrk eisaimember srt scenarioforecastmember mrk astrazenecamember mrk astrazenecamember mrk bayeragmember mrk adempasmember mrk salesbasedmilestonesmember mrk bayeragmember mrk adempasmember mrk salesbasedmilestonesmember mrk eisaimember srt scenarioforecastmember mrk astrazenecamember mrk salesbasedmilestonesmember mrk eisaimember mrk salesbasedmilestonesmember mrk eisaimember mrk lenvimamember mrk salesbasedmilestonesmember mrk astrazenecamember mrk lynparzamember mrk regulatorymilestonesmember mrk eisaimember mrk lenvimamember gaap subsequenteventmember mrk salesbasedmilestonesmember mrk astrazenecamember mrk lynparzamember mrk salesbasedmilestonesmember mrk lynparzamember gaap licensemember mrk eisaimember mrk lenvimamember mrk salesbasedmilestonesmember mrk lenvimamember gaap licensemember mrk eisaimember srt scenarioforecastmember mrk astrazenecamember mrk regulatorymilestonesmember mrk astrazenecamember mrk astrazenecamember gaap othernoncurrentliabilitiesmember gaap collaborativearrangementmember mrk astrazenecamember gaap othercurrentassetsmember gaap collaborativearrangementmember mrk astrazenecamember gaap othercurrentassetsmember gaap collaborativearrangementmember mrk astrazenecamember gaap researchanddevelopmentexpensemember gaap collaborativearrangementmember mrk astrazenecamember gaap costofsalesmember gaap collaborativearrangementmember mrk astrazenecamember gaap sellinggeneralandadministrativeexpensesmember gaap collaborativearrangementmember mrk astrazenecamember gaap costofsalesmember gaap collaborativearrangementmember mrk astrazenecamember gaap salesmember gaap collaborativearrangementmember mrk astrazenecamember gaap salesmember gaap collaborativearrangementmember mrk astrazenecamember gaap salesmember gaap collaborativearrangementmember mrk astrazenecamember gaap sellinggeneralandadministrativeexpensesmember gaap collaborativearrangementmember mrk astrazenecamember gaap sellinggeneralandadministrativeexpensesmember gaap collaborativearrangementmember mrk astrazenecamember gaap researchanddevelopmentexpensemember gaap collaborativearrangementmember mrk astrazenecamember gaap accountspayableandaccruedliabilitiesmember gaap collaborativearrangementmember mrk astrazenecamember gaap accountspayableandaccruedliabilitiesmember gaap collaborativearrangementmember mrk astrazenecamember gaap costofsalesmember gaap collaborativearrangementmember mrk astrazenecamember gaap othernoncurrentliabilitiesmember gaap collaborativearrangementmember mrk astrazenecamember gaap researchanddevelopmentexpensemember gaap collaborativearrangementmember mrk eisaimember gaap accountspayableandaccruedliabilitiesmember gaap collaborativearrangementmember mrk eisaimember gaap accountspayableandaccruedliabilitiesmember gaap collaborativearrangementmember mrk eisaimember gaap salesmember gaap collaborativearrangementmember mrk eisaimember gaap costofsalesmember gaap collaborativearrangementmember mrk eisaimember gaap othernoncurrentliabilitiesmember gaap collaborativearrangementmember mrk eisaimember gaap salesmember gaap collaborativearrangementmember mrk eisaimember gaap othernoncurrentliabilitiesmember gaap collaborativearrangementmember mrk eisaimember gaap othercurrentassetsmember gaap collaborativearrangementmember mrk eisaimember gaap researchanddevelopmentexpensemember gaap collaborativearrangementmember mrk eisaimember gaap othercurrentassetsmember gaap collaborativearrangementmember mrk eisaimember gaap sellinggeneralandadministrativeexpensesmember gaap collaborativearrangementmember mrk eisaimember gaap costofsalesmember gaap collaborativearrangementmember mrk eisaimember gaap sellinggeneralandadministrativeexpensesmember gaap collaborativearrangementmember mrk eisaimember gaap researchanddevelopmentexpensemember gaap collaborativearrangementmember mrk astrazenecamember mrk lynparzamember mrk salesbasedmilestonesmember mrk accelerateddepreciationmember mrk accelerateddepreciationmember gaap otherrestructuringmember gaap otherrestructuringmember gaap onetimeterminationbenefitsmember mrk accelerateddepreciationmember mrk accelerateddepreciationmember gaap onetimeterminationbenefitsmember mrk accelerateddepreciationmember gaap otherrestructuringmember gaap onetimeterminationbenefitsmember gaap otherrestructuringmember gaap otherrestructuringmember gaap onetimeterminationbenefitsmember gaap onetimeterminationbenefitsmember gaap researchanddevelopmentexpensemember gaap onetimeterminationbenefitsmember gaap restructuringchargesmember mrk accelerateddepreciationmember gaap sellinggeneralandadministrativeexpensesmember gaap sellinggeneralandadministrativeexpensesmember mrk accelerateddepreciationmember gaap onetimeterminationbenefitsmember gaap costofsalesmember gaap otherrestructuringmember gaap restructuringchargesmember gaap otherrestructuringmember gaap sellinggeneralandadministrativeexpensesmember gaap otherrestructuringmember gaap costofsalesmember mrk accelerateddepreciationmember gaap costofsalesmember gaap onetimeterminationbenefitsmember gaap costofsalesmember mrk accelerateddepreciationmember gaap costofsalesmember gaap restructuringchargesmember gaap onetimeterminationbenefitsmember gaap costofsalesmember gaap researchanddevelopmentexpensemember mrk accelerateddepreciationmember gaap researchanddevelopmentexpensemember gaap otherrestructuringmember gaap restructuringchargesmember mrk accelerateddepreciationmember gaap researchanddevelopmentexpensemember mrk accelerateddepreciationmember gaap restructuringchargesmember gaap otherrestructuringmember gaap restructuringchargesmember mrk accelerateddepreciationmember gaap researchanddevelopmentexpensemember mrk accelerateddepreciationmember gaap researchanddevelopmentexpensemember gaap otherrestructuringmember gaap sellinggeneralandadministrativeexpensesmember mrk accelerateddepreciationmember gaap restructuringchargesmember gaap sellinggeneralandadministrativeexpensesmember gaap researchanddevelopmentexpensemember gaap otherrestructuringmember gaap costofsalesmember gaap otherrestructuringmember gaap restructuringchargesmember gaap sellinggeneralandadministrativeexpensesmember mrk accelerateddepreciationmember gaap costofsalesmember gaap restructuringchargesmember gaap onetimeterminationbenefitsmember gaap sellinggeneralandadministrativeexpensesmember gaap onetimeterminationbenefitsmember gaap sellinggeneralandadministrativeexpensesmember gaap onetimeterminationbenefitsmember gaap sellinggeneralandadministrativeexpensesmember gaap otherrestructuringmember gaap restructuringchargesmember gaap otherrestructuringmember gaap researchanddevelopmentexpensemember gaap researchanddevelopmentexpensemember gaap sellinggeneralandadministrativeexpensesmember gaap otherrestructuringmember mrk accelerateddepreciationmember gaap costofsalesmember gaap onetimeterminationbenefitsmember gaap costofsalesmember gaap onetimeterminationbenefitsmember gaap researchanddevelopmentexpensemember gaap onetimeterminationbenefitsmember gaap sellinggeneralandadministrativeexpensesmember gaap onetimeterminationbenefitsmember gaap researchanddevelopmentexpensemember gaap onetimeterminationbenefitsmember gaap sellinggeneralandadministrativeexpensesmember gaap restructuringchargesmember gaap researchanddevelopmentexpensemember gaap otherrestructuringmember gaap restructuringchargesmember gaap onetimeterminationbenefitsmember gaap costofsalesmember mrk accelerateddepreciationmember gaap costofsalesmember gaap otherrestructuringmember srt scenarioforecastmember gaap foreignexchangecontractmember gaap salesmember gaap foreignexchangecontractmember gaap othernonoperatingincomeexpensemember gaap foreignexchangecontractmember gaap salesmember gaap foreignexchangecontractmember gaap salesmember gaap foreignexchangecontractmember gaap othernonoperatingincomeexpensemember gaap foreignexchangecontractmember gaap othernonoperatingincomeexpensemember gaap otherassetsmember gaap interestratecontractmember gaap designatedashedginginstrumentmember gaap othernoncurrentliabilitiesmember gaap foreignexchangecontractmember gaap designatedashedginginstrumentmember gaap nondesignatedmember gaap othercurrentassetsmember gaap foreignexchangecontractmember gaap nondesignatedmember gaap nondesignatedmember gaap othernoncurrentliabilitiesmember gaap interestratecontractmember gaap designatedashedginginstrumentmember gaap othercurrentliabilitiesmember gaap interestratecontractmember gaap designatedashedginginstrumentmember gaap othernoncurrentliabilitiesmember gaap foreignexchangecontractmember gaap designatedashedginginstrumentmember gaap othercurrentassetsmember gaap foreignexchangecontractmember gaap designatedashedginginstrumentmember gaap othercurrentliabilitiesmember gaap foreignexchangecontractmember gaap nondesignatedmember gaap othercurrentassetsmember gaap foreignexchangecontractmember gaap designatedashedginginstrumentmember gaap otherassetsmember gaap interestratecontractmember gaap designatedashedginginstrumentmember gaap otherassetsmember gaap foreignexchangecontractmember gaap designatedashedginginstrumentmember gaap othercurrentliabilitiesmember gaap foreignexchangecontractmember gaap designatedashedginginstrumentmember gaap designatedashedginginstrumentmember gaap designatedashedginginstrumentmember gaap otherassetsmember gaap foreignexchangecontractmember gaap designatedashedginginstrumentmember gaap othercurrentliabilitiesmember gaap foreignexchangecontractmember gaap nondesignatedmember gaap othernoncurrentliabilitiesmember gaap interestratecontractmember gaap designatedashedginginstrumentmember gaap othercurrentliabilitiesmember gaap interestratecontractmember gaap designatedashedginginstrumentmember gaap othercurrentliabilitiesmember gaap foreignexchangecontractmember gaap designatedashedginginstrumentmember gaap othercurrentassetsmember gaap foreignexchangecontractmember gaap nondesignatedmember mrk longtermdebtexcludingcurrentmaturitiesmember mrk longtermdebtexcludingcurrentmaturitiesmember mrk longtermdebtcurrentmaturitiesmember mrk longtermdebtcurrentmaturitiesmember gaap interestrateswapmember mrk gaap interestrateswapmember mrk gaap interestrateswapmember mrk gaap interestrateswapmember mrk gaap interestrateswapmember gaap othernonoperatingincomeexpensemember gaap foreignexchangecontractmember gaap foreignexchangecontractmember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember gaap accumulatedgainlosscashflowhedgeincludingnoncontrollinginterestmember gaap foreignexchangecontractmember gaap foreignexchangecontractmember gaap foreignexchangecontractmember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember gaap accumulatedgainlosscashflowhedgeincludingnoncontrollinginterestmember gaap interestrateswapmember gaap interestrateswapmember gaap othernonoperatingincomeexpensemember gaap interestrateswapmember gaap othernonoperatingincomeexpensemember gaap interestrateswapmember gaap foreignexchangecontractmember gaap reclassificationoutofaccumulatedothercomprehensiveincomemember gaap accumulatedgainlosscashflowhedgeincludingnoncontrollinginterestmember gaap interestrateswapmember gaap mrk sanofipasteurmember gaap measurementinputdiscountratemember mrk afferentpharmaceuticalsmember srt maximummember gaap nondesignatedmember mrk mckessoncorporationamerisourcebergencorporationandcardinalhealthinc member gaap accountsreceivablemember gaap customerconcentrationriskmember srt maximummember gaap designatedashedginginstrumentmember mrk sanofipasteurmember mrk sanofipasteurmember gaap assetbackedsecuritiesmember mrk eurodominatednotesmember gaap othernonoperatingincomeexpensemember mrk eurodominatednotesmember gaap othernonoperatingincomeexpensemember mrk eurodominatednotesmember gaap othernonoperatingincomeexpensemember mrk eurodominatednotesmember mrk eurodominatednotesmember mrk eurodominatednotesmember gaap foreigngovernmentdebtsecuritiesmember gaap assetbackedsecuritiesmember gaap corporatedebtsecuritiesmember gaap usgovernmentagenciesdebtsecuritiesmember gaap usgovernmentagenciesdebtsecuritiesmember gaap corporatedebtsecuritiesmember gaap commercialpapermember gaap mortgagebackedsecuritiesmember gaap foreigngovernmentdebtsecuritiesmember gaap commercialpapermember gaap mortgagebackedsecuritiesmember gaap assetbackedsecuritiesmember gaap interestratecontractmember gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap usgovernmentagenciesdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreigngovernmentdebtsecuritiesmember gaap fairvaluemeasurementsrecurringmember gaap interestratecontractmember gaap gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap assetbackedsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreignexchangecontractmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreignexchangecontractmember gaap gaap fairvaluemeasurementsrecurringmember gaap interestratecontractmember gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap equitysecuritiesmember gaap foreignexchangeoptionmember gaap gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap corporatedebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap usgovernmentagenciesdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap corporatedebtsecuritiesmember gaap interestratecontractmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreignexchangeoptionmember gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap equitysecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap corporatedebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap usgovernmentagenciesdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap commercialpapermember gaap gaap fairvaluemeasurementsrecurringmember gaap foreigngovernmentdebtsecuritiesmember gaap fairvaluemeasurementsrecurringmember gaap equitysecuritiesmember gaap interestratecontractmember gaap gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap usgovernmentagenciesdebtsecuritiesmember gaap foreignexchangecontractmember gaap gaap fairvaluemeasurementsrecurringmember gaap fairvaluemeasurementsrecurringmember gaap mortgagebackedsecuritiesmember gaap foreignexchangecontractmember gaap fairvaluemeasurementsrecurringmember gaap fairvaluemeasurementsrecurringmember gaap foreigngovernmentdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreignexchangecontractmember gaap gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreignexchangecontractmember gaap gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreigngovernmentdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap commercialpapermember gaap gaap fairvaluemeasurementsrecurringmember gaap equitysecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap corporatedebtsecuritiesmember gaap fairvaluemeasurementsrecurringmember gaap usgovernmentagenciesdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap equitysecuritiesmember gaap fairvaluemeasurementsrecurringmember gaap commercialpapermember gaap fairvaluemeasurementsrecurringmember gaap fairvaluemeasurementsrecurringmember gaap corporatedebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap interestratecontractmember gaap gaap fairvaluemeasurementsrecurringmember gaap fairvaluemeasurementsrecurringmember gaap mortgagebackedsecuritiesmember gaap interestratecontractmember gaap gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap assetbackedsecuritiesmember gaap foreignexchangeoptionmember gaap gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap mortgagebackedsecuritiesmember gaap fairvaluemeasurementsrecurringmember gaap assetbackedsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap commercialpapermember gaap gaap fairvaluemeasurementsrecurringmember gaap corporatedebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreigngovernmentdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap corporatedebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap assetbackedsecuritiesmember gaap interestratecontractmember gaap gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap equitysecuritiesmember gaap foreignexchangecontractmember gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap commercialpapermember gaap fairvaluemeasurementsrecurringmember gaap corporatedebtsecuritiesmember gaap foreignexchangeoptionmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreignexchangeoptionmember gaap gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap assetbackedsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap assetbackedsecuritiesmember gaap fairvaluemeasurementsrecurringmember gaap equitysecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreigngovernmentdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap assetbackedsecuritiesmember gaap fairvaluemeasurementsrecurringmember gaap assetbackedsecuritiesmember gaap foreignexchangeoptionmember gaap gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap mortgagebackedsecuritiesmember gaap foreignexchangecontractmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreignexchangeoptionmember gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap usgovernmentagenciesdebtsecuritiesmember gaap fairvaluemeasurementsrecurringmember gaap commercialpapermember gaap gaap fairvaluemeasurementsrecurringmember gaap equitysecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap usgovernmentagenciesdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap mortgagebackedsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap mortgagebackedsecuritiesmember gaap foreignexchangeoptionmember gaap gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreigngovernmentdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap commercialpapermember gaap gaap fairvaluemeasurementsrecurringmember gaap mortgagebackedsecuritiesmember gaap fairvaluemeasurementsrecurringmember gaap usgovernmentagenciesdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap commercialpapermember gaap fairvaluemeasurementsrecurringmember gaap foreigngovernmentdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap mortgagebackedsecuritiesmember mrk inventoriesproducedinpreparationforproductlaunchesmember mrk inventorynotexpectedtobesoldwithinoneyearmember mrk inventorynotexpectedtobesoldwithinoneyearmember mrk inventoriesproducedinpreparationforproductlaunchesmember mrk pharmaceuticalsegmentmember mrk pharmaceuticalsegmentmember mrk animalhealthsegmentmember mrk animalhealthsegmentmember gaap allothersegmentsmember mrk pharmaceuticalsegmentmember gaap allothersegmentsmember mrk animalhealthsegmentmember mrk pharmaceuticalsegmentmember mrk animalhealthsegmentmember gaap allothersegmentsmember gaap allothersegmentsmember mrk pharmaceuticalsegmentmember gaap allothersegmentsmember mrk animalhealthsegmentmember mrk dificidmember gaap developedtechnologyrightsmember mrk uprifosbuvirmember mrk iometpharmaltdmember mrk smartcellsprogrammember mrk bridionmember gaap developedtechnologyrightsmember mrk sivextromember gaap developedtechnologyrightsmember mrk sivextromember mrk implanonnexplanonmember gaap developedtechnologyrightsmember mrk zerbaxamember gaap developedtechnologyrightsmember mrk intronamember mrk animalhealthmember gaap tradenamesmember mrk simponimember gaap developedtechnologyrightsmember mrk gaap developedtechnologyrightsmember mrk verubecestatmember gaap inprocessresearchanddevelopmentmember gaap otherintangibleassetsmember gaap inprocessresearchanddevelopmentmember gaap licensemember gaap developedtechnologyrightsmember gaap tradenamesmember gaap licensemember gaap tradenamesmember gaap developedtechnologyrightsmember gaap otherintangibleassetsmember mrk othervariableratedebtmember srt scenarioforecastmember mrk sixpointthreepercentagedebenturesdueontwothousandandtwentysixmember gaap buildingmember mrk gaap commercialpapermember gaap vehiclesmember mrk notessubjecttorepaymentatoptionofholdermember gaap commercialpapermember mrk notessubjecttorepaymentatoptionofholdermember mrk mrk mrk mrk othervariableratedebtmember mrk sixpointfivezeropercentagenotesdueontwothousandandthirtythreemember mrk mrk sixpointfivefivepercentagenotesdueontwothousandandthirtysevenmember mrk mrk mrk mrk mrk otherlongtermdebtmember mrk mrk mrk mrk mrk mrk otherlongtermdebtmember mrk mrk mrk mrk mrk mrk sixpointfivezeropercentagenotesdueontwothousandandthirtythreemember mrk mrk mrk fivepointsevenfivepercentagenotesdueontwothousandandthirtysixmember mrk mrk fivepointninefivepercentagedebenturesdueontwothousandandtwentyeightmember mrk fivepointninefivepercentagedebenturesdueontwothousandandtwentyeightmember mrk sixpointthreepercentagedebenturesdueontwothousandandtwentysixmember mrk mrk mrk mrk mrk mrk sixpointfourpercentagedebenturesdueontwothousandandtwentyeightmember mrk threepointsixzeropercentagenotesdueontwothousandandfortytwomember mrk mrk mrk sixpointfourpercentagedebenturesdueontwothousandandtwentyeightmember mrk fivepointeightfivepercentagenotesdueontwothousandandthirtyninemember mrk threepointsixzeropercentagenotesdueontwothousandandfortytwomember mrk mrk fivepointeightfivepercentagenotesdueontwothousandandthirtyninemember mrk mrk mrk mrk mrk mrk mrk mrk mrk fivepointsevenfivepercentagenotesdueontwothousandandthirtysixmember mrk sixpointfivefivepercentagenotesdueontwothousandandthirtysevenmember mrk mrk mrk californiastatecourtmember mrk fosamaxmember mrk januviamember mrk casescompanyagreedtotollstatuteoflimitationsmember mrk commercialandotherlitigationmember mrk federalmember mrk fosamaxmember mrk commercialandotherlitigationmember mrk federalmember mrk fosamaxmember mrk fosamaxmember mrk commercialandotherlitigationmember mrk januviamember mrk federalmember mrk fosamaxmember mrk commercialandotherlitigationmember mrk otherstatecourtmember mrk januviamember mrk newjerseymember mrk fosamaxmember mrk legaldefensecostsmember mrk otherstatecourtmember mrk fosamaxmember mrk legaldefensecostsmember mrk mrk acceleratedsharerepurchaseagreementmember mrk acceleratedsharerepurchaseagreementmember mrk acceleratedsharerepurchaseagreementmember mrk acceleratedsharerepurchaseagreementmember mrk acceleratedsharerepurchaseagreementmember gaap commonstockmember gaap commonstockmember gaap commonstockmember gaap restrictedstockunitsrsumember gaap performancesharesmember gaap performancesharesmember gaap restrictedstockunitsrsumember gaap performancesharesmember gaap restrictedstockunitsrsumember country country country gaap foreignplanmember gaap pensionplansdefinedbenefitmember country country gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember country gaap foreignplanmember gaap pensionplansdefinedbenefitmember country gaap pensionplansdefinedbenefitmember gaap otherpostretirementbenefitplansdefinedbenefitmember gaap otherpostretirementbenefitplansdefinedbenefitmember gaap otherpostretirementbenefitplansdefinedbenefitmember country gaap pensionplansdefinedbenefitmember country gaap pensionplansdefinedbenefitmember gaap otherpostretirementbenefitplansdefinedbenefitmember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk realestateinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap country gaap pensionplansdefinedbenefitmember mrk insurancecontractsotherinvestmentsmember gaap country gaap pensionplansdefinedbenefitmember mrk realestateinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap country gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap country gaap pensionplansdefinedbenefitmember mrk realestateinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk insurancecontractsotherinvestmentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk realestateinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk insurancecontractsotherinvestmentsmember gaap country gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap country gaap pensionplansdefinedbenefitmember mrk realestateinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk insurancecontractsotherinvestmentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk realestateinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember gaap country gaap pensionplansdefinedbenefitmember mrk realestateinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk realestateinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap country gaap pensionplansdefinedbenefitmember mrk insurancecontractsotherinvestmentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk insurancecontractsotherinvestmentsmember gaap country gaap pensionplansdefinedbenefitmember mrk insurancecontractsotherinvestmentsmember gaap country gaap pensionplansdefinedbenefitmember gaap country gaap pensionplansdefinedbenefitmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk realestateinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap country gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk insurancecontractsotherinvestmentsmember gaap country gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap country gaap pensionplansdefinedbenefitmember mrk insurancecontractsotherinvestmentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk insurancecontractsotherinvestmentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk realestateinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap country gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember gaap cashandcashequivalentsmember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap otherpostretirementbenefitplansdefinedbenefitmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember gaap cashandcashequivalentsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember gaap cashandcashequivalentsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap otherpostretirementbenefitplansdefinedbenefitmember gaap cashandcashequivalentsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember gaap cashandcashequivalentsmember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap otherpostretirementbenefitplansdefinedbenefitmember gaap cashandcashequivalentsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember gaap cashandcashequivalentsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember gaap cashandcashequivalentsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap otherpostretirementbenefitplansdefinedbenefitmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember gaap cashandcashequivalentsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember gaap cashandcashequivalentsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap otherpostretirementbenefitplansdefinedbenefitmember country gaap pensionplansdefinedbenefitmember srt maximummember gaap definedbenefitplanequitysecuritiesusmember country srt minimummember srt scenarioforecastmember country srt maximummember mrk definedbenefitplancashandotherinvestmentsmember country gaap pensionplansdefinedbenefitmember srt minimummember gaap definedbenefitplanequitysecuritiesusmember country srt maximummember country srt maximummember srt scenarioforecastmember country country gaap pensionplansdefinedbenefitmember srt maximummember gaap fixedincomeinvestmentsmember country srt maximummember gaap definedbenefitplanequitysecuritiesnonusmember country gaap pensionplansdefinedbenefitmember srt minimummember gaap definedbenefitplanequitysecuritiesnonusmember country srt minimummember country gaap gaap pensionplansdefinedbenefitmember gaap gaap pensionplansdefinedbenefitmember srt minimummember gaap fixedincomeinvestmentsmember country country gaap pensionplansdefinedbenefitmember gaap otherpostretirementbenefitplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk realestateinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember gaap country gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap country gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember country gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember gaap country gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk insurancecontractsotherinvestmentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap country gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember gaap country gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember gaap country gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk insurancecontractsotherinvestmentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember country gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk fixedincomeobligationsinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk fixedincomeobligationsinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap country gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap country gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember country gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk realestateinvestmentfundsmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk realestateinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk realestateinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk fixedincomeobligationsinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember gaap country gaap pensionplansdefinedbenefitmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk fixedincomeobligationsinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember country gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember country gaap pensionplansdefinedbenefitmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember gaap country gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember country gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember country gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap country gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember country gaap pensionplansdefinedbenefitmember mrk fixedincomeobligationsinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap country gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember country gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk realestateinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap country gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember country gaap pensionplansdefinedbenefitmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk insurancecontractsotherinvestmentsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk fixedincomeobligationsinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk fixedincomeobligationsinvestmentfundsmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk fixedincomeobligationsinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk insurancecontractsotherinvestmentsmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk insurancecontractsotherinvestmentsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk insurancecontractsotherinvestmentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk insurancecontractsotherinvestmentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk realestateinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk realestateinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember mrk fixedincomeobligationsinvestmentfundsmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap country gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember gaap country gaap pensionplansdefinedbenefitmember mrk insurancecontractsotherinvestmentsmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember country gaap pensionplansdefinedbenefitmember mrk realestateinvestmentfundsmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap country gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk fixedincomeobligationsinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember country gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk developedmarketsequitiesinvestmentfundsmember gaap country gaap pensionplansdefinedbenefitmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember mrk emergingmarketsequitiesinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsinvestmentfundsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsfixedincomesecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember country gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk governmentandagencyobligationsinvestmentfundsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap country gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk developedmarketsequitysecuritiesmember country gaap pensionplansdefinedbenefitmember gaap otherinvestmentsmember gaap gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember country gaap pensionplansdefinedbenefitmember mrk corporateobligationsfixedincomesecuritiesmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember gaap definedbenefitplancashandcashequivalentsmember gaap fairvaluemeasuredatnetassetvaluepersharemember gaap foreignplanmember gaap pensionplansdefinedbenefitmember mrk cgrpreceptorantagonistsmember srt partnershipinterestmember mrk healthcareservicesmember srt partnershipinterestmember mrk patentlitigationmember mrk healthcareservicesmember gaap otherassetsmember gaap otherassetsmember gaap domesticcountrymember gaap internalrevenueserviceirsmember gaap domesticcountrymember gaap internalrevenueserviceirsmember gaap foreigncountrymember gaap othernoncurrentliabilitiesmember mrk consumercarebusinessmember mrk incometaxespayablemember gaap accumulatedtranslationadjustmentmember gaap accumulatedgainlossnetcashflowhedgeparentmember gaap accumulatednetunrealizedinvestmentgainlossmember gaap accumulatednetunrealizedinvestmentgainlossmember gaap accumulateddefinedbenefitplansadjustmentmember gaap accumulatedgainlossnetcashflowhedgeparentmember gaap accumulatednetunrealizedinvestmentgainlossmember gaap accumulatedgainlossnetcashflowhedgeparentmember gaap accumulatednetunrealizedinvestmentgainlossmember gaap accumulateddefinedbenefitplansadjustmentmember gaap accumulatedtranslationadjustmentmember gaap accumulateddefinedbenefitplansadjustmentmember gaap accumulatedgainlossnetcashflowhedgeparentmember gaap accumulateddefinedbenefitplansadjustmentmember gaap accumulatedtranslationadjustmentmember gaap accumulateddefinedbenefitplansadjustmentmember gaap accumulatedgainlossnetcashflowhedgeparentmember gaap accumulatedgainlossnetcashflowhedgeparentmember gaap accumulatedtranslationadjustmentmember gaap accumulateddefinedbenefitplansadjustmentmember gaap accumulatedtranslationadjustmentmember gaap accumulatednetunrealizedinvestmentgainlossmember gaap accumulatedgainlossnetcashflowhedgeparentmember gaap accumulatedtranslationadjustmentmember gaap accumulatedtranslationadjustmentmember gaap accumulatednetunrealizedinvestmentgainlossmember gaap accumulatedgainlossnetcashflowhedgeparentmember gaap accumulateddefinedbenefitplansadjustmentmember gaap accumulatednetunrealizedinvestmentgainlossmember gaap accumulateddefinedbenefitplansadjustmentmember gaap accumulatedtranslationadjustmentmember gaap accumulatednetunrealizedinvestmentgainlossmember gaap accumulatedothercomprehensiveincomemember mrk pensionplannetlossmember mrk pensionplanpriorservicecostmember mrk pensionplannetlossmember mrk otherpostretirementbenefitplanpriorservicecostmember mrk otherpostretirementbenefitplannetlossmember mrk otherpostretirementbenefitplanpriorservicecostmember mrk otherpostretirementbenefitplannetlossmember mrk pensionplanpriorservicecostmember gaap materialreconcilingitemsmember gaap materialreconcilingitemsmember gaap materialreconcilingitemsmember gaap operatingsegmentsmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk pharmaceuticalsegmentmember gaap corporatenonsegmentmember gaap operatingsegmentsmember gaap operatingsegmentsmember mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk pharmaceuticalsegmentmember gaap corporatenonsegmentmember gaap corporatenonsegmentmember gaap operatingsegmentsmember gaap operatingsegmentsmember gaap allothersegmentsmember gaap operatingsegmentsmember gaap allothersegmentsmember gaap operatingsegmentsmember mrk animalhealthsegmentmember gaap operatingsegmentsmember gaap allothersegmentsmember gaap operatingsegmentsmember mrk othercountriesmember srt asiapacificmember srt latinamericamember srt asiapacificmember country srt latinamericamember srt asiapacificmember mrk othercountriesmember mrk othercountriesmember gaap emeamember country cn country country country cn country jp gaap emeamember country cn gaap emeamember country jp srt latinamericamember country jp country jp mrk othercountriesmember srt latinamericamember country jp srt asiapacificmember mrk othercountriesmember country country cn srt latinamericamember country jp gaap emeamember gaap emeamember srt asiapacificmember gaap emeamember srt latinamericamember country cn srt asiapacificmember mrk othercountriesmember country cn country country gaap operatingsegmentsmember country gaap operatingsegmentsmember mrk bridionmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk follistimaqmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk emendmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk rotateqmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cozaarhyzaarmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk vytorinmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk singulairmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk alliancerevenuelynparzamember country mrk pharmaceuticalsegmentmember gaap corporatenonsegmentmember mrk internationalmember gaap operatingsegmentsmember mrk internationalmember mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk proquadmmriivarivaxmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk primaxinmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk lenvimamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk zetiamember mrk internationalmember mrk pharmaceuticalsegmentmember mrk internationalmember gaap operatingsegmentsmember mrk lenvimamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk belsomramember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk bridionmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk noxafilmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk proquadmmriivarivaxmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk noxafilmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk simponimember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk emendmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk follistimaqmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk lenvimamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk implanonnexplanonmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk arcoxiamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk vaqtamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk noxafilmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk emendmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk belsomramember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk noxafilmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk arcoxiamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk livestockmember mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk remicademember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cozaarhyzaarmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk remicademember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cozaarhyzaarmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk alliancerevenuelynparzamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk alliancerevenuelynparzamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk belsomramember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk vaqtamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk janumetmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk proquadmmriivarivaxmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk vytorinmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk vaqtamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk isentressisentresshdmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk simponimember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk isentressisentresshdmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk singulairmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk nuvaringmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk adempasmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk internationalmember gaap operatingsegmentsmember mrk lenvimamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk emendmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk livestockmember country mrk animalhealthsegmentmember gaap operatingsegmentsmember country gaap operatingsegmentsmember mrk primaxinmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk implanonnexplanonmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk bridionmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk invanzmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk alliancerevenuelynparzamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk follistimaqmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk zetiamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk isentressisentresshdmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk livestockmember country mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk adempasmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk primaxinmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk janumetmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk zetiamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk livestockmember mrk internationalmember mrk animalhealthsegmentmember gaap corporatenonsegmentmember country gaap operatingsegmentsmember mrk janumetmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk emendmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk nuvaringmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk companionanimalsmember mrk internationalmember mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk januviamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk januviamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk zepatiermember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk primaxinmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk noxafilmember country mrk pharmaceuticalsegmentmember gaap corporatenonsegmentmember mrk internationalmember gaap operatingsegmentsmember mrk implanonnexplanonmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk rotateqmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk invanzmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk belsomramember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk zetiamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk primaxinmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cubicinmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk rotateqmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk primaxinmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk livestockmember mrk internationalmember mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk invanzmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cancidasmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cubicinmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk atozetmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk alliancerevenuelynparzamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk follistimaqmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cubicinmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk keytrudamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk zetiamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk alliancerevenuelynparzamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk adempasmember mrk pharmaceuticalsegmentmember gaap corporatenonsegmentmember country gaap operatingsegmentsmember mrk zepatiermember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember country gaap allothersegmentsmember gaap operatingsegmentsmember mrk nasonexmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk companionanimalsmember country mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk internationalmember gaap operatingsegmentsmember mrk lenvimamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk isentressisentresshdmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember country gaap operatingsegmentsmember mrk primaxinmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cancidasmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cubicinmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk proquadmmriivarivaxmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk zetiamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk rotateqmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk atozetmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk follistimaqmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk nasonexmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk arcoxiamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk belsomramember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk otherpharmaceuticalmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk implanonnexplanonmember country mrk pharmaceuticalsegmentmember mrk internationalmember gaap operatingsegmentsmember mrk zetiamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk lenvimamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cancidasmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk proquadmmriivarivaxmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk singulairmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk keytrudamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk adempasmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk janumetmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk internationalmember gaap allothersegmentsmember gaap operatingsegmentsmember mrk januviamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk otherpharmaceuticalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember country gaap allothersegmentsmember gaap operatingsegmentsmember mrk vytorinmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk nasonexmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk zetiamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk keytrudamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk nuvaringmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cancidasmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk alliancerevenuelynparzamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk zepatiermember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk bridionmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cancidasmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk remicademember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk vaqtamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk atozetmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk simponimember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk vaqtamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk vaqtamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk primaxinmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk arcoxiamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk alliancerevenuelynparzamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk januviamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk arcoxiamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk atozetmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cozaarhyzaarmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk vytorinmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk otherpharmaceuticalmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cancidasmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk invanzmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk nasonexmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk nasonexmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk emendmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk proquadmmriivarivaxmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk singulairmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk follistimaqmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk arcoxiamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk proquadmmriivarivaxmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cancidasmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk nuvaringmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk isentressisentresshdmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk atozetmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk bridionmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk singulairmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk alliancerevenuelynparzamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk otherpharmaceuticalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk nuvaringmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember country mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk internationalmember gaap allothersegmentsmember gaap operatingsegmentsmember mrk companionanimalsmember mrk internationalmember mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk zetiamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk arcoxiamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk simponimember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk noxafilmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk vytorinmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk keytrudamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk zepatiermember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk nasonexmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk simponimember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk implanonnexplanonmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk livestockmember mrk internationalmember mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk remicademember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk nasonexmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk rotateqmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk janumetmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk atozetmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk simponimember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk bridionmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk follistimaqmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cozaarhyzaarmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk arcoxiamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk proquadmmriivarivaxmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk vaqtamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk lenvimamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk nasonexmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk atozetmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk otherpharmaceuticalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cubicinmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk follistimaqmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk januviamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk livestockmember mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember country mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk vytorinmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk janumetmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk companionanimalsmember mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk rotateqmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk proquadmmriivarivaxmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk otherpharmaceuticalmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk rotateqmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk vytorinmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk vaqtamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk bridionmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk januviamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk rotateqmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cubicinmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk singulairmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk remicademember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk noxafilmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk nuvaringmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk singulairmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk zepatiermember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk vaqtamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk lenvimamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk isentressisentresshdmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk internationalmember gaap allothersegmentsmember gaap operatingsegmentsmember mrk cubicinmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk janumetmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk bridionmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk nuvaringmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk isentressisentresshdmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk noxafilmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk internationalmember gaap operatingsegmentsmember mrk internationalmember mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk belsomramember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cubicinmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk keytrudamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk keytrudamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk keytrudamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk atozetmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk zepatiermember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk implanonnexplanonmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cozaarhyzaarmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk companionanimalsmember mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk simponimember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk livestockmember country mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk otherpharmaceuticalmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk emendmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk otherpharmaceuticalmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk zepatiermember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk belsomramember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk invanzmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk remicademember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk belsomramember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk zepatiermember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk vytorinmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk simponimember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk companionanimalsmember country mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk nuvaringmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cubicinmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk primaxinmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk invanzmember mrk pharmaceuticalsegmentmember gaap corporatenonsegmentmember country gaap operatingsegmentsmember mrk vytorinmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cozaarhyzaarmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk nasonexmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk adempasmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk follistimaqmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk bridionmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk noxafilmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap corporatenonsegmentmember mrk internationalmember gaap operatingsegmentsmember mrk adempasmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk livestockmember mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk remicademember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk isentressisentresshdmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk implanonnexplanonmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk nuvaringmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember country gaap allothersegmentsmember gaap operatingsegmentsmember mrk invanzmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cozaarhyzaarmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk implanonnexplanonmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cozaarhyzaarmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk companionanimalsmember mrk internationalmember mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk emendmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk internationalmember mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk belsomramember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk otherpharmaceuticalmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk rotateqmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk atozetmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk keytrudamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk simponimember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk invanzmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk janumetmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cancidasmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk isentressisentresshdmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk adempasmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember country mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk janumetmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk adempasmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk remicademember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk januviamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk implanonnexplanonmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk cancidasmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk singulairmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk zepatiermember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk companionanimalsmember mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk adempasmember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk arcoxiamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk singulairmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk januviamember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk keytrudamember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk remicademember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk lenvimamember country mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk emendmember mrk internationalmember mrk pharmaceuticalsegmentmember gaap operatingsegmentsmember mrk invanzmember mrk internationalmember mrk pharmaceuticalsegmentmember mrk internationalmember gaap operatingsegmentsmember mrk companionanimalsmember country mrk animalhealthsegmentmember gaap operatingsegmentsmember mrk januviamember country mrk pharmaceuticalsegmentmember xbrli pure usd xbrli share xbrli share aud usd eur mrk segment mrk interest_rate_swap mrk legalmatter filed with the security and exchange commission on february united statessecurities and exchange commissionwashington mark one annual report pursuant to section or of the security exchange act of the fiscal year ended december or transition report pursuant to section or of the security exchange act of the transition period from to commission file no _________________________________merck co inc galloping hill roadkenilworthnew new state or other jurisdiction of incorporation employer identification no security registered pursuant to section of the act title of each classtrading symbol name of each exchange on which registeredcommon stock par value mrknew york stock note due york stock note due york stock note due york stock note due york stock note due york stock exchangenumber of share of common stock par value outstanding of january aggregate market value of common stock par value held by non affiliate on june based on closing price on june indicate by check mark if the registrant is well known seasoned issuer defined in rule of the security act yes no indicate by check mark if the registrant is not required to file report pursuant to section or section of the act yes no indicate by check mark whether the registrant filed all report required to be filed by section or of the security exchange act of the preceding month or for shorter period that the registrant required to file such report and ha been subject to such filing requirement for the past day yes no indicate by check mark whether the registrant ha submitted electronically every interactive data file required to be submitted pursuant to rule of regulation of this chapter during the preceding month or for such shorter period that the registrant wa required to submit such file yes no indicate by check mark whether the registrant is large accelerated filer an accelerated filer non accelerated filer smaller reporting company or an emerging growth company see the definition of large accelerated filer accelerated filer smaller reporting company and emerging growth company in rule of the exchange act check one large accelerated filer accelerated filer non accelerated filer smaller reporting company emerging growth company if an emerging growth company indicate by check mark if the registrant ha elected not to use the extended transition period for complying with any new or revised financial accounting standard provided pursuant to section of the exchange act indicate by check mark whether the registrant is shell company defined in rule of the exchange act yes no document incorporated by reference document part of form kproxy statement for the annual meeting of shareholder to be held may to be filed with the security and exchange commission within day the close of the fiscal year covered by this report part iiitable of contentstable of content pagepart iitem risk cautionary factor that may affect future unresolved staff legal mine safety executive officer of the iiitem market for registrant common equity related stockholder matter and issuer purchase of equity selected financial management discussion and analysis of financial condition and result of quantitative and qualitative disclosure about market financial statement and supplementary financial note to consolidated financial report of independent registered public accounting supplementary change in and disagreement with accountant on accounting and financial control and management other iiiitem director executive officer and corporate executive security ownership of certain beneficial owner and management and relatedstockholder certain relationship and related transaction and director principal accountant fee and ivitem exhibit and financial statement item form of contentspart item business merck co inc merck or the company is global health care company that delivers innovative health solution through it prescription medicine vaccine biologic therapy and animal health product the company operation are principally managed on product basis and include four operating segment which are the pharmaceutical animal health healthcare service and alliance segment the pharmaceutical segment includes human health pharmaceutical and vaccine product human health pharmaceutical product consist of therapeutic and preventive agent generally sold by prescription for the treatment of human disorder the company sell these human health pharmaceutical product primarily to drug wholesaler and retailer hospital government agency and managed health care provider such health maintenance organization pharmacy benefit manager and other institution human health vaccine product consist of preventive pediatric adolescent and adult vaccine primarily administered at physician office the company sell these human health vaccine primarily to physician wholesaler physician distributor and government entity the animal health segment discovers develops manufacture and market wide range of veterinary pharmaceutical and vaccine product well health management solution and service for the prevention treatment and control of disease in all major livestock and companion animal specie the company also offer an extensive suite of digitally connected identification traceability and monitoring product the company sell it product to veterinarian distributor and animal producer the healthcare service segment provides service and solution that focus on engagement health analytics and clinical service to improve the value of care delivered to patient the company ha recently sold certain business in the healthcare service segment and is in the process of divesting the remaining business the company continues to look for investment opportunity in this area of health care the approach to these investment ha shifted toward venture capital investment in third party opposed to wholly owned business the alliance segment primarily includes activity from the company relationship with astrazeneca lp related to sale of nexium and prilosec which concluded in the company wa incorporated in new jersey in all product or service mark appearing in type form different from that of the surrounding text are trademark or service mark owned licensed to promoted or distributed by merck it subsidiary or affiliate except noted all other trademark or service mark are those of respective owner planned spin off of woman health legacy brand and biosimilars into new company in february merck announced it intention to spin off the spin off product from it woman health trusted legacy brand and biosimilars business into new yet to be named independent publicly traded company newco through distribution of newco publicly traded stock to company shareholder the distribution is expected to qualify tax free to the company and it shareholder for federal income tax purpose the legacy brand included in the transaction consist of dermatology pain respiratory and select cardiovascular product including zetia and vytorin well the rest of merck diversified brand franchise merck existing research pipeline program will continue to be owned and developed within merck planned newco will have development capability initially focused on late stage development and life cycle management and is expected over time to develop research capability in selected therapeutic area the spin off is expected to be completed in the first half of subject to market and certain other condition see risk factor risk related to the proposed spin off of newco of contentsproduct salestotal company sale including sale of the company top pharmaceutical product well sale of animal health product follows in million sale gardasil ii isentress revenue other revenue are primarily comprised of healthcare service segment revenue third party manufacturing sale and miscellaneous corporate revenue including revenue hedging activity pharmaceuticalthe pharmaceutical segment includes human health pharmaceutical and vaccine product human health pharmaceutical product consist of therapeutic and preventive agent generally sold by prescription for the treatment of human disorder human health vaccine product consist of preventive pediatric adolescent and adult vaccine primarily administered at physician office certain of the product within the company franchise are follows oncologykeytruda pembrolizumab the company anti pd programmed death receptor therapy monotherapy for the treatment of certain patient with melanoma non small cell lung cancer nsclc small cell lung cancer sclc head and neck squamous cell carcinoma hnscc classical hodgkin lymphoma chl primary mediastinal large cell lymphoma pmbcl urothelial carcinoma microsatellite instability high msi or mismatch repair deficient cancer gastric or gastroesophageal junction adenocarcinoma esophageal cancer cervical cancer hepatocellular carcinoma and merkel cell carcinoma keytruda is also used for the treatment of certain patient in combination with chemotherapy for metastatic squamous and non squamous nsclc in combination with chemotherapy for hnscc in combination with axitinib for renal cell carcinoma and in combination with lenvatinib for endometrial carcinoma and emend aprepitant for the prevention of chemotherapy induced and post operative nausea and vomiting in addition the company recognizes alliance revenue related to sale of lynparza olaparib an oral poly adp ribose polymerase parp inhibitor for certain type of advanced ovarian breast and pancreatic cancer and lenvima lenvatinib for certain type of thyroid cancer hepatocellular carcinoma in combination with everolimus for certain patient with renal cell carcinoma and in combination with keytruda for certain patient with endometrial carcinoma vaccinesgardasil human papillomavirus quadrivalent type and vaccine recombinant gardasil human papillomavirus valent vaccine recombinant vaccine to help prevent certain disease caused by certain type of human papillomavirus hpv proquad measles mumps rubella and varicella virus vaccine live pediatric combination vaccine to help protect measles mumps rubella and varicella ii measles mumps and rubella virus vaccine live vaccine to help prevent measles mumps and rubella varivax varicella virus vaccine live vaccine to help prevent chickenpox varicella pneumovax pneumococcal vaccine polyvalent vaccine to help prevent pneumococcal disease rotateq rotavirus vaccine live oral pentavalent vaccine to help protect against rotavirus gastroenteritis in infant and child and vaqta hepatitis vaccine inactivated indicated for the prevention of disease caused by hepatitis virus in person month of age and older of contentshospital acute carebridion sugammadex injection medication for the reversal of two type of neuromuscular blocking agent used during surgery noxafil posaconazole for the prevention of invasive fungal infection primaxin imipenem and cilastatin sodium an anti bacterial product invanz ertapenem sodium for the treatment of certain infection cubicin daptomycin for injection an antibiotic for complicated skin and skin structure infection or bacteremia when caused by designated susceptible organism cancidas caspofungin acetate an anti fungal product and prevymis letermovir for the prophylaxis of cytomegalovirus cmv reactivation and disease in adult cmv seropositive recipient of an allogeneic hematopoietic stem cell transplant immunologysimponi golimumab once monthly subcutaneous treatment for certain inflammatory disease and remicade infliximab treatment for inflammatory disease which the company market in europe russia and turkey neurosciencebelsomra suvorexant an orexin receptor antagonist indicated for the treatment of insomnia characterized by difficulty with sleep onset and or sleep maintenance virologyisentress isentress hd raltegravir an hiv integrase inhibitor for use in combination with other antiretroviral agent for the treatment of hiv infection and zepatier elbasvir and grazoprevir for the treatment of adult patient with chronic hepatitis virus hcv genotype gt or infection with ribavirin in certain patient population cardiovascularzetia ezetimibe marketed ezetrol in country outside the united state vytorin ezetimibe simvastatin marketed inegy outside the united state atozet ezetimibe and atorvastatin marketed outside of the united state and rosuzet ezetimibe and rosuvastatin marketed outside of the united state cholesterol modifying medicine and adempas riociguat cardiovascular drug for the treatment of pulmonary arterial hypertension diabetesjanuvia sitagliptin and janumet sitagliptin metformin hcl for the treatment of type diabetes woman healthnuvaring etonogestrel ethinyl estradiol vaginal ring vaginal contraceptive product and implanon etonogestrel implant single rod subdermal contraceptive implant nexplanon etonogestrel implant single radiopaque rod shaped subdermal contraceptive implant animal healththe animal health segment discovers develops manufacture and market wide range of veterinary pharmaceutical vaccine and health management solution and service well an extensive suite of digitally connected identification traceability and monitoring product principal product in this segment include livestock productsnuflor florfenicol antibiotic range for use in cattle and swine bovilis vista vaccine line for infectious disease in cattle banamine flunixin meglumine bovine and swine anti inflammatory estrumate cloprostenol sodium for the treatment of fertility disorder in cattle matrix altrenogest fertility management for swine resflor florfenicol and flunixin meglumine combination broad spectrum antibiotic and non steroidal anti inflammatory drug for bovine respiratory disease zuprevo tildipirosin for bovine respiratory disease zilmax zilpaterol hydrochloride and revalor trenbolone acetate and estradiol to improve production efficiency in beef cattle safe guard fenbendazole de wormer for cattle pac mycoplasma hyopneumoniae bacterin swine pneumonia vaccine porcilis lawsonia intracellularis baterin and circumvent porcine circovirus vaccine type killed baculovirus vector vaccine line for infectious disease in swine nobilis innovax live marek disease vector vaccine line for poultry paracox and coccivac coccidiosis vaccine exzolt systemic treatment for poultry red mite infestation slice emamectin benzoate parasiticide for sea louse in salmon aquavac avirulent live culture norvax vaccine against bacterial and viral disease in fish compact pd vaccine for salmon aquaflor florfenicol antibiotic for farm raised fish and allflex livestock intelligence solution for animal identification monitoring and traceability of contentscompanion animal productsbravecto fluralaner line of oral and topical parasitic control product for dog and cat that last to week nobivac vaccine line for flexible dog and cat vaccination otomax gentamicin sulfate usp betamethasone valerate usp and clotrimazole usp ointment mometamax gentamicin sulfate usp mometasone furoate monohydrate and clotrimazole usp otic suspension posatex orbifloxacin mometasone furoate monohydrate and posaconazole suspension ear ointment for acute and chronic otitis caninsulin vetsulin porcine insulin zinc suspension diabetes mellitus treatment for dog and cat panacur fenbendazole safeguard fenbendazole broad spectrum anthelmintic de wormer for use in many animal regumate altrenogest fertility management for horse prestige vaccine line for horse and scalibor deltamethrin exspot for protecting against bite from flea tick mosquito and sandfly for further discussion of sale of the company product see item management discussion and analysis of financial condition and result of operation below product approvalsset forth below is summary of significant product approval received by the company in productdateapprovalervebodecember food and drug administration fda approved ervebo for the prevention of disease caused by zaire ebolavirus in individual year of age and older november european commission ec granted conditional marketing authorization for ervebo for active immunization of individual year of age or older to protect against ebola virus disease caused by zaire ebola virus keytrudadecember japanese ministry of health labour and welfare mhlw approved keytruda for three new first line indication across advanced renal cell carcinoma rcc and recurrent or distant metastatic head and neck cancer november approved two new regimen of keytruda first line treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma hnscc november china national medical product administration nmpa approved keytruda for first line treatment of metastatic squamous non small cell lung cancer nsclc in combination with chemotherapy october approved keytruda monotherapy for first line treatment of certain patient with advanced nsclc whose tumor express pd september approved keytruda plus lenvima combination treatment for patient with certain type of endometrial carcinoma september approved keytruda in combination with axitinib first line treatment for patient with advanced rcc july approved keytruda for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus in patient whose tumor express pd combined positive score cps cps with disease progression after one of more prior line of systemic therapy of contentskeytrudajune approved keytruda monotherapy for patient with metastatic small cell lung cancer sclc with disease progression on or after platinum based chemotherapy and at least one other prior line of therapy june approved two indication for keytruda for first line treatment of patient with metastatic or with unresectable recurrent hnscc monotherapy for patient whose tumor express pd cps or in combination with platinum and fluorouracil regardless of pd expression april approved keytruda in combination with axitinib for first line treatment of patient with advanced rcc april approved an expanded label for keytruda monotherapy for the first line treatment of patient with stage iii nsclc are not candidate for surgical resection or definitive chemoradiation or metastatic nsclc and whose tumor express pd tumor proportion score tps determined by an fda approved test with no epidermal growth factor receptor egfr or anaplastic lymphoma kinase positive alk genomic tumor aberration april approved new extended dosing schedule for keytruda for all approved monotherapy indication april approved keytruda for first line treatment of metastatic nonsquamous nsclc in combination with chemotherapy march approved keytruda in combination with chemotherapy for first line treatment of adult with metastatic squamous nsclc february approved keytruda for the adjuvant treatment of patient with melanoma with involvement of lymph node following complete resection january approved keytruda for five indication including three expanded us in advanced nsclc one in melanoma well new indication in advanced microsatellite instability high tumor lynparza december approved lynparza for first line maintenance therapy for patient with germline brca mutated gbrca metastatic pancreatic cancer whose disease ha not progressed for at least week of first line platinum based chemotherapy regimen december approved lynparza first line maintenance therapy in brca advanced ovarian cancer july approved lynparza monotherapy for the maintenance treatment of adult patient with advanced brca high grade epithelial ovarian fallopian tube or primary peritoneal cancer june approved lynparza first line maintenance therapy in patient with brca advanced ovarian cancer june approved lynparza for use first line maintenance therapy in patient with brca advanced ovarian cancer april approved lynparza for the treatment of gbrca negative advanced breast cancer pifeltro and delstrigoseptember approved supplemental new drug application sndas for pifeltro doravirine in combination with other antiretroviral agent and delstrigo doravirine lamivudine and tenofovir disoproxil fumarate complete regimen for use in appropriate adult with hiv infection who are virologically suppressed on stable antiretroviral regimen of contentsrecarbriojuly approved recarbrio imipenem cilastatin and relebactam for the treatment of adult with complicated urinary tract and complicated intra abdominal bacterial infection limited or no alternative treatment option are available zerbaxaaugust approved zerbaxa for the treatment of adult with hospital acquired pneumonia including ventilator associated pneumonia to be used in combination with an antibacterial agent active against gram positive pathogen when these are known or suspected to be contributing to the infectious process june approved zerbaxa dose for the treatment of patient year and older with hospital acquired bacterial pneumonia and ventilator associated bacterial pneumonia habp vabp bravectonovember approved bravecto plus topical solution for cat indicated for both external and internal parasite infestation in july merck and astrazeneca entered into global strategic oncology collaboration to co develop and co commercialize astrazeneca lynparza competition and the health care environmentcompetitionthe market in which the company conduct it business and the pharmaceutical industry in general are highly competitive and highly regulated the company competitor include other worldwide research based pharmaceutical company smaller research company with more limited therapeutic focus generic drug manufacturer and animal health care company the company operation may be adversely affected by generic and biosimilar competition the company product mature well technological advance of competitor industry consolidation patent granted to competitor competitive combination product new product of competitor the generic availability of competitor branded product and new information from clinical trial of marketed product or post marketing surveillance in addition patent right are increasingly challenged by competitor and the outcome can be highly uncertain an adverse result in patent dispute can preclude commercialization of product or negatively affect sale of existing product and could result in the payment of royalty or in the recognition of an impairment charge with respect to intangible asset associated with certain product competitive pressure have intensified pressure in the industry have grown pharmaceutical competition involves rigorous search for technological innovation and the ability to market these innovation effectively with it long standing emphasis on research and development the company is well positioned to compete in the search for technological innovation additional resource required to meet market challenge include quality control flexibility to meet customer specification an efficient distribution system and strong technical information service the company is active in acquiring and marketing product through external alliance such licensing arrangement and collaboration and ha been refining it sale and marketing effort to address changing industry condition however the introduction of new product and process by competitor may result in price reduction and product displacement even for product protected by patent for example the number of compound available to treat particular disease typically increase over time and can result in slowed sale growth or reduced sale for the company product in that therapeutic category the highly competitive animal health business is affected by several factor including regulatory and legislative issue scientific and technological advance product innovation the quality and price of the company product effective promotional effort and the frequent introduction of generic product by competitor health care environment and government regulationglobal effort toward health care cost containment continue to exert pressure on product pricing and market access in the united state federal and state government for many year also have pursued method to reduce the cost of drug and vaccine for which they pay for example federal law require the company to pay specified rebate for medicine reimbursed by medicaid and to provide discount for outpatient medicine purchased by certain public health service entity and hospital serving disproportionate share of low income or uninsured patient of contentsagainst this backdrop the united state enacted major health care reform legislation in the patient protection and affordable care act aca various insurance market reform have since advanced and state and federal insurance exchange were launched in with respect to the effect of the law on the pharmaceutical industry the law increased the mandated medicaid rebate from to expanded the rebate to medicaid managed care utilization and increased the type of entity eligible for the federal drug discount program the law also required pharmaceutical manufacturer to pay point of service discount to medicare part beneficiary when they are in the medicare part coverage gap the called donut hole result of the balanced budget act of and effective at the beginning of the point of service discount increased to point of service discount in the coverage gap in addition this point of service discount wa extended to biosimilar product merck recorded reduction to revenue of approximately million million and million in and respectively related to the donut hole provision also pharmaceutical manufacturer are required to pay an annual non tax deductible health care reform fee the total annual industry fee wa billion in and decreased to billion in and is expected to remain at that amount for the fee is assessed on each company in proportion to it share of prior year branded pharmaceutical sale to certain government program such medicare and medicaid the company recorded million million and million of cost within selling general and administrative expense in and respectively for the annual health care reform fee in february the center for medicare medicaid service cm issued the medicaid rebate final rule that implement provision of the aca effective april the rule provides comprehensive guidance on the calculation of average manufacturer price and best price two metric utilized to determine the rebate drug manufacturer are required to pay to state medicaid program the impact of change resulting from the issuance of the rule is not material to merck at this time however the company is still awaiting guidance from cm on two aspect of the rule that were deferred for later implementation these include definition of constitutes product line extension and delay in the participation of the territory in the medicaid drug rebate program april the company will evaluate the financial impact of these two element when they become effective there is significant uncertainty about the future of the aca in particular and health care law in general in the united state the company is participating in the debate and monitoring any proposed change could affect it business the company is unable to predict the likelihood of change to the aca depending on the nature of any repeal and replacement of the aca such action could have material adverse effect on the company business cash flow result of operation financial condition and prospect number of state have passed pharmaceutical price and cost transparency law these law typically require manufacturer to report certain product price information or other financial data to the state law also require manufacturer to provide advance notification of price increase the company expects that state will continue their focus on pharmaceutical price transparency and that this focus will continue to exert pressure on product pricing the company also face increasing pricing pressure globally from managed care organization government agency and program that could negatively affect the company sale and profit margin in the united state these include practice of managed care organization federal and state exchange and institutional and governmental purchaser and ii federal law and regulation related to medicare and medicaid including the medicare prescription drug improvement and modernization act of and the aca change to the health care system enacted part of health care reform in the united state well increased purchasing power of entity that negotiate on behalf of medicare medicaid and private sector beneficiary could result in further pricing pressure an example health care reform is contributing to an increase in the number of patient in the medicaid program which sale of pharmaceutical product are subject to substantial rebate the pharmaceutical industry could be considered potential source of saving via legislative proposal that have been debated but not enacted these type of revenue generating or cost saving proposal include additional direct price control in addition congress and or the administration may consider proposal to allow international reference pricing or under certain condition the importation of medicine from other country the administration ha recently proposed draft rule that would allow importation of certain lower cost prescription drug from canada if the rule is finalized proposed state or certain other non federal governmental entity would be able to submit importation program proposal to the fda for review and authorization of two year program with the opportunity to extend for two more year there will be public comment period on the proposed rule which will expire on march following the comment period the fda will have to review and finalize it of contentsproposal any state or other party can submit their plan to comply with the federal rule if the proposed rule is adopted it likely will be some time before state or other party can actually implement importation plan in october the administration also issued an advance notice of proposed rulemaking to implement an international pricing index ipi model in the united state for product covered under medicare part the proposal would reduce medicare part payment for drug based on market basket of international price allow private sector vendor to negotiate price for drug take title to drug and compete for physician and hospital business and change the physician reimbursement under medicare part from the current model to eliminate the buy and bill system and instead pay physician based on flat fee that approximates the revenue they currently receive from drug public comment on the ipi proposal were accepted through late and it is unclear when the agency may issue proposed rule on the ipi model adoption of one or both of the proposed rule could have material adverse effect on the company business result of operation and financial condition it remains uncertain to what proposal if any may be included part of future federal legislative proposal that would directly or indirectly affect the company in the private sector consolidation and integration among health care provider is major factor in the competitive marketplace for pharmaceutical product health plan and pharmacy benefit manager have been consolidating into fewer larger entity thus enhancing their purchasing strength and importance private third party insurer well government increasingly employ formulary to control cost by negotiating discounted price in exchange for formulary inclusion failure to obtain timely or adequate pricing or formulary placement for merck product or obtaining such placement at unfavorable pricing could adversely impact revenue in addition to formulary tier co pay differential private health insurance company and self insured employer have been raising co payment required from beneficiary particularly for branded pharmaceutical and biotechnology product private health insurance company also are increasingly imposing utilization management tool such clinical protocol requiring prior authorization for branded product if generic product is available or requiring the patient to first fail on one or more generic product before permitting access to branded medicine these management tool are also used in treatment area in which the payer ha taken the position that multiple branded product are therapeutically comparable the payer market concentrate further and more drug become available in generic form pharmaceutical company may face greater pricing pressure from private third party payer in order to provide information about the company pricing practice the company annually post on it website it pricing transparency report for the united state the report provides the company average annual list price net price increase and average discount across the company portfolio dating back to in the company gross sale were reduced by approximately result of rebate discount and return effort toward health care cost containment also remain intense in european country the company face competitive pricing pressure resulting from generic and biosimilar drug in addition majority of country in europe attempt to contain drug cost by engaging in reference pricing in which authority examine pre determined market for published price of drug by brand the authority use price data from those market to set new local price for brand name drug including the company drug guideline for examining reference pricing are usually set in local market and can be changed pursuant to local regulation in addition in japan the pharmaceutical industry is subject to government mandated biennial price reduction of pharmaceutical product and certain vaccine which occurred in and will occur again in furthermore the government can order pricing for specific product if it determines that use of such product will exceed certain threshold defined under applicable re pricing rule pursuant to those rule the japanese government reduced the price of keytruda by effective february additionally keytruda will be subject to another significant price reduction in april under provision of the japanese pricing rule the company business in china ha grown rapidly in the past few year and the importance of china to the company overall pharmaceutical and vaccine business ha increased accordingly continued growth of the company business in china is dependent upon ongoing development of favorable environment for innovative pharmaceutical product and vaccine sustained access for the company current in line product and the absence of trade impediment or adverse pricing control in recent year the chinese government ha introduced and implemented number of structural reform to accelerate the shift to innovative product and reduce cost since there have been multiple new policy introduced by the government to improve access to new innovation reduce the of contentscomplexity of regulatory filing and accelerate the review and approval process this ha led to significant increase in the number of new product being approved each year additionally in the chinese government updated the national reimbursement drug list for the first time in eight year while the mechanism for drug being added to the list evolves inclusion may require price negotiation which could impact the outlook in the market for selected brand in drug were added through two pathway direct inclusion and price negotiation for price negotiation price reduction of approximately on average were required for inclusion while pricing pressure ha always existed in china health care reform ha increased this pressure in part due to the acceleration of generic substitution through volume based procurement vbp in the government implemented the vbp program through tendering process for mature product which have generic substitute with generic quality consistency evaluation approval mature product that have entered into the first two round of vbp have on average price reduction of the expansion of the vbp program remains to be seen the company focus on emerging market in addition to china ha continued government in many emerging market are also focused on constraining health care cost and have enacted price control and related measure such compulsory license that aim to put pressure on the price of pharmaceutical and constrain market access the company anticipates that pricing pressure and market access challenge will continue in to varying degree in the emerging market including china certain market outside of the united state have also implemented other cost management strategy such health technology assessment hta example include the uk france germany ireland italy and sweden the hta process is the procedure according to which the assessment of the public health impact therapeutic impact and the economic and social impact of use of given medicinal product in the national health care system of the individual country is conducted htas generally focus on the clinical efficacy and effectiveness safety cost and cost effectiveness of individual medicinal product well their potential implication for the health care system those element of medicinal product are compared with other treatment option available on the market the outcome of htas will often influence the pricing and reimbursement status granted to medicinal product by the regulatory authority of individual european union eu member state negative hta of one of the company product by leading and recognized hta body could undermine the company ability to obtain reimbursement for such product in the eu member state in which such negative assessment wa issued and also in other eu member state hta procedure require additional data review and administrative process all of which increase the complexity timing and cost of obtaining product reimbursement and exert downward pressure on available reimbursement in the united state htas are also being used by government and private payer beyond pricing and market access challenge other condition in emerging market country can affect the company effort to continue to grow in these market including potential political instability change in trade sanction and embargo significant currency fluctuation and control financial crisis limited or changing availability of funding for health care and other development that may adversely impact the business environment for the company further the company may engage third party agent to assist in operating in emerging market country which may affect it ability to realize continued growth and may also increase the company risk exposure in addressing cost containment pressure the company engages in public policy advocacy with policymakers and continues to work to demonstrate that it medicine provide value to patient and to those who pay for health care the company advocate with government policymakers to encourage long term approach to sustainable health care financing that ensures access to innovative medicine and doe not disproportionately target pharmaceutical source of budget saving in market with historically low rate of health care spending the company encourages those government to increase their investment and adopt market reform in order to improve their citizen access to appropriate health care including medicine operating condition have become more challenging under the global pressure of competition industry regulation and cost containment effort although no one can predict the effect of these and other factor on the company business the company continually take measure to evaluate adapt and improve the organization and it business practice to better meet customer need and belief that it is well positioned to respond to the evolving health care environment and market force the pharmaceutical industry is also subject to regulation by regional country state and local agency around the world focused on standard and process for determining drug safety and effectiveness well condition for sale or reimbursement of contentsof particular importance is the fda in the united state which administers requirement covering the testing approval safety effectiveness manufacturing labeling and marketing of prescription pharmaceutical in some case the fda requirement and practice have increased the amount of time and resource necessary to develop new product and bring them to market in the united state at the same time the fda ha committed to expediting the development and review of product bearing the breakthrough therapy designation which ha accelerated the regulatory review process for medicine with this designation the fda ha also undertaken effort to bring generic competition to market more efficiently and in more timely manner the eu ha adopted directive and other legislation concerning the classification labeling advertising wholesale distribution integrity of the supply chain enhanced pharmacovigilance monitoring and approval for marketing of medicinal product for human use these provide mandatory standard throughout the eu which may be supplemented or implemented with additional regulation by the eu member state in particular eu regulator may approve product subject to number of post authorization condition example of typical post authorization commitment include additional pharmacovigilance the conduct of clinical trial the establishment of patient registry physician or patient education and controlled distribution and prescribing arrangement non compliance with post authorization condition pharmacovigilance and other obligation can lead to regulatory action including the variation suspension or withdrawal of the marketing authorization or other enforcement or regulatory action including the imposition of financial penalty the company policy and procedure are already consistent with the substance of these directive consequently it is believed that they will not have any material effect on the company business the company belief that it will continue to be able to conduct it operation including launching new drug in this regulatory environment see research and development below for discussion of the regulatory approval process access to medicinesas global health care company merck primary role is to discover and develop innovative medicine and vaccine the company also recognizes that it ha an important role to play in helping to improve access to it medicine vaccine and to quality health care around the world the company effort in this regard are wide ranging and include set of principle that the company strives to embed into it operation and business strategy to guide the company worldwide approach to expanding access to health care in addition through innovative social investment including philanthropic program and impact investing merck is also helping to strengthen health system and build capacity particularly in under resourced community the merck patient assistance program provides medicine and adult vaccine for free to people in the united state who not have prescription drug or health insurance coverage and who without the company assistance can not afford their merck medicine and vaccine in merck launched merck for mother long term effort with global health partner to end preventable death from complication of pregnancy and childbirth merck ha also provided fund to the merck foundation an independent grantmaking organization which ha partnered with variety of organization dedicated to improving global health privacy and data protectionthe company is subject to significant number of privacy and data protection law and regulation globally many of which place restriction on the company ability to transfer access and use personal data across it business the legislative and regulatory landscape for privacy and data protection continues to evolve there ha been increased attention to privacy and data protection issue in both developed and emerging market with the potential to affect directly the company business including both the eu general data protection regulation which went into effect on may and imposes penalty of up to of global revenue and the california consumer privacy act which became effective january additional law and regulation enacted in the united state europe asia and latin america increased enforcement and litigation activity in the united state and other developed market and increased regulatory cooperation among privacy authority globally the company ha adopted comprehensive global privacy program to manage these evolving risk which ha been certified compliant with and approved by the asia pacific economic cooperation cross border privacy rule system the eu and swiss privacy shield program and the binding corporate rule in the eu distributionthe company sell it human health pharmaceutical product primarily to drug wholesaler and retailer hospital government agency and managed health care provider such health maintenance organization pharmacy of contentsbenefit manager and other institution human health vaccine are sold primarily to physician wholesaler physician distributor and government entity the company professional representative communicate the effectiveness safety and value of the company pharmaceutical and vaccine product to health care professional in private practice group practice hospital and managed care organization the company sell it animal health product to veterinarian distributor and animal producer raw materialsraw material and supply which are generally available from multiple source are purchased worldwide and are normally available in quantity adequate to meet the need of the company business patent trademark and licensespatent protection is considered in the aggregate to be of material importance to the company marketing of it product in the united state and in most major foreign market patent may cover product per se pharmaceutical formulation process for or intermediate useful in the manufacture of product or the us of product protection for individual product extends for varying period in accordance with the legal life of patent in the various country the protection afforded which may also vary from country to country depends upon the type of patent and it scope of coverage the food and drug administration modernization act includes pediatric exclusivity provision that may provide an additional six month of market exclusivity in the united state for indication of new or currently marketed drug if certain agreed upon pediatric study are completed by the applicant current patent law provides additional patent term for period when the patented product wa under regulatory review by the fda the eu also provides an additional six month of pediatric market exclusivity attached to product supplementary protection certificate spc japan provides the additional term for pediatric study attached to market exclusivity unrelated to patent term patent portfolio developed for product introduced by the company normally provide market exclusivity the company ha the following key patent protection in the united state the eu japan and china including the potential for patent term extension pte and spcs where indicated for the following marketed product of contentsproductyear of expiration year of expiration eu year of expiration japan year of expiration china emend for an lenvima with pending pte patent spcs with pending pte device device not with pending pte patent spcs expiredn agardasil patent spcs patent spcs with pending pte patent spcs patent spcs with pending pte with pending pte patent spcs asteglatro with pending pte patent spcs with pending pte patent spcs with pending pte patent spcs with pending pte patent spcs an with pending pte patent spcs an with pending pte an an anote compound patent unless otherwise noted certain of the product listed may be the subject of patent litigation see item financial statement and supplementary data note contingency and environmental liability below currently no marketing approval the eu date represents the expiration date for the following five country france germany italy spain and the united kingdom major eu market if spc application have been filed but have not been granted in all major eu market both the patent expiry date and the spc expiry date are listed the pte system in japan allows for patent to be extended more once provided the later approval is directed to different indication from that of the previous approval this may result in multiple pte approval for given patent each with it expiration date eligible for month pediatric exclusivity the company ha no marketing right in the japan or china expiration of the distribution agreement with janssen pharmaceutical inc part of global strategic oncology collaboration with eisai being commercialized in worldwide collaboration with bayer ag part of global strategic oncology collaboration with astrazeneca being commercialized and promoted in worldwide except japan collaboration with pfizer inc of contentsthe company also ha the following key patent protection for drug candidate in phase development phase drug candidatecurrently anticipatedyear of expiration in the mk gefapixant vericiguat pneumoconjugate vaccine islatravir doravirine being developed in worldwide collaboration with bayer ag unless otherwise noted the patent in the chart are compound patent each patent may be subject to future patent term restoration of up to five year and six month pediatric market exclusivity either or both of which may be available in addition depending on the circumstance surrounding any final regulatory approval of the compound there may be other listed patent or patent application pending that could have relevance to the product finally approved the relevance of any such application would depend upon the claim that ultimately may be granted and the nature of the final regulatory approval of the product also regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and in some case may provide more effective or longer lasting marketing exclusivity than compound patent estate in the united state the data protection generally run five year from first marketing approval of new chemical entity extended to seven year for an orphan drug indication and year from first marketing approval of biological product while the expiration of product patent normally result in loss of market exclusivity for the covered pharmaceutical product commercial benefit may continue to be derived from later granted patent on process and intermediate related to the most economical method of manufacture of the active ingredient of such product ii patent relating to the use of such product iii patent relating to novel composition and formulation and iv in the united state and certain other country market exclusivity that may be available under relevant law the effect of product patent expiration on pharmaceutical product also depends upon many other factor such the nature of the market and the position of the product in it the growth of the market the complexity and economics of the process for manufacture of the active ingredient of the product and the requirement of new drug provision of the federal food drug and cosmetic act or similar law and regulation in other country addition to market exclusivity are sought in the united state and other country through all relevant law including law increasing patent life some of the benefit of increase in patent life have been partially offset by an increase in the number of incentive for and use of generic product additionally improvement in intellectual property law are sought in the united state and other country through reform of patent and other relevant law and implementation of international treaty for further information with respect to the company patent see item risk factor and item financial statement and supplementary data note contingency and environmental liability below worldwide all of the company important product are sold under trademark that are considered in the aggregate to be of material importance trademark protection continues in some country long used in other country long registered registration is for fixed term and can be renewed indefinitely royalty income in on patent and know how license and other right amounted to million merck also incurred royalty expense amounting to billion in under patent and know how license it hold research and developmentthe company business is characterized by the introduction of new product or new us for existing product through strong research and development program at december approximately people were employed in the company research activity the company prioritizes it research and development effort and focus on candidate that it belief represent breakthrough science that will make difference for patient and payer the company maintains number of long term exploratory and fundamental research program in biology and chemistry well research program directed toward product development the company research and development model is designed to increase productivity and improve the probability of success by prioritizing the of contentscompany research and development resource on candidate the company belief are capable of providing unambiguous promotable advantage to patient and payer and delivering the maximum value of it approved medicine and vaccine through new indication and new formulation merck is pursuing emerging product opportunity independent of therapeutic area or modality small molecule biologics and vaccine and is building it biologics capability the company is committed to ensuring that externally sourced program remain an important component of it pipeline strategy with focus on supplementing it internal research with licensing and external alliance strategy focused on the entire spectrum of collaboration from early research to late stage compound well access to new technology the company clinical pipeline includes candidate in multiple disease area including cancer cardiovascular disease diabetes and other metabolic disease infectious disease neuroscience pain respiratory disease and vaccine in the development of human health product industry practice and government regulation in the united state and most foreign country provide for the determination of effectiveness and safety of new chemical compound through pre clinical test and controlled clinical evaluation before new drug or vaccine may be marketed in the united state recorded data on pre clinical and clinical experience are included in the nda for drug or the biologics license application bla for vaccine or biologic submitted to the fda for the required approval once the company scientist discover new small molecule compound or biologic that they believe ha promise to treat medical condition the company commences pre clinical testing with that compound pre clinical testing includes laboratory testing and animal safety study to gather data on chemistry pharmacology immunogenicity and toxicology pending acceptable pre clinical data the company will initiate clinical testing in accordance with established regulatory requirement the clinical testing begin with phase study which are designed to ass safety tolerability pharmacokinetics and preliminary pharmacodynamic activity of the compound in human if favorable additional larger phase study are initiated to determine the efficacy of the compound in the affected population define appropriate dosing for the compound well identify any adverse effect that could limit the compound usefulness in some situation the clinical program incorporates adaptive design methodology to use accumulating data to decide how to modify aspect of the ongoing clinical study it continues without undermining the validity and integrity of the trial one type of adaptive clinical trial is an adaptive phase trial design two stage trial design consisting of phase proof of concept stage and phase dose optimization finding stage if data from the phase trial are satisfactory the company commences large scale phase trial to confirm the compound efficacy and safety another type of adaptive clinical trial is an adaptive phase trial design study that includes an interim analysis and an adaptation that change the trial from feature common in phase study multiple dose group to design similar to phase trial an adaptive phase trial design reduces timeline by eliminating activity which would be required to start separate study upon completion of phase trial if satisfactory the company submits regulatory filing with the appropriate regulatory agency around the world to have the product candidate approved for marketing there can be no assurance that compound that is the result of any particular program will obtain the regulatory approval necessary for it to be marketed vaccine development follows the same general pathway for drug pre clinical testing focus on the vaccine safety and ability to elicit protective immune response immunogenicity pre marketing vaccine clinical trial are typically done in three phase initial phase clinical study are conducted in normal subject to evaluate the safety tolerability and immunogenicity of the vaccine candidate phase study are dose ranging study finally phase trial provide the necessary data on effectiveness and safety if successful the company submits regulatory filing with the appropriate regulatory agency in the united state the fda review process begin once complete nda or bla is submitted received and accepted for review by the agency within day after receipt the fda determines if the application is sufficiently complete to permit substantive review the fda also ass at that time whether the application will be granted priority review or standard review pursuant to the prescription drug user fee act pdufa the fda review period target for ndas or original blas is either six month for priority review or ten month for standard review from the time the application is deemed sufficiently complete once the review timeline are determined the fda will generally act upon the application within those timeline unless major amendment ha been submitted either at the company own initiative or the fda request to the pending application if this occurs the fda may extend the review period to allow for review of the new information but by no more than three month extension to the review period are communicated to the company the fda can act on an application either by issuing an approval letter or by issuing complete response letter crl stating that the application will not be approved in it present form and describing all deficiency that the fda ha identified the company wish to pursue an application after receiving crl it can resubmit the application with information that address the question or issue identified by the fda in of contentsorder to support approval resubmissions are subject to review period target which vary depending on the underlying submission type and the content of the resubmission the fda ha four program designation fast track breakthrough therapy accelerated approval and priority review to facilitate and expedite development and review of new drug to address unmet medical need in the treatment of serious or life threatening condition the fast track designation provides pharmaceutical manufacturer with opportunity for frequent interaction with fda reviewer during the product development and the ability for the manufacturer to do rolling submission of the nda bla rolling submission allows completed portion of the application to be submitted and reviewed by the fda on an ongoing basis the breakthrough therapy designation provides manufacturer with all of the feature of the fast track designation well intensive guidance on implementing an efficient development program for the product and commitment by the fda to involve senior manager and experienced staff in the review the accelerated approval designation allows the fda to approve product based on an effect on surrogate or intermediate endpoint that is reasonably likely to predict product clinical benefit and generally requires the manufacturer to conduct required post approval confirmatory trial to verify the clinical benefit the priority review designation mean that the fda goal is to take action on the nda bla within six month compared to ten month under standard review in addition under the generating antibiotic incentive act the fda may grant qualified infectious disease product qidp status to antibacterial or antifungal drug intended to treat serious or life threatening infection including those caused by antibiotic or antifungal resistant pathogen novel or emerging infectious pathogen or other qualifying pathogen qidp designation offer certain incentive for development of qualifying drug including priority review of the nda when filed eligibility for fast track designation and five year extension of applicable exclusivity provision under the food drug and cosmetic act the primary method the company us to obtain marketing authorization of pharmaceutical product in the eu is through the centralized procedure this procedure is compulsory for certain pharmaceutical product in particular those using biotechnological process and is also available for certain new chemical compound and product company seeking to market an innovative pharmaceutical product through the centralized procedure must file complete set of safety data and efficacy data part of marketing authorization application maa with the european medicine agency ema after the ema evaluates the maa it provides recommendation to the ec and the ec then approves or denies the maa it is also possible for new chemical product to obtain marketing authorization in the eu through mutual recognition procedure in which an application is made to single member state and if the member state approves the pharmaceutical product under national procedure the applicant may submit that approval to the mutual recognition procedure of some or all other member state outside of the united state and the eu the company submits marketing application to national regulatory authority example of such are the ministry of health labour and welfare in japan health canada agncia nacional de vigilncia sanatria in brazil korea food and drug administration in south korea therapeutic good administration in australia and the national medical product administration in china each country ha separate and independent review process and timeline in many market approval time can be longer the regulatory authority requires approval in major market such the united state or the eu and issuance of certificate of pharmaceutical product from that market before initiating their local review process research and development updatethe company currently ha several candidate under regulatory review in the united state and internationally keytruda is an anti pd therapy approved for the treatment of many cancer that is in clinical development for expanded indication these approval were the result of broad clinical development program that currently consists of more than clinical trial including more than trial that combine keytruda with other cancer treatment these study encompass more than cancer type including biliary tract cervical colorectal cutaneous squamous cell endometrial gastric head and neck hepatocellular hodgkin lymphoma non hodgkin lymphoma melanoma mesothelioma nasopharyngeal non small cell lung ovarian pmbcl prostate renal small cell lung triple negative breast and urothelial many of which are currently in phase clinical development further trial are being planned for other cancer keytruda is under review in the eu monotherapy for the first line treatment of patient with stage iii nsclc who are not candidate for surgical resection or definitive chemoradiation or metastatic nsclc and whose tumor express pd tps with no egfr or alk genomic tumor aberration based on result from the phase keynote trial of contentskeytruda is under review in japan monotherapy and in combination with chemotherapy for the first line treatment of advanced gastric or gastroesophageal junction adenocarcinoma based on result from the pivotal phase keynote trial keytruda is also under review in japan monotherapy for the second line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma based on the result of the phase keynote trial merck ha made the decision to withdraw it type ii variation application for keytruda for this indication in the eu in october the fda accepted supplemental bla seeking use of keytruda for the treatment of patient with recurrent and or metastatic cutaneous squamous cell carcinoma cscc that is not curable by surgery or radiation based on the result of the keynote trial the fda set pdufa date of june in february merck announced the fda issued complete response letter crl regarding merck supplemental blas seeking to update the dosing frequency for keytruda to include mg dose infused over minute every six week option in multiple indication the submitted application are based on pharmacokinetic modeling and simulation data presented at the american society of clinical oncology asco annual meeting these data supported the ec approval of mg dosing for keytruda monotherapy indication in march merck is reviewing the letter and will discus next step with the fda additionally keytruda ha received breakthrough therapy designation from the fda in combination with neoadjuvant chemotherapy for the treatment of high risk early stage triple negative breast cancer tnbc and in combination with enfortumab vedotin in the first line setting for the treatment of patient with unresectable locally advanced or metastatic urothelial cancer who are not eligible for cisplatin containing chemotherapy the fda breakthrough therapy designation is intended to expedite the development and review of candidate that is planned for use alone or in combination to treat serious or life threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapy on one or more clinically significant endpoint in september merck announced result from the pivotal neoadjuvant adjuvant phase keynote trial in patient with early stage tnbc the trial investigated regimen of neoadjuvant keytruda plus chemotherapy followed by adjuvant keytruda monotherapy the keytruda regimen compared with regimen of neoadjuvant chemotherapy followed by adjuvant placebo the chemotherapy placebo regimen interim finding were presented at the european society for medical oncology esmo congress in the neoadjuvant phase keytruda plus chemotherapy resulted in statistically significant increase in pathological complete response pcr versus chemotherapy in patient with early stage tnbc the improvement seen when adding keytruda to neoadjuvant chemotherapy wa observed regardless of pd expression in the other dual primary endpoint of event free survival efs with median follow up of month the keytruda regimen reduced the risk of progression in the neoadjuvant phase and recurrence in the adjuvant phase compared with the chemotherapy placebo regimen merck continues to discus interim analysis data from keynote with regulatory authority the keytruda breast cancer clinical development program encompasses several internal and external collaborative study in february merck announced that the pivotal phase keynote trial investigating keytruda in combination with chemotherapy met one of it dual primary endpoint of progression free survival pfs in patient with metastatic triple negative breast cancer mtnbc whose tumor expressed pd cps based on an interim analysis conducted by an independent data monitoring committee dmc first line treatment with keytruda in combination with chemotherapy nab paclitaxel paclitaxel or gemcitabine carboplatin demonstrated statistically significant and clinically meaningful improvement in pfs compared to chemotherapy alone in these patient based on the recommendation of the dmc the trial will continue without change to evaluate the other dual primary endpoint of overall survival in may merck announced that the phase keynote trial evaluating keytruda monotherapy for the second or third line treatment of patient with metastatic tnbc not meet it pre specified primary endpoint of superior compared to chemotherapy other endpoint were not formally tested per the study protocol the primary endpoint of wa not met in june merck announced full result from the pivotal phase keynote trial evaluating keytruda monotherapy and in combination with chemotherapy for the first line treatment of advanced gastric or gastroesophageal junction adenocarcinoma in the monotherapy arm of the study keytruda met primary endpoint by demonstrating noninferiority to chemotherapy the current standard of care for in patient whose tumor expressed pd cps in the combination arm of keynote keytruda plus chemotherapy wa not found to be statistically superior for cps or cps or pfs cps compared with chemotherapy alone result were presented at the american society of clinical oncology asco annual meeting in september the fda of contentsapproved keytruda third line treatment for previously treated patient with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer whose tumor express pd cps determined by an fda approved test keynote wa potential confirmatory trial for this accelerated third line approval in addition to keynote additional first line phase study in merck gastric clinical program include keynote and keynote well keynote in the neoadjuvant and adjuvant treatment setting in january merck announced that the phase keynote trial investigating keytruda in combination with chemotherapy met one of it dual primary endpoint of pfs in the first line treatment of patient with extensive stage sclc at the final analysis of the study there wa also an improvement in for patient treated with keytruda in combination with chemotherapy compared to chemotherapy alone however these result did not meet statistical significance per the pre specified statistical plan result will be presented at an upcoming medical meeting and discussed with regulatory authority lynparza is an oral parp inhibitor currently approved for certain type of advanced ovarian breast and pancreatic cancer being co developed for multiple cancer type part of collaboration with astrazeneca lynparza is under review in the eu first line maintenance monotherapy for patient with gbrcam metastatic pancreatic cancer whose disease ha not progressed following first line platinum based chemotherapy lynparza wa approved for this indication by the fda in december based on result from the phase polo trial decision from the ema is expected in the second half of in january the fda accepted supplemental nda for lynparza in combination with bevacizumab for the maintenance treatment of woman with advanced ovarian cancer whose disease showed complete or partial response to first line treatment with platinum based chemotherapy and bevacizumab based on the result from the pivotal phase paola trial pdufa date is set for the second quarter of this indication is also under review in the eu in january the fda accepted for priority review supplemental nda for lynparza for the treatment of patient with metastatic castration resistant prostate cancer mcrpc and deleterious or suspected deleterious germline or somatic homologous recombination repair hrr gene mutation who have progressed following prior treatment with new hormonal agent based on positive result from the phase profound trial pdufa date is set for the second quarter of this indication is also under review in the eu in june merck and astrazeneca presented full result from the phase solo trial which evaluated lynparza compared to chemotherapy for the treatment of platinum sensitive relapsed patient with gbrcam advanced ovarian cancer who have received two or more prior line of chemotherapy the result from the trial showed statistically significant and clinically meaningful improvement in objective response rate orr in the lynparza arm compared to the chemotherapy arm the key secondary endpoint of pfs wa also significantly increased in the lynparza arm compared to the chemotherapy arm the result were presented at the asco annual meeting mk selumetinib is mek inhibitor being co developed part of strategic collaboration with astrazeneca selumetinib is under priority review with the fda potential new medicine for pediatric patient aged three year and older with neurofibromatosis type and symptomatic inoperable plexiform neurofibroma this regulatory submission wa based on positive result from the national cancer institute cancer therapy evaluation program sponsored sprint phase stratum trial pdufa date is set for the second quarter of is under review in japan for an initial indication in female for the prevention of certain hpv related disease and precursor in february the fda accepted for priority review supplemental bla for gardasil for the prevention of certain head and neck cancer caused by vaccine type hpv in female and male through year of age the fda set pdufa date of june in addition to the candidate under regulatory review the company ha several drug candidate in phase clinical development in addition to the keytruda program discussed above lynparza in addition to the indication under review discussed above is in phase development in combination with keytruda for the treatment of nsclc lenvima is an orally available tyrosine kinase inhibitor currently approved for certain type of thyroid cancer hcc and in combination for certain patient with rcc being co developed part of strategic collaboration with eisai pursuant to the agreement the company will jointly initiate clinical study evaluating the keytruda lenvima combination in six type of cancer endometrial cancer nsclc hcc hnscc bladder cancer and melanoma well basket trial targeting multiple cancer type the fda granted breakthrough therapy designation of contentsfor keytruda in combination with lenvima both for the potential treatment of patient with advanced and or metastatic rcc and for the potential treatment of patient with unresectable hcc not amenable to locoregional treatment mk gefapixant is selective non narcotic orally administered receptor antagonist being investigated in phase trial for the treatment of refractory chronic cough and in phase trial for the treatment of woman with endometriosis related pain mk vericiguat is sgc stimulator for the potential treatment of patient with worsening chronic heart failure being developed part of worldwide strategic collaboration merck and bayer vericiguat is being studied in patient suffering from chronic heart failure with reduced ejection fraction phase clinical trial and from chronic heart failure with preserved ejection fraction phase clinical trial in november merck announced that the phase victoria study evaluating the efficacy and safety of vericiguat met the primary efficacy endpoint vericiguat reduced the risk of the composite endpoint of heart failure hospitalization or cardiovascular death in patient with worsening chronic heart failure with reduced ejection fraction compared to placebo when given in combination with available heart failure therapy the result of the victoria study will be presented at an upcoming medical meeting in is an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease in june merck initiated the first phase study in the adult population for the prevention of invasive pneumococcal disease currently six phase adult study are ongoing including study in healthy adult year of age or older adult with risk factor for pneumococcal disease those infected with hiv and those who are recipient of allogeneic hematopoietic stem cell transplant in october merck began the first phase study in the pediatric population currently eight study are ongoing including study in healthy infant and in child afflicted with sickle cell disease ha received breakthrough therapy designation from the fda for the prevention of invasive pneumococcal disease caused by the vaccine serotypes in pediatric patient week to year of age and in adult the chart below reflects the company research pipeline of february candidate shown in phase include specific product and the date such candidate entered into phase development candidate shown in phase include the most advanced compound with specific mechanism or if listed compound have the same mechanism they are each currently intended for commercialization in given therapeutic area small molecule and biologics are given mk number designation and vaccine candidate are given number designation except otherwise noted candidate in phase additional indication in the same therapeutic area other than with respect to cancer and additional claim line extension or formulation for in line product are not shown of contentsphase phase entry date under reviewcancercancernew molecular entity vaccinesmk keytrudamk keytrudapediatric neurofibromatosis type solid tumorsbiliary tract september mk selumetinib mk october hpv vaccinerenal cell carcinomacervical october eu human papillomavirus valent vaccine mk colorectal november recombinant jpn solid tumor cutaneous squamous cell carcinoma certain supplemental filingsmk lynparza august eu canceradvanced solid tumorsendometrial august eu mk keytrudamk vicriviroc esophageal december eu first line metastatic non small cell lungcolorectalgastric may eu cancer keynote eu mk lenvima hepatocellular may eu first line metastatic gastric cancerbiliary tractmesothelioma may keynote jpn nasopharyngeal april recurrent locally advanced or metastaticmelanomaovarian december esophageal cancer keynote mk prostate may jpn non small cell lung small cell lung may eu recurrent and or metastatic cutaneous mk lynparza squamous cell carcinomahematological malignanciesnon small cell lung june keynote mk mk lenvima alternative dosing regimen hematological malignanciesbladder may non small cell lungendometrial june eu mk lynparza mk head and neck squamous cell carcinoma first line gbrcam pancreatic cancer non small cell lung february polo eu mk melanoma march first line maintenance newly diagnosednon small cell lung non small cell lung march advanced ovarian cancer paola cytomegalovirus cough eu gefapixant march metastatic prostate cancer profound hiv infectionheart failure eu mk islatravir mk vericiguat september footnote overgrowth syndrome hiv infection being developed in collaboration mk islatravir doravirine february being developed in combination with pediatric neurofibromatosis type vaccinekeytruda mk selumetinib eu june the company received crl in february respiratory syncytial virus merck is reviewing the letter and willmk discus next step with the fda schizophrenia mk employeesas of december the company had approximately employee worldwide with approximately employed in the united state including puerto rico approximately of worldwide employee of the company are represented by various collective bargaining group restructuring activitiesin early merck approved new global restructuring program restructuring program part of worldwide initiative focused on further optimizing the company manufacturing and supply network well reducing it global real estate footprint this program is continuation of the company plant rationalization build on prior restructuring program and doe not include any action associated with the planned spin off of newco the company continues to evaluate it global footprint and overall operating model it ha subsequently identified additional action under the restructuring program and could identify further action over time the action currently contemplated under the restructuring program are expected to be substantially completed by the end of action under previous global restructuring program have been substantially completed environmental mattersthe company belief that there are no compliance issue associated with applicable environmental law and regulation that would have material adverse effect on the company the company is also remediating environmental contamination resulting from past industrial activity at certain of it site expenditure for remediation and environmental liability were million in and are estimated at million in the aggregate for the year through these amount do not consider potential recovery from other party the company ha taken an active role in identifying and accruing for these cost and in management opinion the liability for all environmental matter that are probable and reasonably estimable have been accrued and totaled million and million at december and respectively although it is not possible to predict with certainty the outcome of contentsof these matter or the ultimate cost of remediation management doe not believe that any reasonably possible expenditure that may be incurred in excess of the liability accrued should exceed million in the aggregate management also doe not believe that these expenditure should have material adverse effect on the company financial condition result of operation liquidity or capital resource for any year merck belief that climate change could present risk to it business some of the potential impact of climate change to it business include increased operating cost due to additional regulatory requirement physical risk to the company facility water limitation and disruption to it supply chain these potential risk are integrated into the company business planning including investment in reducing energy water use and greenhouse gas emission the company doe not believe these risk are material to it business at this time geographic area informationthe company operation outside the united state are conducted primarily through subsidiary sale worldwide by subsidiary outside the united state percentage of total company sale were of sale in each of and the company worldwide business is subject to risk of currency fluctuation governmental action and other governmental proceeding abroad the company doe not regard these risk deterrent to further expansion of it operation abroad however the company closely review it method of operation and adopts strategy responsive to changing economic and political condition merck ha operation in country located in latin america the middle east africa eastern europe and asia pacific business in these developing area while sometimes le stable offer important opportunity for growth over time available informationthe company internet website address is www merck com the company will make available free of charge at the investor portion of it website it annual report on form quarterly report on form current report on form and all amendment to those report filed or furnished pursuant to section or of the security exchange act of amended soon reasonably practicable after such report are electronically filed with or furnished to the security and exchange commission sec the address of that website is www sec gov in addition the company will provide without charge copy of it annual report on form including financial statement and schedule upon the written request of any shareholder to the office of the secretary merck co inc galloping hill road kenilworth nj the company corporate governance guideline and the charter of the board of director four standing committee are available on the company website at www merck com about leadership and all such information is available in print to any shareholder who request it from the company item risk factor investor should carefully consider all of the information set forth in this form including the following risk factor before deciding to invest in any of the company security the risk below are not the only one the company face additional risk not currently known to the company or that the company presently deems immaterial may also impair it business operation the company business financial condition result of operation or prospect could be materially adversely affected by any of these risk this form also contains forward looking statement that involve risk and uncertainty the company result could materially differ from those anticipated in these forward looking statement result of certain factor including the risk it face described below and elsewhere see cautionary factor that may affect future result below the company is dependent on it patent right and if it patent right are invalidated or circumvented it business could be materially adversely affected patent protection is considered in the aggregate to be of material importance to the company marketing of human health and animal health product in the united state and in most major foreign market patent covering product that it ha introduced normally provide market exclusivity which is important for the successful marketing of contentsand sale of it product the company seek patent covering each of it product in each of the market where it intends to sell the product and where meaningful patent protection is available even if the company succeeds in obtaining patent covering it product third party or government authority may challenge or seek to invalidate or circumvent it patent and patent application it is important for the company business to defend successfully the patent right that provide market exclusivity for it product the company is often involved in patent dispute relating to challenge to it patent or claim by third party of infringement against the company the company defends it patent both within and outside the united state including by filing claim of infringement against other party see item financial statement and supplementary data note contingency and environmental liability below in particular manufacturer of generic pharmaceutical product from time to time file abbreviated ndas with the fda seeking to market generic form of the company product prior to the expiration of relevant patent owned or licensed by the company the company normally responds by defending it patent including by filing lawsuit alleging patent infringement patent litigation and other challenge to the company patent are costly and unpredictable and may deprive the company of market exclusivity for patented product or in some case third party patent may prevent the company from marketing and selling product in particular geographic area additionally certain foreign government have indicated that compulsory license to patent may be granted in the case of national emergency or in other circumstance which could diminish or eliminate sale and profit from those region and negatively affect the company result of operation further court decision relating to other company patent potential legislation in both the and certain foreign market relating to patent well regulatory initiative may result in more general weakening of intellectual property protection if one or more important product lose patent protection in profitable market sale of those product are likely to decline significantly result of generic version of those product becoming available the company result of operation may be adversely affected by the lost sale unless and until the company ha launched commercially successful product that replace the lost sale in addition if product that were measured at fair value and capitalized in connection with acquisition experience difficulty in the market that negatively affect product cash flow the company may recognize material non cash impairment charge with respect to the value of those product chart listing the patent protection for certain of the company marketed product and patent protection for candidate in phase clinical development is set forth above in item business patent trademark and license the company product lose market exclusivity the company generally experience significant and rapid loss of sale from those product the company depends upon patent to provide it with exclusive marketing right for it product for some period of time loss of patent protection for one of the company product typically lead to significant and rapid loss of sale for that product lower priced generic version of that drug become available in the case of product that contribute significantly to the company sale the loss of market exclusivity can have material adverse effect on the company business cash flow result of operation financial condition and prospect for example the patent that provided and eu market exclusivity for certain form of noxafil expired in july and december respectively and the company anticipates significant decline in and eu noxafil sale also the patent that provided market exclusivity for nuvaring expired in april and generic competition began in december the company anticipates rapid and substantial decline in nuvaring sale in result of this generic competition in addition the patent that provide market exclusivity for januvia and janumet in the expire in july although six month pediatric exclusivity may extend this date the patent that provides market exclusivity for januvia in the eu expires in july although pediatric exclusivity may extend this date to september finally the spc that provides market exclusivity for janumet in the eu expires in april the company anticipates sale of januvia and janumet in these market will decline substantially after these patent expiry of contentskey product generate significant amount of the company profit and cash flow and any event that adversely affect the market for it leading product could have material adverse effect on the company result of operation and financial condition the company ability to generate profit and operating cash flow depends largely upon the continued profitability of the company key product such keytruda gardasil gardasil januvia janumet and bridion in particular in the company oncology portfolio led by keytruda represented the majority of the company revenue and earnings growth result of the company dependence on key product any event that adversely affect any of these product or the market for any of these product could have significant adverse impact on result of operation and cash flow these event could include loss of patent protection increased cost associated with manufacturing generic or over the counter availability of the company product or competitive product the discovery of previously unknown side effect result of post approval trial increased competition from the introduction of new more effective treatment and discontinuation or removal from the market of the product for any reason such event could have material adverse effect on the sale of any such product the company research and development effort may not succeed in developing commercially successful product and the company may not be able to acquire commercially successful product in other way in consequence the company may not be able to replace sale of successful product that have lost patent protection like other major pharmaceutical company in order to remain competitive the company must continue to launch new product expected decline in sale of product after the loss of market exclusivity mean that the company future success is dependent on it pipeline of new product including new product that it may develop through collaboration and joint venture and product that it is able to obtain through license or acquisition to accomplish this the company commits substantial effort fund and other resource to research and development both through it own dedicated resource and through various collaboration with third party there is high rate of failure inherent in the research and development process for new drug result there is high risk that fund invested by the company in research program will not generate financial return this risk profile is compounded by the fact that this research ha long investment cycle to bring pharmaceutical compound from the discovery phase to market may take decade or more and failure can occur at any point in the process including later in the process after significant fund have been invested for description of the research and development process see item business research and development above each phase of testing is highly regulated and during each phase there is substantial risk that the company will encounter serious obstacle or will not achieve it goal therefore the company may abandon product in which it ha invested substantial amount of time and resource some of the risk encountered in the research and development process include the following pre clinical testing of new compound may yield disappointing result competing product from other manufacturer may reach the market first clinical trial of new drug may not be successful new drug may not be effective or may have harmful side effect new drug may not be approved by the regulator for it intended use it may not be possible to obtain patent for new drug payer may refuse to cover or reimburse the new product or sale of new product may be disappointing the company can not state with certainty when or whether any of it product now under development will be approved or launched whether it will be able to develop license or otherwise acquire compound product candidate or product or whether any product once launched will be commercially successful the company must maintain continuous flow of successful new product and successful new indication or brand extension for existing product sufficient both to cover it substantial research and development cost and to replace sale that are lost profitable product lose market exclusivity or are displaced by competing product or therapy failure to do so in the short term or long term would have material adverse effect on the company business result of operation cash flow financial condition and prospect the company success is dependent on the successful development and marketing of new product which are subject to substantial risk product that appear promising in development may fail to reach the market or fail to succeed for numerous reason including the following of content finding of ineffectiveness superior safety or efficacy of competing product or harmful side effect in clinical or pre clinical testing failure to receive the necessary regulatory approval including delay in the approval of new product and new indication or the anticipated labeling and uncertainty about the time required to obtain regulatory approval and the benefit risk standard applied by regulatory agency in determining whether to grant approval failure in certain market to obtain reimbursement commensurate with the level of innovation and clinical benefit presented by the product lack of economic feasibility due to manufacturing cost or other factor and preclusion from commercialization by the proprietary right of others in the future if certain pipeline program are cancelled or if the company belief that their commercial prospect have been reduced the company may recognize material non cash impairment charge for those program that were measured at fair value and capitalized in connection with acquisition or certain collaboration failure to successfully develop and market new product in the short term or long term would have material adverse effect on the company business result of operation cash flow financial condition and prospect the company product including product in development can not be marketed unless the company obtains and maintains regulatory approval the company activity including research pre clinical testing clinical trial and the manufacturing and marketing of it product are subject to extensive regulation by numerous federal state and local governmental authority in the united state including the fda and by foreign regulatory authority including in the eu japan and china in the united state the fda administers requirement covering the testing approval safety effectiveness manufacturing labeling and marketing of prescription pharmaceutical in many case the fda requirement have increased the amount of time and money necessary to develop new product and bring them to market in the united state regulation outside the united state also is primarily focused on drug safety and effectiveness and in many case reduction in the cost of drug the fda and foreign regulatory authority including in japan and china have substantial discretion to require additional testing to delay or withhold registration and marketing approval and to otherwise preclude distribution and sale of product even if the company is successful in developing new product it will not be able to market any of those product unless and until it ha obtained all required regulatory approval in each jurisdiction where it proposes to market the new product once obtained the company must maintain approval long it plan to market it new product in each jurisdiction where approval is required the company failure to obtain approval significant delay in the approval process or it failure to maintain approval in any jurisdiction will prevent it from selling the product in that jurisdiction the company would not be able to realize revenue for those new product in any jurisdiction where it doe not have approval development following regulatory approval may adversely affect sale of the company product even after product reach the market certain development following regulatory approval may decrease demand for the company product including the following result in post approval phase trial or other study the re review of product that are already marketed the recall or loss of marketing approval of product that are already marketed changing government standard or public expectation regarding safety efficacy quality or labeling change and scrutiny of advertising and promotion in the past several year clinical trial and post marketing surveillance of certain marketed drug of the company and of competitor within the industry have raised concern that have led to recall withdrawal or adverse of contentslabeling of marketed product clinical trial and post marketing surveillance of certain marketed drug also have raised concern among some prescribers and patient relating to the safety or efficacy of pharmaceutical product in general that have negatively affected the sale of such product in addition increased scrutiny of the outcome of clinical trial ha led to increased volatility in market reaction further these matter often attract litigation and even where the basis for the litigation is groundless considerable resource may be needed to respond in addition following in the wake of product withdrawal and other significant safety issue health authority such the fda the ema japan pmda and china nmpa have increased their focus on safety when assessing the benefit risk balance of drug some health authority appear to have become more cautious when making decision about approvability of new product or indication if previously unknown side effect are discovered or if there is an increase in negative publicity regarding known side effect of any of the company product it could significantly reduce demand for the product or require the company to take action that could negatively affect sale including removing the product from the market restricting it distribution or applying for labeling change further in the current environment in which all pharmaceutical company operate the company is at risk for product liability and consumer protection claim and civil and criminal governmental action related to it product research and or marketing activity in addition dissemination of promotional material through evolving digital channel serf to increase visibility and scrutiny in the marketplace the company face intense competition from lower cost generic product in general the company face increasing competition from lower cost generic product the patent right that protect it product are of varying strength and duration in addition in some country patent protection is significantly weaker than in the united state or in the eu in the united state and the eu political pressure to reduce spending on prescription drug ha led to legislation and other measure that encourage the use of generic and biosimilar product although it is the company policy to actively protect it patent right generic challenge to the company product can arise at any time and the company patent may not prevent the emergence of generic competition for it product loss of patent protection for product typically is followed promptly by generic substitute reducing the company sale of that product availability of generic substitute for the company drug may adversely affect it result of operation and cash flow in addition proposal emerge from time to time in the united state and other country for legislation to further encourage the early and rapid approval of generic drug any such proposal that is enacted into law could worsen this substantial negative effect on the company sale and potentially it business cash flow result of operation financial condition and prospect the company face intense competition from competitor product the company product face intense competition from competitor product this competition may increase new product enter the market in such an event the competitor product may be safer or more effective more convenient to use have better insurance coverage or reimbursement level or be more effectively marketed and sold than the company product alternatively in the case of generic competition including the generic availability of competitor branded product they may be equally safe and effective product that are sold at substantially lower price than the company product result if the company fails to maintain it competitive position this could have material adverse effect on it business cash flow result of operation financial condition and prospect in addition if product that were measured at fair value and capitalized in connection with acquisition experience difficulty in the market that negatively impact product cash flow the company may recognize material non cash impairment charge with respect to the value of those product the company face continued pricing pressure with respect to it product the company face continued pricing pressure globally and particularly in mature market from managed care organization government agency and program that could negatively affect the company sale and profit margin in the united state these include practice of managed care group and institutional and governmental purchaser ii federal law and regulation related to medicare and medicaid including the medicare prescription drug improvement and modernization act of and the aca and iii state activity aimed at increasing price transparency including new law noted above in item competition and the health care environment health of contentscare environment and government regulation change to the health care system enacted part of health care reform in the united state well increased purchasing power of entity that negotiate on behalf of medicare medicaid and private sector beneficiary could result in further pricing pressure in addition in the united state larger customer have received higher rebate on drug in certain highly competitive category the company must also compete to be placed on formulary of managed care organization exclusion of product from formulary can lead to reduced usage in the managed care organization in order to provide information about the company pricing practice the company annually post on it website it pricing transparency report for the united state the report provides the company average annual list price and net price increase across the company portfolio dating back to in the company gross sale were reduced by approximately result of rebate discount and return outside the united state numerous major market including the eu japan and china have pervasive government involvement in funding health care and in that regard fix the pricing and reimbursement of pharmaceutical and vaccine product consequently in those market the company is subject to government decision making and budgetary action with respect to it product in japan the pharmaceutical industry is subject to government mandated biennial price reduction of pharmaceutical product and certain vaccine which will occur again in furthermore the government can order re pricing for specific product if it determines that use of such product will exceed certain threshold defined under applicable re pricing rule for example pursuant to re pricing rule the japanese government reduced the price of keytruda by effective february additionally keytruda will be subject to another significant price reduction in april under provision of the japanese pricing rule the company expects pricing pressure to continue in the future the health care industry in the united state ha been and will continue to be subject to increasing regulation and political action the company belief that the health care industry will continue to be subject to increasing regulation well political and legal action future proposal to reform the health care system are considered by the executive branch congress and state legislature in the united state enacted major health care reform legislation in the form of the aca various insurance market reform have advanced and state and federal insurance exchange were launched in the aca increased the mandated medicaid rebate from to expanded the rebate to medicaid managed care utilization and increased the type of entity eligible for the federal drug discount program the aca also requires pharmaceutical manufacturer to pay point of service discount to medicare part beneficiary when they are in the medicare part coverage gap the so called donut hole which increased to in and wa extended to biosimilar product in the company revenue wa reduced by approximately million due to this requirement also pharmaceutical manufacturer are required to pay an annual non tax deductible health care reform fee in the company recorded million of cost for this annual fee in the center for medicare medicaid service cm issued the medicaid rebate final rule that implement provision of the aca effective april the rule provides comprehensive guidance on the calculation of average manufacturer price and best price two metric utilized to determine the rebate drug manufacturer are required to pay to state medicaid program the impact of change resulting from the issuance of the rule is not material to merck at this time however the company is still awaiting guidance from cm on two aspect of the rule that were deferred for later implementation these include definition of what constitutes product line extension and delay in the participation of the territory in the medicaid drug rebate program until april the company will evaluate the financial impact of these two element when they become effective in addition discussed above in competition and the health care environment the administration ha recently proposed draft rule that would allow importation of certain lower cost prescription drug from canada if the rule is finalized proposed state or certain other non federal governmental entity would be able to submit importation program proposal to the fda for review and authorization of two year program with the opportunity to extend for two more year there will be public comment period on the proposed rule which will expire on march following the comment period the fda will have to review and finalize it proposal before any state or other of contentsparties can submit their plan to comply with the federal rule if the proposed rule is adopted it likely will be some time before state or other party can actually implement importation plan also in october the administration issued an advance notice of proposed rulemaking to implement an international pricing index ipi model in the united state for product covered under medicare part the proposal would reduce medicare part payment for drug based on market basket of international price allow private sector vendor to negotiate price for drug take title to drug and compete for physician and hospital business and change the physician reimbursement under medicare part from the current model to eliminate the buy and bill system and instead pay physician based on flat fee that approximates the revenue they currently receive from drug public comment on the ipi proposal were accepted through late and it is unclear when the agency may issue proposed rule on the ipi model adoption of one or both of the proposed rule could have material adverse effect on the company business result of operation and financial condition the company can not predict the likelihood of additional future change in the health care industry in general or the pharmaceutical industry in particular or what impact they may have on the company business cash flow result of operation financial condition and prospect the company is increasingly dependent on sophisticated software application and computing infrastructure in the company experienced network cyber attack that led to disruption of it worldwide operation including manufacturing research and sale operation the company could be target of future cyber attack the company is increasingly dependent on sophisticated software application and complex information technology system and computing infrastructure collectively it system to conduct critical operation certain of these system are managed hosted provided or used by third party to assist in conducting the company business disruption degradation or manipulation of these it system through intentional or accidental mean by the company employee third party with authorized access or unauthorized third party could adversely affect key business process cyber attack against the company it system or third party provider it system such cloud based system could result in exposure of confidential information the modification of critical data and or the failure of critical operation misuse of any of these it system could result in the disclosure of sensitive personal information or the theft of trade secret intellectual property or other confidential business information the company continues to leverage new and innovative technology across the enterprise to improve the efficacy and efficiency of it business process the use of which can create new risk in the company experienced network cyber attack that led to disruption of it worldwide operation including manufacturing research and sale operation and resulting loss the company ha insurance coverage insuring against loss resulting from cyber attack and ha received proceeds in connection with the cyber attack however there are dispute with certain of the insurer about the availability of some of the insurance coverage for claim related to the cyber attack the company ha implemented variety of measure to further enhance and modernize it system to guard against similar attack in the future and also is pursuing an enterprise wide effort to enhance the company resiliency against future cyber attack including incident similar to the attack the objective of these effort is not only to protect against future cyber attack but also to improve the speed of the company recovery from such attack and enable continued business operation to the greatest extent possible during any recovery period although the aggregate impact of cyber attack and network disruption including the cyber attack on the company operation and financial condition ha not been material to date the company continues to be target of event of this nature and expects them to continue the company monitor it data information technology and personnel usage of company it system to reduce these risk and continues to do so on an ongoing basis for any current or potential threat there can be no assurance that the company effort to protect it data and it system or the effort of third party provider to protect their it system will be successful in preventing disruption to the company operation including it manufacturing research and sale operation such disruption have in the past and could in the future result in loss of revenue or the loss of critical or sensitive information from the company or the company third party provider database or it system and have in the past and could in the future also result in financial legal business or reputational harm to the company and substantial remediation cost of contentsthe company is subject to variety of and international law and regulation the company is currently subject to number of government law and regulation and in the future could become subject to new government law and regulation the cost of compliance with such law and regulation or the negative result of non compliance could adversely affect the business cash flow result of operation financial condition and prospect of the company these law and regulation include additional healthcare reform initiative in the united state or in other country including additional mandatory discount or fee ii the foreign corrupt practice act or other anti bribery and corruption law iii new law regulation and judicial or other governmental decision affecting pricing drug reimbursement and access or marketing within or across jurisdiction iv change in intellectual property law change in accounting standard vi new and increasing data privacy regulation and enforcement particularly in the eu and the united state vii legislative mandate or preference for local manufacturing of pharmaceutical or vaccine product viii emerging and new global regulatory requirement for reporting payment and other value transfer to healthcare professional ix environmental regulation and the potential impact of importation restriction embargo trade sanction and legislative and or other regulatory change the uncertainty in global economic condition together with cost reduction measure being taken by certain government could negatively affect the company operating result uncertainty in global economic and geopolitical condition may result in slowdown to the global economy that could affect the company business by reducing the price that drug wholesaler and retailer hospital government agency and managed health care provider may be able or willing to pay for the company product or by reducing the demand for the company product which could in turn negatively impact the company sale and result in material adverse effect on the company business cash flow result of operation financial condition and prospect global effort toward health care cost containment continue to exert pressure on product pricing and market access worldwide change to the health care system part of health care reform well increased purchasing power of entity that negotiate on behalf of medicare medicaid and private sector beneficiary have contributed to pricing pressure in several international market government mandated pricing action have reduced price of generic and patented drug in addition the company revenue performance in wa negatively affected by other cost reduction measure taken by government and other third party to lower health care cost the company anticipates all of these action and additional action in the future will continue to negatively affect revenue performance if credit and economic condition worsen the resulting economic and currency impact in the affected market and globally could have material adverse effect on the company result the company ha significant global operation which expose it to additional risk and any adverse event could have material adverse effect on the company result of operation and financial condition the extent of the company operation outside the united state is significant risk inherent in conducting global business include change in medical reimbursement policy and program and pricing restriction in key market multiple regulatory requirement that could restrict the company ability to manufacture and sell it product in key market trade protection measure and import or export licensing requirement including the imposition of trade sanction or similar restriction by the united state or other government foreign exchange fluctuation diminished protection of intellectual property in some country and possible nationalization and expropriation in addition there may be change to the company business and political position if there is instability disruption or destruction in significant geographic region regardless of cause including war terrorism riot civil insurrection or social unrest and natural or man made disaster including famine flood fire earthquake storm or disease of contentsin the united kingdom uk held referendum in which voter approved an exit from the eu commonly referred to brexit result of that referendum and subsequent negotiation the uk left the eu on january transitional period will apply from january until december and during this period the eu will treat the uk if it were an eu member state and the uk will continue to participate in the eu custom union allowing for the freedom of movement for people and good during the transitional period the eu and the uk will continue to negotiate trade agreement to formalize the term of the uk future relationship with the eu the company ha taken action and made certain contingency plan for scenario in which the uk and the eu do not reach mutually satisfactory understanding to future trade agreement it is not possible at this time to predict whether there will be any such understanding before the end of or if such an understanding is reached whether it term will vary in way that result in greater restriction on import and export between the uk and eu country increased regulatory complexity and or cross border labor issue that could materially adversely impact the company business operation in the uk failure to attract and retain highly qualified personnel could affect the company ability to successfully develop and commercialize product the company success is largely dependent on it continued ability to attract and retain highly qualified scientific technical and management personnel well personnel with expertise in clinical research and development governmental regulation and commercialization competition for qualified personnel in the pharmaceutical industry is intense the company can not be sure that it will be able to attract and retain quality personnel or that the cost of so will not materially increase in the past the company ha experienced difficulty and delay in manufacturing certain of it product including vaccine merck ha in the past experienced difficulty in manufacturing certain of it product including vaccine in addition the network cyber attack experienced by the company in june led to disruption of the company operation including it manufacturing operation the company may in the future experience difficulty and delay inherent in manufacturing it product such failure of the company or any of it vendor or supplier to comply with current good manufacturing practice and other applicable regulation and quality assurance guideline that could lead to manufacturing shutdown product shortage and delay in product manufacturing ii delay related to the construction of new facility or the expansion of existing facility including those intended to support future demand for the company product and iii other manufacturing or distribution problem including change in manufacturing production site and limit to manufacturing capacity due to regulatory requirement change in type of product produced or physical limitation that could impact continuous supply in addition the company could experience difficulty or delay in manufacturing it product caused by natural disaster such hurricane for example in the company lone manufacturing plant in puerto rico wa negatively affected by hurricane maria manufacturing difficulty can result in product shortage leading to lost sale and reputational harm to the company the company may not be able to realize the expected benefit of it investment in emerging market the company ha been taking step to increase it sale in emerging market however there is no guarantee that the company effort to expand sale in these market will succeed some country within emerging market may be especially vulnerable to period of global financial instability or may have limited resource to spend on health care in order for the company to successfully implement it emerging market strategy it must attract and retain qualified personnel the company may also be required to increase it reliance on third party agent within le developed market in addition many of these country have currency that fluctuate substantially and if such currency devalue and the company can not offset the devaluation the company financial performance within such country could be adversely affected the company business in china ha grown rapidly in the past few year and the importance of china to the company overall pharmaceutical and vaccine business outside the united state ha increased accordingly continued growth of the company business in china is dependent upon ongoing development of favorable environment for innovative pharmaceutical product and vaccine sustained access for the company currently marketed product and the absence of trade impediment or adverse pricing control noted above in health care environment and government regulation pricing pressure in china ha increased the chinese government ha been taking step to reduce cost including implementing healthcare reform that ha led to the acceleration of generic of contentssubstitution where available while pricing pressure ha always existed in china health care reform ha increased this pressure in part due to the acceleration of generic substitution through the government vbp program in the government implemented the vbp program through tendering process for mature product which have generic substitute with generic quality consistency evaluation approval mature product that have entered into the first two round of vbp had on average price reduction of the expansion of the vbp program remains to be seen in addition the company anticipates that the reported inquiry made by various governmental authority involving multinational pharmaceutical company in china may continue also in december new coronavirus now known covid which ha proved to be highly contagious emerged in wuhan china the outbreak of the virus ha caused material disruption to the chinese economy including it health care system which will have negative effect on the company first quarter result which at this time is not expected to be material since the future course and duration of the covid outbreak are unknown the company is currently unable to determine whether the outbreak will have further negative effect on the company result in the outbreak of covid currently ha also had limited effect on the company supply chain of drug into and raw material of china the outbreak ha also negatively affected certain of the company clinical trial for all these reason sale within emerging market carry significant risk however failure to maintain the company presence in emerging market could have material adverse effect on the company business cash flow result of operation financial condition and prospect the company is exposed to market risk from fluctuation in currency exchange rate and interest rate the company operates in multiple jurisdiction and virtually all sale are denominated in currency of the local jurisdiction additionally the company ha entered and will enter into business development transaction borrowing or other financial transaction that may give rise to currency and interest rate exposure since the company can not with certainty foresee and mitigate against such adverse fluctuation fluctuation in currency exchange rate interest rate and inflation could negatively affect the company business cash flow result of operation financial condition and prospect in order to mitigate against the adverse impact of these market fluctuation the company will from time to time enter into hedging agreement while hedging agreement such currency option and forward and interest rate swap may limit some of the exposure to exchange rate and interest rate fluctuation such attempt to mitigate these risk may be costly and not always successful certain of the company interest rate derivative and investment are based on the london interbank offered rate libor and portion of merck indebtedness bear interest at variable interest rate primarily based on libor libor is the subject of recent national international and other regulatory guidance and proposal for reform which may cause libor to cease to exist entirely after while the company expects that reasonable alternative to libor will be implemented prior to the target date the company can not predict the consequence and timing of these development which could include an increase in interest expense and may also require the amendment of contract that reference libor the company is subject to evolving and complex tax law which may result in additional liability that may affect result of operation and financial condition the company is subject to evolving and complex tax law in the jurisdiction in which it operates significant judgment is required for determining the company tax liability and the company tax return are periodically examined by various tax authority the company belief that it accrual for tax contingency is adequate for all open year based on past experience interpretation of tax law and judgment about potential action by tax authority however due to the complexity of tax contingency the ultimate resolution of any tax matter may result in payment greater or le than amount accrued in addition the company may be negatively affected by change in tax law or new tax law affecting for example tax rate and or revised tax law interpretation in domestic or foreign jurisdiction of contentspharmaceutical product can develop unexpected safety or efficacy concern unexpected safety or efficacy concern can arise with respect to marketed product whether or not scientifically justified leading to product recall withdrawal or declining sale well product liability consumer fraud and or other claim including potential civil or criminal governmental action reliance on third party relationship and outsourcing arrangement could materially adversely affect the company business the company depends on third party including supplier alliance with other pharmaceutical and biotechnology company and third party service provider for key aspect of it business including development manufacture and commercialization of it product and support for it it system failure of these third party to meet their contractual regulatory and other obligation to the company or the development of factor that materially disrupt the relationship between the company and these third party could have material adverse effect on the company business negative event in the animal health industry could have material adverse effect on future result of operation and financial condition future sale of key animal health product could be adversely affected by number of risk factor including certain risk that are specific to the animal health business for example the outbreak of disease carried by animal such african swine fever could lead to their widespread death and precautionary destruction well the reduced consumption and demand for animal which could adversely affect the company result of operation also the outbreak of any highly contagious disease near the company main production site could require the company to immediately halt production of vaccine at such site or force the company to incur substantial expense in procuring raw material or vaccine elsewhere other risk specific to animal health include epidemic and pandemic government procurement and pricing practice weather and global agribusiness economic event the animal health segment of the company business becomes more significant the impact of any such event on future result of operation would also become more significant biologics and vaccine carry unique risk and uncertainty which could have material adverse effect on the company future result of operation and financial condition the successful development testing manufacturing and commercialization of biologics and vaccine particularly human and animal health vaccine is long complex expensive and uncertain process there are unique risk and uncertainty related to biologics and vaccine including there may be limited access to and supply of normal and diseased tissue sample cell line pathogen bacteria viral strain and other biological material in addition government regulation in multiple jurisdiction such the united state and the eu could result in restricted access to or transport or use of such material if the company loses access to sufficient source of such material or if tighter restriction are imposed on the use of such material the company may not be able to conduct research activity planned and may incur additional development cost the development manufacturing and marketing of biologics and vaccine are subject to regulation by the fda the ema and other regulatory body these regulation are often more complex and extensive than the regulation applicable to other pharmaceutical product for example in the united state bla including both pre clinical and clinical trial data and extensive data regarding the manufacturing procedure is required for human vaccine candidate and fda approval is generally required for the release of each manufactured commercial lot manufacturing biologics and vaccine especially in large quantity is often complex and may require the use of innovative technology to handle living micro organism each lot of an approved biologic and vaccine must undergo thorough testing for identity strength quality purity and potency manufacturing biologics requires facility specifically designed for and validated for this purpose and sophisticated quality assurance and quality control procedure are necessary slight deviation anywhere in the manufacturing process including filling labeling packaging storage and shipping and quality control and testing may result in lot failure product recall or spoilage when change are made to of contentsthe manufacturing process the company may be required to provide pre clinical and clinical data showing the comparable identity strength quality purity or potency of the product before and after such change biologics and vaccine are frequently costly to manufacture because production ingredient are derived from living animal or plant material and most biologics and vaccine can not be made synthetically in particular keeping up with the demand for vaccine may be difficult due to the complexity of producing vaccine the use of biologically derived ingredient can lead to variability in the manufacturing process and could lead to allegation of harm including infection or allergic reaction which allegation would be reviewed through standard investigation process that could lead to closure of product facility due to possible contamination any of these event could result in substantial cost product liability insurance for product may be limited cost prohibitive or unavailable result of number of factor product liability insurance ha become le available while the cost of such insurance ha increased significantly the company is subject to substantial number of product liability claim see item financial statement and supplementary data note contingency and environmental liability below for more information on the company current product liability litigation with respect to product liability the company self insures substantially all of it risk the availability of commercial insurance ha become more restrictive the company ha evaluated it risk and ha determined that the cost of obtaining product liability insurance outweighs the likely benefit of the coverage that is available and such ha no insurance for most product liability the company will continually ass the most efficient mean to address it risk however there can be no guarantee that insurance coverage will be obtained or if obtained will be sufficient to fully cover product liability that may arise social medium platform present risk and challenge the inappropriate and or unauthorized use of certain social medium channel could cause brand damage or information leakage or could lead to legal implication including from the improper collection and or dissemination of personally identifiable information in addition negative or inaccurate post or comment about the company or it product on any social networking platform could damage the company reputation brand image and goodwill further the disclosure of non public company sensitive information by the company workforce or others through external medium channel could lead to information loss although there is an internal company social medium policy that guide employee on appropriate personal and professional use of social medium about the company the process in place may not completely secure and protect information identifying new point of entry social medium continues to expand also present new challenge risk related to the proposed spin off of newco the proposed spin off of newco may not be completed on the term or timeline currently contemplated if at all and may not achieve the expected result in february the company announced it intention to spin off product from it woman health trusted legacy brand and biosimilars business into new yet to be named independent publicly traded company newco through distribution of newco publicly traded stock to company shareholder the distribution is expected to qualify tax free to the company and it shareholder for federal income tax purpose the transaction is expected to be completed in the first half of completion of the spin off will be subject to number of factor and condition and there can be no assurance that the company will be able to complete the spin off on the term or on the timeline that wa announced if at all unanticipated development could delay prevent or otherwise adversely affect the proposed spin off including but not limited to disruption in general or financial market condition or potential problem or delay in obtaining various regulatory and tax approval or clearance in addition consummation of the proposed spin off will require final approval from the company board of director of contentsthe cost to complete the proposed spin off will be significant in addition the company may be unable to achieve some or all of the strategic and financial benefit that it expects to achieve from the spin off of newco the company will incur significant expense in connection with the spin off in addition the company may not be able to achieve the full strategic and financial benefit that are expected to result from the spin off the anticipated benefit of the spin off are based on number of assumption some of which may prove incorrect following the spin off the price of share of the company common stock may fluctuate significantly the company can not predict the effect of the spin off on the trading price of share of it common stock and the market value of share of it common stock may be le than equal to or greater than the market value of share of it common stock prior to the spin off in addition the price of merck common stock may be more volatile around the time of the spin off there could be significant income tax liability if the spin off or certain related transaction are determined to be taxable for federal income tax purpose the company expects that prior to completion of the spin off it will receive an opinion from it tax counsel that concludes among other thing that the spin off of all of the outstanding newco share to merck shareholder and certain related transaction will qualify tax free to merck and it shareholder under section and of the internal revenue code except to the extent of any cash received in lieu of fractional share of newco common stock any such opinion is not binding on the internal revenue service irs accordingly while the company belief the risk is low the irs may reach conclusion with respect to the spin off that are different from the conclusion reached in the opinion the opinion will rely on certain fact assumption representation and undertaking from merck and newco regarding the past and future conduct of the company respective business and other matter which if incomplete incorrect or not satisfied could alter the conclusion of the party giving such opinion if the proposed spin off ultimately is determined to be taxable which the company belief is unlikely the spin off could be treated taxable dividend to merck shareholder for federal income tax purpose and merck shareholder could incur significant federal income tax liability in addition merck would recognize taxable gain to the extent that the fair market value of newco common stock exceeds merck tax basis in such stock on the date of the spin off cautionary factor that may affect future result cautionary statement under the private security litigation reform act of this report and other written report and oral statement made from time to time by the company may contain so called forward looking statement all of which are based on management current expectation and are subject to risk and uncertainty which may cause result to differ materially from those set forth in the statement one can identify these forward looking statement by their use of word such anticipates expects plan will estimate forecast project and other word of similar meaning or negative variation of any of the foregoing one can also identify them by the fact that they do not relate strictly to historical or current fact these statement are likely to address the company growth strategy financial result product development product approval product potential and development program one must carefully consider any such statement and should understand that many factor could cause actual result to differ materially from the company forward looking statement these factor include inaccurate assumption and broad variety of other risk and uncertainty including some that are known and some that are not no forward looking statement can be guaranteed and actual future result may vary materially the company doe not assume the obligation to update any forward looking statement the company caution you not to place undue reliance on these forward looking statement although it is not possible to predict or identify all such factor they may include the following competition from generic and or biosimilar product the company product lose patent protection increased brand competition in therapeutic area important to the company long term business performance of content the difficulty and uncertainty inherent in new product development the outcome of the lengthy and complex process of new product development is inherently uncertain drug candidate can fail at any stage of the process and one or more late stage product candidate could fail to receive regulatory approval new product candidate may appear promising in development but fail to reach the market because of efficacy or safety concern the inability to obtain necessary regulatory approval the difficulty or excessive cost to manufacture and or the infringement of patent or intellectual property right of others furthermore the sale of new product may prove to be disappointing and fail to reach anticipated level pricing pressure both in the united state and abroad including rule and practice of managed care group judicial decision and governmental law and regulation related to medicare medicaid and health care reform pharmaceutical reimbursement and pricing in general change in government law and regulation including law governing intellectual property and the enforcement thereof affecting the company business efficacy or safety concern with respect to marketed product whether or not scientifically justified leading to product recall withdrawal or declining sale significant change in customer relationship or change in the behavior and spending pattern of purchaser of health care product and service including delaying medical procedure rationing prescription medication reducing the frequency of physician visit and foregoing health care insurance coverage legal factor including product liability claim antitrust litigation and governmental investigation including tax dispute environmental concern and patent dispute with branded and generic competitor any of which could preclude commercialization of product or negatively affect the profitability of existing product cyber attack on the company or third party provider information technology system which could disrupt the company operation lost market opportunity resulting from delay and uncertainty in the approval process of the fda and foreign regulatory authority increased focus on privacy issue in country around the world including the united state and the eu the legislative and regulatory landscape for privacy and data protection continues to evolve and there ha been an increasing amount of focus on privacy and data protection issue with the potential to affect directly the company business including recently enacted law in majority of state in the united state requiring security breach notification change in tax law including change related to the taxation of foreign earnings change in accounting pronouncement promulgated by standard setting or regulatory body including the financial accounting standard board and the sec that are adverse to the company economic factor over which the company ha no control including change in inflation interest rate and foreign currency exchange rate the proposed spin off might be delayed or the cost to complete the spin off might be more significant than expected this list should not be considered an exhaustive statement of all potential risk and uncertainty see risk factor above item unresolved staff comment none item property the company corporate headquarters is located in kenilworth new jersey the company also maintains operational or divisional headquarters in kenilworth new jersey madison new jersey and upper gwynedd pennsylvania principal research facility are located in rahway and kenilworth new jersey west point pennsylvania palo alto california boston massachusetts south san francisco california and elkhorn nebraska animal health principal research facility outside the united state are located in the united kingdom switzerland of contentsand china merck manufacturing operation are headquartered in whitehouse station new jersey the company also ha production facility for human health product at nine location in the united state and puerto rico outside the united state through subsidiary the company owns or ha an interest in manufacturing plant or other property in japan singapore south africa and other country in western europe central and south america and asia capital expenditure were billion in billion in and billion in in the united state these amounted to billion in billion in and billion in abroad such expenditure amounted to billion in billion in and million in the company and it subsidiary own their principal facility and manufacturing plant under title that they consider to be satisfactory the company belief that it property are in good operating condition and that it machinery and equipment have been well maintained the company belief that it plant for the manufacture of product are suitable for their intended purpose and have capacity and projected capacity including previously disclosed capital expansion project that will be adequate for current and projected need for existing company product some capacity of the plant is being converted with any needed modification to the requirement of newly introduced and future product item legal proceeding the information called for by this item is incorporated herein by reference to item financial statement and supplementary data note contingency and environmental liability item mine safety disclosure not applicable of contentsexecutive officer of the registrant age of february all officer listed below serve at the pleasure of the board of director none of these officer wa elected pursuant to any arrangement or understanding between the officer and any other person nameageoffices and business experiencekenneth president and chief executive officer since december sanat vice president and president merck manufacturing division since march senior vice president operation merck manufacturing division november march frank vice president chief commercial officer since january president global oncology business unit october december robert vice president global service and chief financial officer since april executive vice president and chief financial officer april april richard deluca jr vice president and president merck animal health since september michael vice president chief ethic and compliance officer since march senior vice president international legal and compliance january march vice president international legal and compliance july january julie vice president and chief patient officer strategic communication global public policy and population health since july executive vice president for strategic communication global public policy and population health january july rita vice president finance global controller since march steven vice president chief human resource officer since october executive vice president chief human resource officer december october and executive vice president human resource monsanto company august december michael vice president chief marketing officer since january president global vaccine global human health september january managing director united kingdom and ireland global human health january september roger perlmutter ph vice president and president merck research laboratory since april jennifer vice president general counsel and corporate secretary since january executive vice president and general counsel april january partner covington burling llp january march of contentspart ii item market for registrant common equity related stockholder matter and issuer purchase of equity security the principal market for trading of the company common stock is the new york stock exchange nyse under the symbol mrk of january there were approximately shareholder of record of the company common stock issuer purchase of equity security for the three month ended december were follows issuer purchase of equity security in million period total numberof sharespurchased average pricepaid pershare approximate dollar value of sharesthat may yet be purchasedunder the plan or program october october november december all share purchased during the period were made part of plan approved by the board of director in october to purchase up to billion in merck share for it treasury of contentsperformance graphthe following graph assumes investment on december and reinvestment of all dividend in each of the company common share the index and composite peer group of major and european based pharmaceutical company which are abbvie inc amgen inc astrazeneca plc bristol myers squibb company johnson johnson eli lilly and company glaxosmithkline plc novartis ag pfizer inc roche holding ag and sanofi sa comparison of five year cumulative total return merck co inc composite peer group and index end ofperiod value merck peer grp grp compound annual growth rate peer group average wa calculated on market cap weighted basis this performance graph will not be deemed to be incorporated by reference into any filing under the security act of or the security exchange act of except to the extent that the company specifically incorporates it by reference in addition the performance graph will not be deemed to be soliciting material or to be filed with the sec or subject to regulation or other than provided in regulation or to the liability of section of the security exchange act of except to the extent that the company specifically request that such information be treated soliciting material or specifically incorporates it by reference into filing under the security act or the exchange act of contentsitem selected financial data the following selected financial data should be read in conjunction with item management discussion and analysis of financial condition and result of operation and consolidated financial statement and note thereto contained in item financial statement and supplementary data of this report merck co inc and subsidiary in million except per share amount result for year sale of general and and income expense before on net loss income attributable to noncontrolling interest income attributable to merck co inc earnings per common share attributable to merck co inc common shareholder per common share assuming dilution attributable to merck co inc common shareholder dividend dividend declared per common share common share outstanding million common share outstanding assuming dilution million end position working capital plant and equipment term end statistic number of stockholder of of amount for include charge for the acquisition of peloton therapeutic inc amount for include charge related to the formation of collaboration with eisai co ltd amount for include provisional net tax charge related to the enactment of tax legislation and charge related to the formation of collaboration with astrazeneca plc amount for include charge related to the settlement of worldwide patent litigation related to keytruda amount for include net charge related to the settlement of vioxx shareholder class action litigation foreign exchange loss related to venezuela gain on the disposition of business and other asset and the favorable benefit of certain tax item of contentsitem management discussion and analysis of financial condition and result of operation the following section of this form generally discus and result and year to year comparison between and discussion of result and year to year comparison between and that are not included in this form can be found in management discussion and analysis of financial condition and result of operation in part ii item of the company annual report on form for the fiscal year ended december filed on february description of merck businessmerck co inc merck or the company is global health care company that delivers innovative health solution through it prescription medicine vaccine biologic therapy and animal health product the company operation are principally managed on product basis and include four operating segment which are the pharmaceutical animal health healthcare service and alliance segment the pharmaceutical and animal health segment are the only reportable segment the pharmaceutical segment includes human health pharmaceutical and vaccine product human health pharmaceutical product consist of therapeutic and preventive agent generally sold by prescription for the treatment of human disorder the company sell these human health pharmaceutical product primarily to drug wholesaler and retailer hospital government agency and managed health care provider such health maintenance organization pharmacy benefit manager and other institution human health vaccine product consist of preventive pediatric adolescent and adult vaccine primarily administered at physician office the company sell these human health vaccine primarily to physician wholesaler physician distributor and government entity the animal health segment discovers develops manufacture and market wide range of veterinary pharmaceutical and vaccine product well health management solution and service for the prevention treatment and control of disease in all major livestock and companion animal specie the company also offer an extensive suite of digitally connected identification traceability and monitoring product the company sell it product to veterinarian distributor and animal producer the healthcare service segment provides service and solution that focus on engagement health analytics and clinical service to improve the value of care delivered to patient the company ha recently sold certain business in the healthcare service segment and is in the process of divesting the remaining business while the company continues to look for investment opportunity in this area of health care the approach to these investment ha shifted toward venture capital investment in third party opposed to wholly owned business the alliance segment primarily includes activity from the company relationship with astrazeneca lp related to sale of nexium and prilosec which concluded in planned spin off of woman health legacy brand and biosimilars into new company in february merck announced it intention to spin off product from it woman health trusted legacy brand and biosimilars business into new yet to be named independent publicly traded company newco through distribution of newco publicly traded stock to company shareholder the distribution is expected to qualify tax free to the company and it shareholder for federal income tax purpose the legacy brand included in the transaction consist of dermatology pain respiratory and select cardiovascular product including zetia and vytorin well the rest of merck diversified brand franchise merck existing research pipeline program will continue to be owned and developed within merck planned newco will have development capability initially focused on late stage development and life cycle management and is expected over time to develop research capability in selected therapeutic area the spin off is expected to be completed in the first half of subject to market and certain other condition overviewmerck performance during demonstrates execution in both commercial and research operation driven by focus on key growth driver and innovative pipeline investment reinforcing the company science led strategy in merck enhanced it portfolio and pipeline with external innovation increased investment in new capital project focused primarily on expanding manufacturing capacity across merck key business and returned capital to shareholder of contentsworldwide sale were billion in an increase of compared with including unfavorable effect from foreign exchange the sale increase wa driven primarily by merck growth pillar of oncology human health vaccine certain hospital acute care product and animal health growth in these area wa partially offset by the ongoing effect of generic competition particularly in the diversified brand and cardiovascular franchise well by competitive pressure particularly in the diabetes and virology franchise merck continued to prioritize business development aimed at enhancing it portfolio and strengthening it pipeline by executing several business development transaction in to expand it oncology presence merck completed the acquisition of peloton therapeutic inc peloton clinical stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidate for the treatment of cancer and other disease and immune design late stage immunotherapy company employing next generation in vivo approach to enable the body immune system to fight disease merck also announced an agreement to acquire arqule inc arqule biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of cancer and other disease the acquisition closed in january to augment merck animal health business the company acquired antelliq group antelliq leader in digital animal identification traceability and monitoring solution during the company received numerous regulatory approval and progressed many important pipeline candidate through clinical development within oncology keytruda received multiple additional approval in the united state european union eu china and japan monotherapy in the therapeutic area of non small cell lung cancer nsclc small cell lung cancer sclc esophageal cancer and in combination with axitinib for the treatment of renal cell carcinoma rcc in combination with chemotherapy for head and neck squamous cell carcinoma hnscc and in combination with lenvima for endometrial carcinoma lynparza which is being developed in collaboration with astrazeneca plc astrazeneca received food and drug administration fda approval for the treatment of appropriate patient with germline brca mutated gbrcam pancreatic cancer and european commission ec approval for use in certain patient with advanced ovarian cancer and advanced or metastatic breast cancer in addition to oncology the company received regulatory approval in the hospital acute care and vaccine therapeutic area the fda approved recarbrio imipenem cilastatin and relebactam for injection new combination antibacterial for the treatment of certain patient with complicated urinary tract infection caused by certain gram negative microorganism recarbrio wa approved by the ec in february the fda and ec also approved expanded indication for zerbaxa for the treatment of patient with hospital acquired bacterial pneumonia and ventilator associated bacterial pneumonia habp vabp caused by certain susceptible gram negative microorganism additionally ervebo ebola zaire vaccine live vaccine for the prevention of disease caused by zaire ebolavirus in adult wa approved in the united state and received conditional approval in the eu in addition to the recent regulatory approval discussed above the company advanced it late stage pipeline particularly in oncology with several regulatory submission for keytruda lynparza and lenvima in the united state and internationally the company phase oncology program include keytruda in the therapeutic area of biliary tract breast cervical colorectal cutaneous squamous cell endometrial esophageal gastric hepatocellular mesothelioma nasopharyngeal ovarian prostate and small cell lung cancer lynparza in combination with keytruda for non small cell lung cancer and lenvima in combination with keytruda for bladder endometrial head and neck melanoma and non small cell lung cancer additionally the company ha candidate in phase clinical development in several other therapeutic area including an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease that received breakthrough therapy designation from the fda for the prevention of invasive pneumococcal disease caused by the vaccine serotypes in pediatric patient week to year of age and in adult mk gefapixant selective non narcotic orally administered receptor antagonist being developed for the treatment of refractory chronic cough mk islatravir an investigational nucleoside reverse transcriptase translocation inhibitor nrtti in combination with doravirine for the treatment of hiv infection and mk vericiguat an investigational treatment for heart failure being developed in collaboration see research and development below the company is allocating resource to effectively support it commercial opportunity in the near term while making the necessary investment to support long term growth research and development expense in reflect higher clinical development spending and increased investment in discovery research and early drug development of contentsin november merck board of director approved an increase to the company quarterly dividend raising it to per share from per share on the company outstanding common stock during the company returned billion to shareholder through dividend and share repurchase earnings per common share assuming dilution attributable to common shareholder eps for were compared with in eps in both year reflects the impact of acquisition and divestiture related cost well restructuring cost and certain other item certain other item in include charge related to the acquisition of peloton and in include charge related to the formation of collaboration with eisai co ltd eisai non gaap eps which excludes these item wa in and in see non gaap income and non gaap eps below pricingglobal effort toward health care cost containment continue to exert pressure on product pricing and market access worldwide change to the health care system part of health care reform well increased purchasing power of entity that negotiate on behalf of medicare medicaid and private sector beneficiary have contributed to pricing pressure in several international market government mandated pricing action have reduced price of generic and patented drug in addition the company revenue performance in wa negatively affected by other cost reduction measure taken by government and other third party to lower health care cost the company anticipates all of these action and additional action in the future will continue to negatively affect revenue performance operating resultssales in million change change excludingexchange change change excludingexchange state plus international may not equal total due to rounding worldwide sale grew in driven primarily by higher sale in the oncology franchise reflecting strong growth of keytruda well increased alliance revenue related to lynparza and lenvima also contributing to revenue growth were higher sale of vaccine including gardasil gardasil varivax proquad and ii well increased sale of certain hospital acute care product including bridion higher sale of animal health product also drove revenue growth in sale growth in wa partially offset by the effect of generic competition for cardiovascular product zetia and vytorin hospital acute care product invanz cubicin and noxafil oncology product emend and product within the diversified brand franchise well biosimilar competition for immunology product remicade the diversified brand franchise includes certain product that are approaching the expiration of their marketing exclusivity or that are no longer protected by patent in developed market lower sale of diabetes product januvia and janumet and hiv product isentress isentress hd also partially offset revenue growth in sale in the united state grew in driven primarily by higher sale of keytruda combined sale of proquad ii and varivax and bridion well higher alliance revenue from lenvima and lynparza revenue growth wa partially offset by lower sale of januvia janumet invanz emend isentress isentress hd cubicin and noxafil international sale grew in performance in international market wa led by china which had total sale of billion in representing growth of compared with including unfavorable effect from foreign exchange the increase in international sale primarily reflects growth in keytruda gardasil gardasil combined sale of proquad ii and varivax well higher alliance revenue from lynparza and lenvima sale growth wa partially offset by lower sale of zetia vytorin zepatier remicade and product within the diversified brand franchise international sale represented of total sale in both and see note to the consolidated financial statement for detail on sale of the company product discussion of performance for select product in the franchise follows of contentspharmaceutical segmentoncology in million change change excludingexchange change change excludingexchange revenue lynparza revenue lenvima calculation not meaningful alliance revenue represents merck share of profit which are product sale net of cost of sale and commercialization cost see note to the consolidated financial statement keytruda is an anti pd therapy that ha been approved for the treatment of multiple malignancy including cervical cancer classical hodgkin lymphoma chl esophageal cancer gastric or gastroesophageal junction adenocarcinoma hnscc hepatocellular carcinoma hcc nsclc sclc melanoma merkel cell carcinoma microsatellite instability high msi or mismatch repair deficient cancer primary mediastinal large cell lymphoma pmbcl rcc and urothelial carcinoma the keytruda clinical development program includes study across broad range of cancer type see research and development below in january the fda approved keytruda monotherapy for the treatment of certain patient with bacillus calmette guerin bcg unresponsive high risk non muscle invasive bladder cancer nmibc based on the result of the keynote trial in july the fda approved keytruda monotherapy for the treatment of certain patient with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumor express pd combined positive score cps determined by an fda approved test based on the result of the keynote and keynote trial in june the fda approved keytruda monotherapy or in combination with chemotherapy for the first line treatment of patient with metastatic or unresectable recurrent hnscc based on result from the pivotal phase keynote trial keytruda wa initially approved for hnscc under the fda accelerated approval process based on data from the phase keynote trial in accordance with the accelerated approval process continued approval wa contingent upon verification and description of clinical benefit which ha now been demonstrated in keynote and ha resulted in the fda converting the accelerated approval to full regular approval keytruda wa approved for these indication by the ec in november and by japan ministry of health labour and welfare mhlw in december also in june the fda approved keytruda monotherapy for the treatment of certain patient with metastatic sclc based on pooled data from the keynote cohort and keynote cohort clinical trial in april the fda approved keytruda in combination with inlyta axitinib tyrosine kinase inhibitor for the first line treatment of patient with advanced rcc the most common type of kidney cancer based on finding from the pivotal phase keynote trial keytruda wa approved for this indication by the ec in september and by japan mhlw in december also in april the fda approved an expanded label for keytruda monotherapy for the first line treatment of patient with nsclc expressing pd tumor proportion score tps determined by an fda approved test with no egfr or alk genomic tumor aberration in stage iii disease where patient are not candidate for surgical resection or definitive chemoradiation and in metastatic disease the approval wa based on result from the phase keynote trial in september the fda approved the combination of keytruda plus lenvima for the treatment of certain patient with advanced endometrial carcinoma that is not msi or mismatch repair deficient of contentsin march the ec approved keytruda in combination with carboplatin and either paclitaxel or nab paclitaxel for the first line treatment of adult with metastatic squamous nsclc based on data from the phase keynote trial keytruda wa approved for this indication by the fda in october in april the ec approved new extended dosing schedule of mg every six week delivered an intravenous infusion over minute for all approved monotherapy indication in the eu the dose is available in addition to the formerly approved dose of keytruda mg every three week infused over minute additionally in keytruda received the following approval from china national medical product administration nmpa in combination with pemetrexed and platinum chemotherapy for the first line treatment of patient with metastatic nonsquamous nsclc with no egfr or alk genomic tumor aberration based on data from the pivotal phase keynote trial monotherapy for the first line treatment of patient with locally advanced or metastatic nsclc whose tumor express pd determined by nmpa approved test with no egfr or alk genomic tumor aberration based on the result from the phase keynote trial and in combination with carboplatin and paclitaxel for the first line treatment of patient with metastatic squamous nsclc based on finding from the pivotal phase keynote trial global sale of keytruda grew in driven by higher demand the company continues to launch keytruda with multiple new indication globally sale in the united state continue to build across the multiple approved indication in particular for the treatment of nsclc monotherapy and in combination with chemotherapy for both nonsquamous and squamous metastatic nsclc along with uptake in the recently launched rcc and adjuvant melanoma indication other indication contributing to sale growth include hnscc urothelial carcinoma melanoma and msi cancer keytruda sale growth in international market wa driven primarily by performance in europe japan and china reflecting increased use in the treatment of nsclc well for the more recently approved indication described above the company is party to certain third party license agreement pursuant to which the company pay royalty on sale of keytruda under the term of the more significant of these agreement merck pay royalty of on worldwide sale of keytruda through to one third party this royalty will decline to for through and will terminate thereafter the company pay an additional royalty on worldwide sale of keytruda to another third party the termination date of which varies by country this royalty will expire in the united state in and in major european market in the royalty are included in cost of sale pursuant to re pricing rule the japanese government reduced the price of keytruda by effective february additionally keytruda will be subject to another significant price reduction in april under provision of the japanese pricing rule lynparza an oral poly adp ribose polymerase parp inhibitor being developed part of collaboration with astrazeneca entered into in july see note to the consolidated financial statement is approved for the treatment of certain type of advanced ovarian breast and pancreatic cancer the increase in alliance revenue related to lynparza in wa driven primarily by expanded use in the united state the eu japan and china reflecting in part the ongoing launch of new indication lynparza received approval for the treatment of certain type of advanced ovarian cancer in the united state in december in the eu and in japan in june and in china in december based on the result of the phase solo trial also in april the ec approved lynparza for the treatment of certain adult patient with advanced breast cancer based on the result of the phase olympiad trial additionally in december the fda approved lynparza for the maintenance treatment of certain adult patient with advanced pancreatic cancer based on the result of the phase polo trial lenvima an oral receptor tyrosine kinase inhibitor being developed part of collaboration with eisai entered into in march see note to the consolidated financial statement is approved for the treatment of certain type of thyroid cancer hcc and in combination with evorolimus for certain patient with rcc additionally in september the fda approved the combination of keytruda plus lenvima for the treatment of certain patient with advanced endometrial carcinoma that is not msi or mismatch repair deficient this mark the first approval for the combination of keytruda plus lenvima the increase in alliance revenue related to lenvima in reflects strong performance in the treatment of hcc following recent worldwide launch well full year of collaboration activity in of contentsglobal sale of emend for the prevention of chemotherapy induced and post operative nausea and vomiting declined in driven primarily by lower demand and pricing in the united state due to competition including recent generic competition for emend for injection following patent expiry in september the patent that provided market exclusivity for emend expired in and the patent that provided market exclusivity in most major european market expired in may additionally emend for injection will lose market exclusivity in major european market in august the company anticipates that sale of emend for injection in these market will decline significantly thereafter vaccine in million change change excludingexchange change change excludingexchange gardasil sale of gardasil gardasil vaccine to help prevent certain cancer and other disease caused by certain type of hpv grew in driven primarily by higher demand in the asia pacific region particularly in china and higher demand in certain european market reflecting increased vaccination rate for both boy and girl growth wa partially offset by lower sale in the united state the sale decline wa driven by the borrowing of gardasil dos from the center for disease and control prevention cdc pediatric vaccine stockpile offset in part by higher demand and pricing in the company borrowed dos of gardasil from the cdc pediatric vaccine stockpile the borrowing reduced sale in by approximately million and the company recognized corresponding liability during the company replenished dos borrowed from the cdc pediatric vaccine stockpile in resulting in the recognition of sale of million in and reversal of the liability related to that borrowing the decision of japan mhlw to suspend the active recommendation for hpv vaccination is still under review the company is party to certain third party license agreement pursuant to which the company pay royalty on sale of gardasil gardasil under the term of the more significant of these agreement merck pay royalty on worldwide sale of gardasil gardasil to one third party this agreement expires in december and an additional royalty on sale of gardasil gardasil in the united state to another third party this agreement expires in december the royalty are included in cost of sale global sale of proquad pediatric combination vaccine to help protect against measles mumps rubella and varicella grew in driven primarily by higher volume and pricing in the united state well volume growth in the eu largely reflecting competitor supply issue worldwide sale of ii vaccine to help protect against measles mumps and rubella grew in driven primarily by higher sale in the united sates reflecting increased demand due to measles outbreak well higher pricing the company anticipates that sale of ii will decline in driven by lower expected demand related to fewer measles outbreak global sale of varivax vaccine to help prevent chickenpox varicella grew in driven primarily by government tender in latin america well higher pricing and volume growth in the united state varivax sale are expected to decline in due in part to the timing of government tender and competition in select latin american market global sale of rotateq vaccine to help protect against rotavirus gastroenteritis in infant and child grew in driven primarily by continued uptake from the launch in china and higher volume in the united state partially offset by lower volume in latin america of contentsin december the fda approved ervebo for the prevention of disease caused by zaire ebolavirus in individual year of age and older previously announced merck is working to initiate manufacturing of licensed dos and expects these dos to start becoming available in approximately the third quarter of merck is working closely with the government the world health organization who unicef and gavi the vaccine alliance to plan for how eventual licensed dos will support future public health preparedness and response effort against zaire ebolavirus disease merck is not seeking to profit from sale of this vaccine rather to ensure the vaccine is sustainable by recovering manufacturing and operational cost associated with the program ervebo wa also granted conditional marking authorization by the ec additionally merck ha made submission to african country national regulatory authority in collaboration with the african vaccine regulatory forum that will allow the vaccine to be registered in african country considered to be at risk for ebola outbreak by the who in february merck confirmed that four african country have approved ervebo approval in additional country in africa are anticipated in the near future hospital acute care in million change change excludingexchange change change excludingexchange sale of bridion for the reversal of two type of neuromuscular blocking agent used during surgery grew in driven by higher demand globally particularly in the united state worldwide sale of noxafil for the prevention of invasive fungal infection declined in driven primarily by generic competition in the united state the patent that provided market exclusivity for certain form of noxafil representing the majority of noxafil sale expired in july accordingly the company is experiencing decline in noxafil sale result of generic competition and expects the decline to continue additionally the patent for noxafil expired in number of major european market in december result the company anticipates sale of noxafil in these market will decline significantly in future period global sale of invanz for the treatment of certain infection declined in driven by generic competition in the united state the patent that provided market exclusivity for invanz expired in november and generic competition began in the second half of the company subsequently experienced significant decline in invanz sale in the united state result of this generic competition and ha since lost most of it invanz sale global sale of cubicin an antibiotic for complicated skin and skin structure infection or bacteremia when caused by designated susceptible organism declined in resulting primarily from ongoing generic competition in the united state following expiration of the composition patent for cubicin in in the fda and ec approved expanded indication for zerbaxa for the treatment of habp vabp caused by certain susceptible gram negative microorganism based on the result of the pivotal phase aspect np trial zerbaxa wa previously approved in the united state and eu for the treatment of adult with certain complicated urinary tract and intra abdominal infection in july the fda approved recarbrio for injection new combination antibacterial for the treatment of adult who have limited or no alternative treatment option with complicated urinary tract infection and complicated intra abdominal infection caused by certain susceptible gram negative microorganism recarbrio wa approved by the ec in february merck anticipates making recarbrio available in the first half of in january the fda approved dificid fidaxomicin for oral suspension and dificid tablet for the treatment of clostridioides formerly clostridium difficile associated diarrhea in child aged six month and older of contentsimmunology in million change change excludingexchange change change excludingexchange of simponi once monthly subcutaneous treatment for certain inflammatory disease marketed by the company in europe russia and turkey declined in driven by the unfavorable effect of foreign exchange and lower pricing in europe sale of simponi are being unfavorably affected by the launch of biosimilars for competing product the company expects this competition will continue to unfavorably affect sale of simponi sale of remicade treatment for inflammatory disease marketed by the company in europe russia and turkey declined in driven by ongoing biosimilar competition in the company marketing territory the company lost market exclusivity for remicade in major european market in and no longer ha market exclusivity in any of it marketing territory the company is experiencing pricing and volume decline in these market result of biosimilar competition and expects the decline to continue virology in million change change excludingexchange change change excludingexchange isentress hd sale of isentress isentress hd an hiv integrase inhibitor for use in combination with other antiretroviral agent for the treatment of hiv infection declined in primarily reflecting lower demand in the united state and in the eu due to competitive pressure in september the fda approved supplemental new drug application nda for pifeltro doravirine in combination with other antiretroviral agent and for delstrigo doravirine lamivudine tenofovir disoproxil fumarate complete regimen that expand their indication to include adult patient with hiv infection who are virologically suppressed on stable antiretroviral regimen cardiovascular in million change change excludingexchange change change excludingexchange vytorin global sale of zetia marketed in most country outside the united state ezetrol and vytorin marketed outside the united state inegy medicine for lowering ldl cholesterol declined in driven primarily by lower sale in the eu the eu patent for ezetrol and inegy expired in april and april respectively accordingly the company is experiencing sale decline in these market result of generic competition and expects the decline to continue the sale decline wa also attributable to loss of exclusivity in australia merck lost market exclusivity in the united state for zetia in and vytorin in and subsequently lost nearly all sale of these product result of generic competition sale of atozet marketed outside of the united state medicine for lowering ldl cholesterol grew in primarily driven by higher demand in the eu and in korea sale of rosuzet marketed outside of the united state medicine for lowering ldl cholesterol more than doubled in primarily driven by the launch in japan well higher demand in korea of contentsadempas cardiovascular drug for the treatment of pulmonary arterial hypertension is part of worldwide clinical development collaboration with bayer ag bayer to market and develop soluble guanylate cyclase sgc modulators including adempas see note to the consolidated financial statement the increase in alliance revenue of in wa driven both by higher profit from bayer and higher sale of adempas in merck marketing territory diabetes in million change change excludingexchange change change excludingexchange janumet combined sale of januvia and janumet medicine that help lower blood sugar level in adult with type diabetes declined in result of continued pricing pressure in the united state partially offset by higher demand in most international market the company expects pricing pressure to continue the patent that provide market exclusivity for januvia and janumet in the united state expire in july although six month pediatric exclusivity may extend this date the patent that provides market exclusivity for januvia in the eu expires in july although pediatric exclusivity may extend this date to september the supplementary patent certificate that provides market exclusivity for janumet in the eu expires in april the company anticipates sale of januvia and janumet in these market will decline substantially after these patent expiry woman health in million change change excludingexchange change change excludingexchange sale of nuvaring vaginal contraceptive product declined in driven primarily by lower demand in the eu due to generic competition largely offset by higher sale in the united state reflecting higher pricing that wa partially offset by lower demand the patent that provided market exclusivity for nuvaring expired in april and generic competition began in december the company anticipates rapid and substantial decline in nuvaring sale in result of this generic competition worldwide sale of implanon nexplanon single rod subdermal contraceptive implant grew in primarily driven by higher demand and pricing in the united state biosimilars in million change change excludingexchange change change excludingexchange calculation not meaningful biosimilar product are marketed by the company pursuant to an agreement with samsung bioepis co ltd samsung to develop and commercialize multiple pre specified biosimilar candidate currently the company market renflexis infliximab abda tumor necrosis factor tnf antagonist biosimilar to remicade infliximab for the treatment of certain inflammatory disease ontruzant trastuzumab dttb human epidermal growth factor receptor neu receptor antagonist biosimilar to herceptin trastuzumab for the treatment of positive breast cancer and overexpressing gastric cancer and brenzys etanercept biosimilar tnf antagonist biosimilar to enbrel for the treatment of certain inflammatory disease merck commercialization territory under the agreement vary by product sale growth of biosimilars in wa driven by continued uptake of renflexis in united state since launch in continued uptake of ontruzant in the eu since launch in and the launch of brenzys in brazil in of contentsanimal health segment in million change change excludingexchange change change excludingexchange of livestock product grew in predominantly due to product obtained in the april acquisition of antelliq leader in digital animal identification traceability and monitoring solution see note to the consolidated financial statement growth in sale of livestock product wa also driven by higher demand for aqua and swine product sale of companion animal product grew in driven primarily by higher demand for the bravecto line of product for parasitic control cost expense and other in million change change of sale general and and income expense greater than cost of salescost of sale wa billion in compared with billion in cost of sale includes the amortization of intangible asset recorded in connection with business acquisition which totaled billion in compared with billion in cost of sale also includes the amortization of amount capitalized in connection with collaboration of million in compared with million in see note to the consolidated financial statement additionally cost in include intangible asset impairment charge of million related to marketed product recorded in connection with business acquisition see note to the consolidated financial statement the company may recognize additional non cash impairment charge in the future related to intangible asset that were measured at fair value and capitalized in connection with business acquisition and such charge could be material cost in include million charge related to the termination of collaboration agreement with samsung for insulin glargine see note to the consolidated financial statement also included in cost of sale are expense associated with restructuring activity which amounted to million in compared with million in primarily reflecting accelerated depreciation and asset write offs related to the planned sale or closure of manufacturing facility separation cost associated with manufacturing related headcount reduction have been incurred and are reflected in restructuring cost discussed below gross margin wa in compared with in the gross margin improvement in reflects the charge recorded in in connection with the termination of the collaboration agreement with samsung noted above favorable product mix and lower amortization of intangible asset noted above these improvement in gross margin were partially offset by unfavorable manufacturing variance inventory write offs pricing pressure and higher restructuring cost selling general and administrativeselling general and administrative sg expense were billion in an increase of compared with driven primarily by higher administrative cost acquisition and divestiture related cost largely related to the acquisition of antelliq promotional expense primarily in support of strategic brand and restructuring cost partially offset by the favorable effect of foreign exchange and lower selling cost sg expense in include restructuring cost of million related primarily to accelerated depreciation for facility to be closed or divested separation cost associated with sale force reduction have been incurred and are reflected in restructuring cost discussed below sg expense include acquisition and divestiture related cost of million in compared of contentswith million in consisting of integration transaction and certain other cost related to business acquisition and divestiture research and developmentresearch and development expense were billion in an increase of compared with the increase wa driven primarily by million charge in for the acquisition of peloton see note to the consolidated financial statement well higher expense related to clinical development and increased investment in discovery research and early drug development the increase in expense in wa partially offset by billion charge in related to the formation of an oncology collaboration with eisai see note to the consolidated financial statement million charge in related to the acquisition of viralytics limited viralytics see note to the consolidated financial statement and the favorable effect of foreign exchange expense are comprised of the cost directly incurred by merck research laboratory mrl the company research and development division that focus on human health related activity which were billion in compared with billion in also included in expense are animal health research cost licensing cost and cost incurred by other division in support of activity including depreciation production and general and administrative which in the aggregate were billion in and billion in expense also include in process research and development ipr impairment charge of million and million in and respectively see note to the consolidated financial statement the company may recognize additional non cash impairment charge in the future related to the cancellation or delay of other pipeline program that were measured at fair value and capitalized in connection with business acquisition and such charge could be material in addition expense include expense or income related to change in the estimated fair value measurement of liability for contingent consideration recorded in connection with business acquisition during and the company recorded net reduction in expense of million and million respectively related to change in these estimate restructuring costsin early merck approved new global restructuring program restructuring program part of worldwide initiative focused on further optimizing the company manufacturing and supply network well reducing it global real estate footprint this program is continuation of the company plant rationalization build on prior restructuring program and doe not include any action associated with the planned spin off of newco the company continues to evaluate it global footprint and overall operating model it ha subsequently identified additional action under the restructuring program and could identify further action over time the action currently contemplated under the restructuring program are expected to be substantially completed by the end of with the cumulative pretax cost to be incurred by the company to implement the program now estimated to be approximately billion the company expects to record charge of approximately million in related to the restructuring program the company anticipates the action under the restructuring program to result in annual net cost saving of approximately million by the end of action under previous global restructuring program have been substantially completed restructuring cost primarily representing separation and other related cost associated with these restructuring activity were million in and million in separation cost incurred were associated with actual headcount reduction well estimated expense under existing severance program for headcount reduction that were probable and could be reasonably estimated also included in restructuring cost are asset abandonment facility shut and other related cost well employee related cost such curtailment settlement and termination charge associated with pension and other postretirement benefit plan and share based compensation plan cost for segment reporting restructuring cost are unallocated expense additional cost associated with the company restructuring activity are included in cost of sale selling general and administrative and research and development the company recorded aggregate pretax cost of million in and million in related to restructuring program activity see note to the consolidated financial statement of contentsother income expense netfor detail on the component of other income expense net see note to the consolidated financial statement segment profit in million segment profit health segment non reportable segment profit income before tax segment profit are comprised of segment sale le standard cost well sg expense directly incurred by the segment animal health segment profit are comprised of segment sale le all cost of sale well sg and expense directly incurred by the segment for internal management reporting presented to the chief operating decision maker merck doe not allocate the remaining cost of sale not included in segment profit described above research and development expense incurred by mrl or general and administrative expense the cost of financing these activity separate division maintain responsibility for monitoring and managing these cost including depreciation related to fixed asset utilized by these division and therefore they are not included in segment profit also excluded from the determination of segment profit are cost related to restructuring activity and acquisition and divestiture related cost including amortization of purchase accounting adjustment intangible asset impairment charge and change in the estimated fair value measurement of liability for contingent consideration additionally segment profit do not reflect other expense from corporate and manufacturing cost center and other miscellaneous income or expense these unallocated item are reflected in other in the above table also included in other are miscellaneous corporate profit loss well operating profit loss related to third party manufacturing sale during result of change to the company internal reporting structure certain cost that were previously included in the pharmaceutical segment are now being included part of non segment expense within mrl prior period pharmaceutical segment profit have been recast to reflect these change on comparable basis pharmaceutical segment profit grew in compared with driven primarily by higher sale well lower selling cost animal health segment profit declined in driven primarily by unfavorable product mix higher investment in selling and product development and the unfavorable effect of foreign exchange partially offset by higher sale tax on incomethe effective income tax rate of in and in reflect the impact of acquisition and divestiture related cost restructuring cost and the beneficial impact of foreign earnings including product mix the effective income tax rate in also reflects the favorable impact of million net tax benefit related to the settlement of certain federal income tax matter see note to the consolidated financial statement and the reversal of tax reserve established in connection with the divestiture of merck consumer care mcc business due to the lapse in the statute of limitation in addition the effective income tax rate in reflects the unfavorable impact of charge for the acquisition of peloton for which no tax benefit wa recognized and charge of million related to the finalization of treasury regulation for the transition tax associated with the enactment of tax legislation known the tax cut and job act tcja see note to the consolidated financial statement the effective income tax rate in includes measurement period adjustment to the provisional amount recorded in associated with the enactment of the tcja including million related to the transition tax in addition the effective income tax rate for reflects the unfavorable impact of charge recorded in connection with the formation of collaboration with eisai and charge related to the termination of collaboration agreement with samsung for which no tax benefit wa recognized of contentsnet loss income attributable to noncontrolling interestsnet loss income attributable to noncontrolling interest wa million in compared with million in the loss in and were driven primarily by the portion of goodwill impairment charge related to certain business in the healthcare service segment that are attributable to noncontrolling interest net income and earnings per common sharenet income attributable to merck co inc wa billion in and billion in eps wa in and in non gaap income and non gaap epsnon gaap income and non gaap eps are alternative view of the company performance that merck is providing because management belief this information enhances investor understanding of the company result it permit investor to understand how management ass performance non gaap income and non gaap eps exclude certain item because of the nature of these item and the impact that they have on the analysis of underlying business performance and trend the excluded item which should not be considered non recurring consist of acquisition and divestiture related cost restructuring cost and certain other item these excluded item are significant component in understanding and assessing financial performance non gaap income and non gaap eps are important internal measure for the company senior management receives monthly analysis of operating result that includes non gaap eps management us these measure internally for planning and forecasting purpose and to measure the performance of the company along with other metric in addition senior management annual compensation is derived in part using non gaap pretax income since non gaap income and non gaap eps are not measure determined in accordance with gaap they have no standardized meaning prescribed by gaap and therefore may not be comparable to the calculation of similar measure of other company the information on non gaap income and non gaap eps should be considered in addition to but not substitute for or superior to net income and eps prepared in accordance with generally accepted accounting principle in the united state gaap of contentsa reconciliation between gaap financial measure and non gaap financial measure is follows in million except per share amount before tax reported under gaap decrease for excluded item acquisition and divestiture related item charge for the acquisition of charge related to the formation of an oncology collaboration with eisai charge related to the termination of collaboration with samsung charge for the acquisition of viralytics charge related to the formation of an oncology collaboration with astrazeneca non gaap income before on income reported under tax benefit on excluded item tax charge related to the enactment of the tcja and subsequent finalization of related treasury regulation net tax benefit from the settlement of certain federal income tax benefit from the reversal of tax reserve related to the divestiture of tax benefit related to the settlement of state income tax matter gaap tax on gaap net net loss income attributable to noncontrolling interest reported under gaap and divestiture related cost attributable to noncontrolling interest non gaap net income attributable to noncontrolling gaap net income attributable to merck co inc assuming dilution reported under gaap gaap eps assuming dilution the estimated tax impact on the excluded item is determined by applying the statutory rate of the originating territory of the non gaap adjustment amount in wa provisional see note to the consolidated financial statement acquisition and divestiture related costsnon gaap income and non gaap eps exclude the impact of certain amount recorded in connection with business acquisition and divestiture these amount include the amortization of intangible asset and amortization of purchase accounting adjustment to inventory well intangible asset impairment charge and expense or income related to change in the estimated fair value measurement of liability for contingent consideration also excluded are integration transaction and certain other cost associated with business acquisition and divestiture restructuring costsnon gaap income and non gaap eps exclude cost related to restructuring action see note to the consolidated financial statement these amount include employee separation cost and accelerated depreciation associated with facility to be closed or divested accelerated depreciation cost represent the difference between the depreciation expense to be recognized over the revised useful life of the asset based upon the anticipated date the site of contentswill be closed or divested or the equipment disposed of and depreciation expense determined utilizing the useful life prior to the restructuring action restructuring cost also include asset abandonment facility shut down and other related cost well employee related cost such curtailment settlement and termination charge associated with pension and other postretirement benefit plan and share based compensation cost certain other itemsthese item are adjusted for after they are evaluated on an individual basis considering their quantitative and qualitative aspect typically these consist of item that are unusual in nature significant to the result of particular period or not indicative of future operating result excluded from non gaap income and non gaap eps in is charge for the acquisition of peloton see note to the consolidated financial statement tax charge related to the finalization of treasury regulation related to the tcja net tax benefit related to the settlement of certain federal income tax matter and tax benefit related to the reversal of tax reserve established in connection with the divestiture of mcc see note to the consolidated financial statement excluded from non gaap income and non gaap eps in is charge related to the formation of collaboration with eisai see note to the consolidated financial statement charge related to the termination of collaboration agreement with samsung for insulin glargine see note to the consolidated financial statement charge for the acquisition of viralytics see note to the consolidated financial statement and measurement period adjustment related to the provisional amount recorded for the tcja see note to the consolidated financial statement excluded from non gaap income and non gaap eps in is charge related to the formation of collaboration with astrazeneca see note to the consolidated financial statement well provisional net tax charge related to the enactment of the tcja net tax benefit related to the settlement of certain federal income tax matter and tax benefit related to the settlement of state income tax matter see note to the consolidated financial statement research and developmenta chart reflecting the company current research pipeline of february is set forth in item business research and development above research and development updatethe company currently ha several candidate under regulatory review in the united state and internationally keytruda is an anti pd therapy approved for the treatment of many cancer that is in clinical development for expanded indication these approval were the result of broad clinical development program that currently consists of more than clinical trial including more than trial that combine keytruda with other cancer treatment these study encompass more than cancer type including biliary tract cervical colorectal cutaneous squamous cell endometrial gastric head and neck hepatocellular hodgkin lymphoma non hodgkin lymphoma melanoma mesothelioma nasopharyngeal non small cell lung ovarian pmbcl prostate renal small cell lung triple negative breast and urothelial many of which are currently in phase clinical development further trial are being planned for other cancer keytruda is under review in the eu monotherapy for the first line treatment of patient with stage iii nsclc who are not candidate for surgical resection or definitive chemoradiation or metastatic nsclc and whose tumor express pd tps with no egfr or alk genomic tumor aberration based on result from the phase keynote trial keytruda is under review in japan monotherapy and in combination with chemotherapy for the first line treatment of advanced gastric or gastroesophageal junction adenocarcinoma based on result from the pivotal phase keynote trial keytruda is also under review in japan monotherapy for the second line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma based on the result of the phase keynote trial merck ha made the decision to withdraw it type ii variation application for keytruda for this indication in the eu in october the fda accepted supplemental biologics license application bla seeking use of keytruda for the treatment of patient with recurrent and or metastatic cutaneous squamous cell carcinoma cscc that of contentsis not curable by surgery or radiation based on the result of the keynote trial the fda set prescription drug user fee act pdufa date of june in february merck announced the fda issued complete response letter regarding merck supplemental blas seeking to update the dosing frequency for keytruda to include mg dose infused over minute every six week option in multiple indication the submitted application are based on pharmacokinetic modeling and simulation data presented at the american society of clinical oncology asco annual meeting these data supported the ec approval of mg dosing for keytruda monotherapy indication in march merck is reviewing the letter and will discus next step with the fda additionally keytruda ha received breakthrough therapy designation from the fda in combination with neoadjuvant chemotherapy for the treatment of high risk early stage triple negative breast cancer tnbc and in combination with enfortumab vedotin in the first line setting for the treatment of patient with unresectable locally advanced or metastatic urothelial cancer who are not eligible for cisplatin containing chemotherapy the fda breakthrough therapy designation is intended to expedite the development and review of candidate that is planned for use alone or in combination to treat serious or life threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapy on one or more clinically significant endpoint in september merck announced result from the pivotal neoadjuvant adjuvant phase keynote trial in patient with early stage tnbc the trial investigated regimen of neoadjuvant keytruda plus chemotherapy followed by adjuvant keytruda monotherapy the keytruda regimen compared with regimen of neoadjuvant chemotherapy followed by adjuvant placebo the chemotherapy placebo regimen interim finding were presented at the european society for medical oncology esmo congress in the neoadjuvant phase keytruda plus chemotherapy resulted in statistically significant increase in pathological complete response pcr versus chemotherapy in patient with early stage tnbc the improvement seen when adding keytruda to neoadjuvant chemotherapy wa observed regardless of pd expression in the other dual primary endpoint of event free survival efs with median follow up of month the keytruda regimen reduced the risk of progression in the neoadjuvant phase and recurrence in the adjuvant phase compared with the chemotherapy placebo regimen merck continues to discus interim analysis data from keynote with regulatory authority the keytruda breast cancer clinical development program encompasses several internal and external collaborative study in february merck announced that the pivotal phase keynote trial investigating keytruda in combination with chemotherapy met one of it dual primary endpoint of progression free survival pfs in patient with metastatic triple negative breast cancer mtnbc whose tumor expressed pd cps based on an interim analysis conducted by an independent data monitoring committee dmc first line treatment with keytruda in combination with chemotherapy nab paclitaxel paclitaxel or gemcitabine carboplatin demonstrated statistically significant and clinically meaningful improvement in pfs compared to chemotherapy alone in these patient based on the recommendation of the dmc the trial will continue without change to evaluate the other dual primary endpoint of overall survival in may merck announced that the phase keynote trial evaluating keytruda monotherapy for the second or third line treatment of patient with metastatic tnbc did not meet it pre specified primary endpoint of superior compared to chemotherapy other endpoint were not formally tested per the study protocol because the primary endpoint of wa not met in june merck announced full result from the pivotal phase keynote trial evaluating keytruda monotherapy and in combination with chemotherapy for the first line treatment of advanced gastric or gastroesophageal junction adenocarcinoma in the monotherapy arm of the study keytruda met primary endpoint by demonstrating noninferiority to chemotherapy the current standard of care for in patient whose tumor expressed pd cps in the combination arm of keynote keytruda plus chemotherapy wa not found to be statistically superior for cps or cps or pfs cps compared with chemotherapy alone result were presented at the asco annual meeting in september the fda approved keytruda third line treatment for previously treated patient with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer whose tumor express pd cps determined by an fda approved test keynote wa potential confirmatory trial for this accelerated third line approval in addition to keynote additional first line phase of study in merck gastric clinical program include keynote and keynote well keynote in the neoadjuvant and adjuvant treatment setting in january merck announced that the phase keynote trial investigating keytruda in combination with chemotherapy met one of it dual primary endpoint of pfs in the first line treatment of patient with extensive stage sclc at the final analysis of the study there wa also an improvement in for patient treated with keytruda in combination with chemotherapy compared to chemotherapy alone however these result did not meet statistical significance per the pre specified statistical plan result will be presented at an upcoming medical meeting and discussed with regulatory authority lynparza is an oral parp inhibitor currently approved for certain type of advanced ovarian breast and pancreatic cancer being co developed for multiple cancer type part of collaboration with astrazeneca see note to the consolidated financial statement lynparza is under review in the eu first line maintenance monotherapy for patient with gbrcam metastatic pancreatic cancer whose disease ha not progressed following first line platinum based chemotherapy lynparza wa approved for this indication by the fda in december based on result from the phase polo trial decision from the european medicine agency ema is expected in the second half of in january the fda accepted supplemental nda for lynparza in combination with bevacizumab for the maintenance treatment of woman with advanced ovarian cancer whose disease showed complete or partial response to first line treatment with platinum based chemotherapy and bevacizumab based on the result from the pivotal phase paola trial pdufa date is set for the second quarter of this indication is also under review in the eu in january the fda accepted for priority review supplemental nda for lynparza for the treatment of patient with metastatic castration resistant prostate cancer mcrpc and deleterious or suspected deleterious germline or somatic homologous recombination repair hrr gene mutation who have progressed following prior treatment with new hormonal agent based on positive result from the phase profound trial pdufa date is set for the second quarter of this indication is also under review in the eu in june merck and astrazeneca presented full result from the phase solo trial which evaluated lynparza compared to chemotherapy for the treatment of platinum sensitive relapsed patient with gbrcam advanced ovarian cancer who have received two or more prior line of chemotherapy the result from the trial showed statistically significant and clinically meaningful improvement in objective response rate orr in the lynparza arm compared to the chemotherapy arm the key secondary endpoint of pfs wa also significantly increased in the lynparza arm compared to the chemotherapy arm the result were presented at the asco annual meeting mk selumetinib is mek inhibitor being co developed part of strategic collaboration with astrazeneca see note to the consolidated financial statement selumetinib is under priority review with the fda potential new medicine for pediatric patient aged three year and older with neurofibromatosis type and symptomatic inoperable plexiform neurofibroma this regulatory submission wa based on positive result from the national cancer institute cancer therapy evaluation program sponsored sprint phase stratum trial pdufa date is set for the second quarter of is under review in japan for an initial indication in female for the prevention of certain hpv related disease and precursor in february the fda accepted for priority review supplemental bla for gardasil for the prevention of certain head and neck cancer caused by vaccine type hpv in female and male through year of age the fda set pdufa date of june in addition to the candidate under regulatory review the company ha several drug candidate in phase clinical development in addition to the keytruda program discussed above lynparza in addition to the indication under review discussed above is in phase development in combination with keytruda for the treatment of nsclc lenvima is an orally available tyrosine kinase inhibitor currently approved for certain type of thyroid cancer hcc and in combination for certain patient with rcc being co developed part of strategic collaboration with eisai see note to the consolidated financial statement pursuant to the agreement the company will jointly of contentsinitiate clinical study evaluating the keytruda lenvima combination in six type of cancer endometrial cancer nsclc hcc hnscc bladder cancer and melanoma well basket trial targeting multiple cancer type the fda granted breakthrough therapy designation for keytruda in combination with lenvima both for the potential treatment of patient with advanced and or metastatic rcc and for the potential treatment of patient with unresectable hcc not amenable to locoregional treatment mk gefapixant is selective non narcotic orally administered receptor antagonist being investigated in phase trial for the treatment of refractory chronic cough and in phase trial for the treatment of woman with endometriosis related pain mk vericiguat is sgc stimulator for the potential treatment of patient with worsening chronic heart failure being developed part of worldwide strategic collaboration between merck and bayer see note to the consolidated financial statement vericiguat is being studied in patient suffering from chronic heart failure with reduced ejection fraction phase clinical trial and from chronic heart failure with preserved ejection fraction phase clinical trial in november merck announced that the phase victoria study evaluating the efficacy and safety of vericiguat met the primary efficacy endpoint vericiguat reduced the risk of the composite endpoint of heart failure hospitalization or cardiovascular death in patient with worsening chronic heart failure with reduced ejection fraction compared to placebo when given in combination with available heart failure therapy the result of the victoria study will be presented at an upcoming medical meeting in is an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease in june merck initiated the first phase study in the adult population for the prevention of invasive pneumococcal disease currently six phase adult study are ongoing including study in healthy adult year of age or older adult with risk factor for pneumococcal disease those infected with hiv and those who are recipient of allogeneic hematopoietic stem cell transplant in october merck began the first phase study in the pediatric population currently eight study are ongoing including study in healthy infant and in child afflicted with sickle cell disease ha received breakthrough therapy designation from the fda for the prevention of invasive pneumococcal disease caused by the vaccine serotypes in pediatric patient week to year of age and in adult the company maintains number of long term exploratory and fundamental research program in biology and chemistry well research program directed toward product development the company research and development model is designed to increase productivity and improve the probability of success by prioritizing the company research and development resource on candidate the company belief are capable of providing unambiguous promotable advantage to patient and payer and delivering the maximum value of it approved medicine and vaccine through new indication and new formulation merck is pursuing emerging product opportunity independent of therapeutic area or modality small molecule biologics and vaccine and is building it biologics capability the company is committed to ensuring that externally sourced program remain an important component of it pipeline strategy with focus on supplementing it internal research with licensing and external alliance strategy focused on the entire spectrum of collaboration from early research to late stage compound well access to new technology the company clinical pipeline includes candidate in multiple disease area including cancer cardiovascular disease diabetes and other metabolic disease infectious disease neuroscience pain respiratory disease and vaccine acquired in process research and developmentin connection with business acquisition the company ha recorded the fair value of in process research project which at the time of acquisition had not yet reached technological feasibility at december the balance of ipr wa billion the ipr project that remain in development are subject to the inherent risk and uncertainty in drug development and it is possible that the company will not be able to successfully develop and complete the ipr program and profitably commercialize the underlying product candidate the time period to receive approval from the fda and other regulatory agency are subject to uncertainty significant delay in the approval process or the company failure to obtain approval at all would delay or prevent the company from realizing revenue from these product additionally if certain of the ipr program fail or are abandoned during development then the company will not realize the future cash flow it ha estimated and recorded ipr of the acquisition date if such of contentscircumstances were to occur the company future operating result could be adversely affected and the company may recognize impairment charge and such charge could be material in and the company recorded ipr impairment charge within research and development expense of million million and million respectively see note to the consolidated financial statement additional research and development will be required before any of the remaining program reach technological feasibility the cost to complete the research project will depend on whether the project are brought to their final stage of development and are ultimately submitted to the fda or other regulatory agency for approval acquisition research collaboration and license agreementsmerck continues to remain focused on pursuing opportunity that have the potential to drive both near and long term growth certain recent transaction are described below merck is actively monitoring the landscape for growth opportunity that meet the company strategic criterion in april merck acquired immune design late stage immunotherapy company employing next generation in vivo approach to enable the body immune system to fight disease for million in cash the transaction wa accounted for an acquisition of business merck recognized intangible asset for ipr of million cash of million and other net asset of million the excess of the consideration transferred over the fair value of net asset acquired of million wa recorded goodwill that wa allocated to the pharmaceutical segment and is not deductible for tax purpose the fair value of the identifiable intangible asset related to ipr were determined using an income approach actual cash flow are likely to be different than those assumed in july merck acquired peloton clinical stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidate targeting hypoxia inducible factor hif for the treatment of patient with cancer and other non oncology disease peloton lead candidate mk formerly is novel oral hif inhibitor in late stage development for renal cell carcinoma merck made an upfront payment of billion in cash additionally former peloton shareholder will be eligible to receive million upon regulatory approval million upon first commercial sale in the united state and up to billion of sale based milestone the transaction wa accounted for an acquisition of an asset merck recorded cash of million deferred tax liability of million and other net liability of million at the acquisition date and research and development expense of million in related to the transaction in january merck acquired arqule inc arqule publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patient with cancer and other disease for billion arqule lead investigational candidate mk formerly arq is novel oral bruton tyrosine kinase btk inhibitor currently in phase dose expansion study for the treatment of cell malignancy the company is in the process of determining the preliminary fair value of asset acquired liability assumed and total consideration transferred in this transaction which will be accounted for an acquisition of business capital expenditurescapital expenditure were billion in billion in and billion in expenditure in the united state were billion in billion in and billion in the increased capital expenditure in reflect investment in new capital project focused primarily on increasing manufacturing capacity for merck key product previously announced the company plan to invest more than billion in new capital project from depreciation expense wa billion in billion in and billion in of which billion in billion in and billion in related to location in the united state total depreciation expense in and included accelerated depreciation of million and million respectively associated with restructuring activity see note to the consolidated financial statement analysis of liquidity and capital resourcesmerck strong financial profile enables it to fund research and development focus on external alliance support in line product and maximize upcoming launch while providing significant cash return to shareholder of contentsselected data in million capital debt to total liability and cash provided by operation to total provided by operating activity wa billion in compared with billion in reflecting stronger operating performance and increased account receivable factoring discussed below cash provided by operating activity continues to be the company primary source of fund to finance operating need capital expenditure treasury stock purchase and dividend paid to shareholder cash used in investing activity wa billion in compared with cash provided by investing activity of billion in the change wa driven primarily by lower proceeds from the sale of security and other investment the acquisition of antelliq and peloton in and higher capital expenditure partially offset by lower purchase of security and other investment cash used in financing activity wa billion in compared with billion in the lower use of cash in financing activity wa driven primarily by proceeds from the issuance of debt and lower purchase of treasury stock reflecting the accelerated share repurchase asr program in discussed below well lower payment on debt partially offset by the repayment of short term borrowing higher dividend paid to shareholder and lower proceeds from the exercise of stock option the company ha account receivable factoring agreement with financial institution in certain country to sell account receivable see note to the consolidated financial statement the company factored billion and billion of account receivable in the fourth quarter of and respectively under these factoring arrangement which reduced outstanding account receivable the cash received from the financial institution is reported within operating activity in the consolidated statement of cash flow in certain of these factoring arrangement for ease of administration the company will collect customer payment related to the factored receivables which it then remit to the financial institution at december the company had collected million on behalf of the financial institution which wa remitted to them in january the net cash flow from these collection are reported financing activity in the consolidated statement of cash flow the company contractual obligation of december are follows payment due by period in million total thereafterpurchase obligation payable and current portion of long term long term related to debt tax benefit transition tax related to the enactment of the tcja payment related to collaboration lease includes future inventory purchase the company ha committed to in connection with certain divestiture of december the company consolidated balance sheet reflects liability for unrecognized tax benefit interest and penalty of billion including million reflected current liability due to the high degree of uncertainty regarding the timing of future cash outflow of liability for unrecognized tax benefit beyond one year reasonable estimate of the period of cash settlement for year beyond can not be made in connection with the enactment of the tcja the company is required to pay one time transition tax which the company ha elected to pay over period of eight year through permitted under the tcja see note to the consolidated financial statement reflects payment under collaborative agreement for sale based milestone that were achieved in and therefore deemed to be contractual obligation but not paid until january see note to the consolidated financial statement amount exclude reasonably certain lease renewal that have not yet been executed see note to the consolidated financial statement of contentspurchase obligation are enforceable and legally binding obligation for purchase of good and service including minimum inventory contract research and development and advertising amount do not include contingent milestone payment related to collaborative arrangement or acquisition they are not considered contractual obligation until the successful achievement of developmental regulatory approval or commercial milestone at december the company ha recognized liability for contingent sale based milestone payment related to collaboration with astrazeneca eisai and bayer where payment remains subject to the achievement of the related sale milestone aggregating billion see note to the consolidated financial statement excluded from research and development obligation are potential future funding commitment of up to approximately million for investment in research venture capital fund loan payable and current portion of long term debt reflects million of long dated note that are subject to repayment at the option of the holder required funding obligation for relating to the company pension and other postretirement benefit plan are not expected to be material however the company currently anticipates contributing approximately million to it pension plan million to it international pension plan and million to it other postretirement benefit plan during in march the company issued billion principal amount of senior unsecured note consisting of million of note due billion of note due billion of note due and billion of note due the company used the net proceeds from the offering of billion for general corporate purpose including the repayment of outstanding commercial paper borrowing in december the company exercised make whole provision on it billion note due and repaid this debt in november the company launched tender offer for certain outstanding note and debenture the company paid million in aggregate consideration applicable purchase price together with accrued interest to redeem million principal amount of debt that wa validly tendered in connection with the tender offer the company ha billion credit facility that matures in june the facility provides backup liquidity for the company commercial paper borrowing facility and is to be used for general corporate purpose the company ha not drawn funding from this facility in march the company filed security registration statement with the security and exchange commission sec under the automatic shelf registration process available to well known seasoned issuer which is effective for three year effective of november the company executed full and unconditional guarantee of the then existing debt of it subsidiary merck sharp dohme corp msd and msd executed full and unconditional guarantee of the then existing debt of the company excluding commercial paper including for payment of principal and interest these guarantee do not extend to debt issued subsequent to that date the company continues to maintain conservative financial profile the company place it cash and investment in instrument that meet high credit quality standard specified in it investment policy guideline these guideline also limit the amount of credit exposure to any one issuer the company doe not participate in any off balance sheet arrangement involving unconsolidated subsidiary that provide financing or potentially expose the company to unrecorded financial obligation in november merck board of director declared quarterly dividend of per share on the company outstanding common stock that wa paid in january in january the board of director declared quarterly dividend of per share on the company common stock for the second quarter of payable in april in october merck board of director authorized purchase of up to billion of merck common stock for it treasury the treasury stock purchase authorization ha no time limit and will be made over time in open market transaction block transaction on or off an exchange or in privately negotiated transaction the company spent billion to purchase million share of it common stock for it treasury during in addition the company received million share in settlement of asr agreement discussed below of december the company remaining share repurchase authorization wa billion the company purchased billion and billion of it common stock during and respectively under authorized share repurchase program of contentson october the company entered into asr agreement with two third party financial institution dealer under the asr agreement merck agreed to purchase billion of merck common stock in total with an initial delivery of million share of merck common stock based on the then current market price made by the dealer to merck and payment of billion made by merck to the dealer on october which were funded with existing cash and investment well short term borrowing upon settlement of the asr agreement in april merck received an additional million share determined by the average daily volume weighted average price of merck common stock during the term of the asr program le negotiated discount bringing the total share received by merck under this program to million financial instrument market risk disclosuresthe company manages the impact of foreign exchange rate movement and interest rate movement on it earnings cash flow and fair value of asset and liability through operational mean and through the use of various financial instrument including derivative instrument significant portion of the company revenue and earnings in foreign affiliate is exposed to change in foreign exchange rate the objective of the company foreign currency risk management program well it interest rate risk management activity are discussed below foreign currency risk managementthe company ha established revenue hedging balance sheet risk management and net investment hedging program to protect against volatility of future foreign currency cash flow and change in fair value caused by change in foreign exchange rate the objective of the revenue hedging program is to reduce the variability caused by change in foreign exchange rate that would affect the dollar value of future cash flow derived from foreign currency denominated sale primarily the euro japanese yen and chinese renminbi to achieve this objective the company will hedge portion of it forecasted foreign currency denominated third party and intercompany distributor entity sale forecasted sale that are expected to occur over it planning cycle typically no more than two year into the future the company will layer in hedge over time increasing the portion of forecasted sale hedged it get closer to the expected date of the forecasted sale the portion of forecasted sale hedged is based on assessment of cost benefit profile that consider natural offsetting exposure revenue and exchange rate volatility and correlation and the cost of hedging instrument the company manages it anticipated transaction exposure principally with purchased local currency put option forward contract and purchased collar option because merck principally sell foreign currency in it revenue hedging program uniform weakening of the dollar would yield the largest overall potential loss in the market value of these hedge instrument the market value of merck hedge would have declined by an estimated million and million at december and respectively from uniform weakening of the dollar the market value wa determined using foreign exchange option pricing model and holding all factor except exchange rate constant although not predictive in nature the company belief that threshold reflects reasonably possible near term change in merck major foreign currency exposure relative to the dollar the cash flow from these contract are reported operating activity in the consolidated statement of cash flow the company manages operating activity and net asset position at each local subsidiary in order to mitigate the effect of exchange on monetary asset and liability the company also us balance sheet risk management program to mitigate the exposure of net monetary asset that are denominated in currency other than subsidiary functional currency from the effect of volatility in foreign exchange in these instance merck principally utilizes forward exchange contract to offset the effect of exchange on exposure denominated in developed country currency primarily the euro and japanese yen for exposure in developing country currency the company will enter into forward contract to partially offset the effect of exchange on exposure when it is deemed economical to do so based on cost benefit analysis that considers the magnitude of the exposure the volatility of the exchange rate and the cost of the hedging instrument the cash flow from these contract are reported operating activity in the consolidated statement of cash flow sensitivity analysis to change in the value of the dollar on foreign currency denominated derivative investment and monetary asset and liability indicated that if the dollar uniformly weakened by against of contentsall currency exposure of the company at december and income before tax would have declined by approximately million and million in and respectively because the company wa in net short payable position relative to it major foreign currency after consideration of forward contract uniform weakening of the dollar will yield the largest overall potential net loss in earnings due to exchange this measurement assumes that change in one foreign currency relative to the dollar would not affect other foreign currency relative to the dollar although not predictive in nature the company belief that threshold reflects reasonably possible near term change in merck major foreign currency exposure relative to the dollar the cash flow from these contract are reported operating activity in the consolidated statement of cash flow the economy of argentina wa determined to be hyperinflationary in consequently in accordance with gaap the company began remeasuring it monetary asset and liability for those operation in earnings the impact to the company result wa immaterial the company also us forward exchange contract to hedge portion of it net investment in foreign operation against movement in exchange rate the forward contract are designated hedge of the net investment in foreign operation the unrealized gain or loss on these contract are recorded in foreign currency translation adjustment within other comprehensive income loss oci and remain in accumulated other comprehensive income loss aoci until either the sale or complete or substantially complete liquidation of the subsidiary the company excludes certain portion of the change in fair value of it derivative instrument from the assessment of hedge effectiveness excluded component change in fair value of the excluded component are recognized in oci the company recognizes in earnings the initial value of the excluded component on straight line basis over the life of the derivative instrument rather than using the mark to market approach the cash flow from these contract are reported investing activity in the consolidated statement of cash flow foreign exchange risk is also managed through the use of foreign currency debt the company senior unsecured euro denominated note have been designated and are effective economic hedge of the net investment in foreign operation accordingly foreign currency transaction gain or loss due to spot rate fluctuation on the euro denominated debt instrument are included in foreign currency translation adjustment within oci interest rate risk managementthe company may use interest rate swap contract on certain investing and borrowing transaction to manage it net exposure to interest rate change and to reduce it overall cost of borrowing the company doe not use leveraged swap and in general doe not leverage any of it investment activity that would put principal capital at risk at december the company wa party to pay floating receive fixed interest rate swap contract designated fair value hedge of fixed rate note in which the notional amount match the amount of the hedged fixed rate note detailed in the table below in million instrumentpar value of debt number of interest rate swap held total swap notional note due note due note due note due interest rate swap contract are designated hedge of the fair value change in the note attributable to change in the benchmark london interbank offered rate libor swap rate the fair value change in the note attributable to change in the libor swap rate are recorded in interest expense along with the offsetting fair value change in the swap contract the cash flow from these contract are reported operating activity in the consolidated statement of cash flow the company investment portfolio includes cash equivalent and short term investment the market value of which are not significantly affected by change in interest rate the market value of the company medium to long term fixed rate investment is modestly affected by change in interest rate change in medium to long term interest rate have more significant impact on the market value of the company fixed rate borrowing which generally have longer maturity sensitivity analysis to measure potential change in the market value of of contentsmerck investment and debt from change in interest rate indicated that one percentage point increase in interest rate at december and would have positively affected the net aggregate market value of these instrument by billion and billion respectively one percentage point decrease at december and would have negatively affected the net aggregate market value by billion and billion respectively the fair value of merck debt wa determined using pricing model reflecting one percentage point shift in the appropriate yield curve the fair value of merck investment were determined using combination of pricing and duration model critical accounting policiesthe company consolidated financial statement are prepared in conformity with gaap and accordingly include certain amount that are based on management best estimate and judgment estimate are used when accounting for amount recorded in connection with acquisition including initial fair value determination of asset and liability primarily ipr other intangible asset and contingent consideration well subsequent fair value measurement additionally estimate are used in determining such item provision for sale discount and return depreciable and amortizable life recoverability of inventory including those produced in preparation for product launch amount recorded for contingency environmental liability accrual for contingent sale based milestone payment and other reserve pension and other postretirement benefit plan assumption share based compensation assumption restructuring cost impairment of long lived asset including intangible asset and goodwill and investment and tax on income because of the uncertainty inherent in such estimate actual result may differ from these estimate application of the following accounting policy result in accounting estimate having the potential for the most significant impact on the financial statement acquisition and dispositionsto determine whether transaction should be accounted for acquisition or disposal of asset or business the company make certain judgment which include assessment of the input process and output associated with the acquired set of activity if the company determines that substantially all of the fair value of gross asset included in transaction is concentrated in single asset or group of similar asset the asset would not represent business to be considered business the asset in transaction need to include an input and substantive process that together significantly contribute to the ability to create output in business combination the acquisition method of accounting requires that the asset acquired and liability assumed be recorded of the date of the acquisition at their respective fair value with limited exception asset acquired and liability assumed in business combination that arise from contingency are generally recognized at fair value if fair value can not be determined the asset or liability is recognized if probable and reasonably estimable if these criterion are not met no asset or liability is recognized fair value is defined the exchange price that would be received for an asset or paid to transfer liability an exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between market participant on the measurement date accordingly the company may be required to value asset at fair value measure that do not reflect the company intended use of those asset any excess of the purchase price consideration transferred over the estimated fair value of net asset acquired is recorded goodwill transaction cost and cost to restructure the acquired company are expensed incurred the operating result of the acquired business are reflected in the company consolidated financial statement after the date of the acquisition the fair value of intangible asset including acquired ipr are determined utilizing information available near the acquisition date based on expectation and assumption that are deemed reasonable by management given the considerable judgment involved in determining fair value the company typically obtains assistance from third party valuation specialist for significant item amount allocated to acquired ipr are capitalized and accounted for indefinite lived intangible asset subject to impairment testing until completion or abandonment of the project upon successful completion of each project merck will make determination to the then useful life of the intangible asset generally determined by the period in which the substantial majority of the cash flow are expected to be generated and begin amortization certain of the company business acquisition involve the potential for future payment of consideration that is contingent upon the achievement of performance milestone including product development milestone and royalty payment on future product sale the fair value of contingent consideration liability is determined at the acquisition date using unobservable input these input include the estimated amount and timing of projected cash flow the probability of success achievement of the contingent event and the risk adjusted discount rate used to present value the probability weighted cash flow subsequent to the acquisition date at each reporting period until the contingency is resolved the contingent consideration liability is of contentsremeasured at current fair value with change either expense or income recorded in earnings change in any of the input may result in significantly different fair value adjustment the judgment made in determining estimated fair value assigned to asset acquired and liability assumed in business combination well asset life can materially affect the company result of operation the fair value of identifiable intangible asset related to currently marketed product and product right are primarily determined by using an income approach through which fair value is estimated based on each asset discounted projected net cash flow the company estimate of market participant net cash flow consider historical and projected pricing margin and expense level the performance of competing product where applicable relevant industry and therapeutic area growth driver and factor current and expected trend in technology and product life cycle the time and investment that will be required to develop product and technology the ability to obtain marketing and regulatory approval the ability to manufacture and commercialize the product the extent and timing of potential new product introduction by the company competitor and the life of each asset underlying patent if any the net cash flow are then probability adjusted where appropriate to consider the uncertainty associated with the underlying assumption well the risk profile of the net cash flow utilized in the valuation the probability adjusted future net cash flow of each product are then discounted to present value utilizing an appropriate discount rate the fair value of identifiable intangible asset related to ipr are also determined using an income approach through which fair value is estimated based on each asset probability adjusted future net cash flow which reflect the different stage of development of each product and the associated probability of successful completion the net cash flow are then discounted to present value using an appropriate discount rate if the company determines the transaction will not be accounted for an acquisition of business the transaction will be accounted for an asset acquisition rather than business combination and therefore no goodwill will be recorded in an asset acquisition acquired ipr with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date in these instance product development milestone are recognized upon achievement and sale based milestone are recognized when the milestone is deemed probable by the company of being achieved revenue recognitionrecognition of revenue requires evidence of contract probable collection of sale proceeds and completion of substantially all performance obligation merck act the principal in substantially all of it customer arrangement and therefore record revenue on gross basis the majority of the company contract related to the pharmaceutical and animal health segment have single performance obligation the promise to transfer good shipping is considered immaterial in the context of the overall customer arrangement and damage or loss of good in transit are rare therefore shipping is not deemed separately recognized performance obligation the vast majority of revenue from sale of product are recognized at point in time when control of the good is transferred to the customer which the company ha determined is when title and risk and reward of ownership transfer to the customer and the company is entitled to payment for business within the company healthcare service segment and certain service in the animal health segment revenue is recognized over time generally ratably over the contract term service are provided these service revenue are not material the nature of the company business give rise to several type of variable consideration including discount and return which are estimated at the time of sale generally using the expected value method although the most likely amount method is used for prompt pay discount in the united state sale discount are issued to customer at the point of sale through an intermediary wholesaler known chargebacks or in the form of rebate additionally sale are generally made with limited right of return under certain condition revenue are recorded net of provision for sale discount and return which are established at the time of sale in addition revenue are recorded net of time value of money discount if collection of account receivable is expected to be in excess of one year the provision for aggregate customer discount cover chargebacks and rebate chargebacks are discount that occur when contracted customer purchase through an intermediary wholesaler the contracted customer generally purchase product from the wholesaler at it contracted price plus mark up the wholesaler in turn charge of contentsthe company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer the provision for chargebacks is based on expected sell through level by the company wholesale customer to contracted customer well estimated wholesaler inventory level rebate are amount owed based upon definitive contractual agreement or legal requirement with private sector and public sector medicaid and medicare part benefit provider after the final dispensing of the product by pharmacy to benefit plan participant the provision for rebate is based on expected patient usage well inventory level in the distribution channel to determine the contractual obligation to the benefit provider the company us historical customer segment utilization mix sale forecast change to product mix and price inventory level in the distribution channel government pricing calculation and prior payment history in order to estimate the expected provision amount accrued for aggregate customer discount are evaluated on quarterly basis through comparison of information provided by the wholesaler health maintenance organization pharmacy benefit manager federal and state agency and other customer to the amount accrued the company continually monitor it provision for aggregate customer discount there were no material adjustment to estimate associated with the aggregate customer discount provision in or summarized information about change in the aggregate customer discount accrual related to sale is follows in million january to prior year payment balance december for chargebacks are reflected direct reduction to account receivable and accrual for rebate current liability the accrued balance relative to these provision included in account receivable and accrued and other current liability were million and billion respectively at december and were million and billion respectively at december outside of the united state variable consideration in the form of discount and rebate are combination of commercially driven discount in highly competitive product class discount required to gain or maintain reimbursement or legislatively mandated rebate in certain european country legislatively mandated rebate are calculated based on an estimate of the government total unbudgeted spending and the company specific payback obligation rebate may also be required based on specific product sale threshold the company applies an estimated factor against it actual invoiced sale to represent the expected level of future discount or rebate obligation associated with the sale the company maintains return policy that allows it pharmaceutical customer to return product within specified period prior to and subsequent to the expiration date generally three to six month before and month after product expiration the estimate of the provision for return is based upon historical experience with actual return additionally the company considers factor such level of inventory in the distribution channel product dating and expiration period whether product have been discontinued entrance in the market of generic competition change in formulary or launch of over the counter product among others the product return provision for pharmaceutical sale percentage of net pharmaceutical sale wa in in and in outside of the united state return are only allowed in certain country on limited basis merck payment term for pharmaceutical customer are typically day from receipt of invoice and for animal health customer are typically day from receipt of invoice however certain product including keytruda have longer payment term up to day outside of the united state payment term are typically day to day although certain market have longer payment term through it distribution program with wholesaler the company encourages wholesaler to align purchase with underlying demand and maintain inventory below specified level the term of the program allow the wholesaler to earn fee upon providing visibility into their inventory level well by achieving certain performance parameter such inventory management customer service level reducing shortage claim and reducing of contentsproduct return information provided through the wholesaler distribution program includes item such sale trend inventory on hand on order quantity and product return wholesaler generally provide only the above mentioned data to the company there is no regulatory requirement to report lot level information to manufacturer which is the level of information needed to determine the remaining shelf life and original sale date of inventory given current wholesaler inventory level which are generally le than month the company belief that collection of order lot information across all wholesale customer would have limited use in estimating sale discount and return inventory produced in preparation for product launchesthe company capitalizes inventory produced in preparation for product launch sufficient to support estimated initial market demand typically capitalization of such inventory doe not begin until the related product candidate are in phase clinical trial and are considered to have high probability of regulatory approval the company monitor the status of each respective product within the regulatory approval process however the company generally doe not disclose specific timing for regulatory approval if the company is aware of any specific risk or contingency other than the normal regulatory approval process or if there are any specific issue identified during the research process relating to safety efficacy manufacturing marketing or labeling the related inventory would generally not be capitalized expiry date of the inventory are affected by the stage of completion the company manages the level of inventory at each stage to optimize the shelf life of the inventory in relation to anticipated market demand in order to avoid product expiry issue for inventory that are capitalized anticipated future sale and shelf life support the realization of the inventory value the inventory shelf life is sufficient to meet initial product launch requirement inventory produced in preparation for product launch capitalized at december and were million and million respectively contingency and environmental liabilitiesthe company is involved in various claim and legal proceeding of nature considered normal to it business including product liability intellectual property and commercial litigation well certain additional matter including governmental and environmental matter see note to the consolidated financial statement the company record accrual for contingency when it is probable that liability ha been incurred and the amount can be reasonably estimated these accrual are adjusted periodically assessment change or additional information becomes available for product liability claim portion of the overall accrual is actuarially determined and considers such factor past experience number of claim reported and estimate of claim incurred but not yet reported individually significant contingent loss are accrued when probable and reasonably estimable legal defense cost expected to be incurred in connection with loss contingency are accrued when probable and reasonably estimable some of the significant factor considered in the review of these legal defense reserve are follows the actual cost incurred by the company the development of the company legal defense strategy and structure in light of the scope of it litigation the number of case being brought against the company the cost and outcome of completed trial and the most current information regarding anticipated timing progression and related cost of pre trial activity and trial in the associated litigation the amount of legal defense reserve of december and of approximately million and million respectively represents the company best estimate of the minimum amount of defense cost to be incurred in connection with it outstanding litigation however event such additional trial and other event that could arise in the course of it litigation could affect the ultimate amount of legal defense cost to be incurred by the company the company will continue to monitor it legal defense cost and review the adequacy of the associated reserve and may determine to increase the reserve at any time in the future if based upon the factor set forth it belief it would be appropriate to do so the company and it subsidiary are party to number of proceeding brought under the comprehensive environmental response compensation and liability act commonly known superfund and other federal and state equivalent when legitimate claim for contribution is asserted liability is initially accrued based upon the estimated transaction cost to manage the site accrual are adjusted site investigation feasibility study and related cost assessment of remedial technique are completed and the extent to which other potentially responsible party who may be jointly and severally liable can be expected to contribute is determined the company is also remediating environmental contamination resulting from past industrial activity at certain of it site and take an active role in identifying and accruing for these cost in the past merck performed worldwide survey to ass all site for potential contamination resulting from past industrial activity where of contentsassessment indicated that physical investigation wa warranted such investigation wa performed providing better evaluation of the need for remedial action where such need wa identified remedial action wa then initiated definitive information became available during the course of investigation and or remedial effort at each site estimate were refined and accrual were established or adjusted accordingly these estimate and related accrual continue to be refined annually the company belief that there are no compliance issue associated with applicable environmental law and regulation that would have material adverse effect on the company expenditure for remediation and environmental liability were million in and are estimated at million in the aggregate for the year through in management opinion the liability for all environmental matter that are probable and reasonably estimable have been accrued and totaled million and million at december and respectively these liability are undiscounted do not consider potential recovery from other party and will be paid out over the period of remediation for the applicable site which are expected to occur primarily over the next year although it is not possible to predict with certainty the outcome of these matter or the ultimate cost of remediation management doe not believe that any reasonably possible expenditure that may be incurred in excess of the liability accrued should exceed million in the aggregate management also doe not believe that these expenditure should result in material adverse effect on the company financial condition result of operation or liquidity for any year share based compensationthe company expense all share based payment award to employee including grant of stock option over the requisite service period based on the grant date fair value of the award the company determines the fair value of certain share based award using the black scholes option pricing model which us both historical and current market data to estimate the fair value this method incorporates various assumption such the risk free interest rate expected volatility expected dividend yield and expected life of the option total pretax share based compensation expense wa million in million in and million in at december there wa million of total pretax unrecognized compensation expense related to nonvested stock option restricted stock unit and performance share unit award which will be recognized over weighted average period of year for segment reporting share based compensation cost are unallocated expense pension and other postretirement benefit plansnet periodic benefit cost for pension plan totaled million in million in and million in net periodic benefit credit for other postretirement benefit plan wa million in million in and million in pension and other postretirement benefit plan information for financial reporting purpose is calculated using actuarial assumption including discount rate for plan benefit obligation and an expected rate of return on plan asset the change in net periodic benefit cost year over year for pension plan are largely attributable to change in the discount rate affecting net loss amortization the company reassesses it benefit plan assumption on regular basis for both the pension and other postretirement benefit plan the discount rate is evaluated on measurement date and modified to reflect the prevailing market rate of portfolio of high quality fixed income debt instrument that would provide the future cash flow needed to pay the benefit included in the benefit obligation they come due the discount rate for the company pension and other postretirement benefit plan ranged from to at december compared with range of to at december the expected rate of return for both the pension and other postretirement benefit plan represents the average rate of return to be earned on plan asset over the period the benefit included in the benefit obligation are to be paid in developing the expected rate of return the company considers long term compound annualized return of historical market data current market condition and actual return on the company plan asset using this reference information the company develops forward looking return expectation for each asset category and weighted average expected long term rate of return for target portfolio allocated across these investment category the expected portfolio performance reflects the contribution of active management appropriate for the expected rate of return for the company pension and other postretirement benefit plan will range from to compared to range of to in the decrease reflects lower expected asset return and modest shift in asset allocation the company ha established investment guideline for it pension and other postretirement plan to create an asset allocation that is expected to deliver rate of return sufficient to meet the long term obligation of each plan given an acceptable level of risk the target investment portfolio of the company pension and other of contentspostretirement benefit plan is allocated to in equity to in international equity to in fixed income investment and up to in cash and other investment the portfolio equity weighting is consistent with the long term nature of the plan benefit obligation the expected annual standard deviation of return of the target portfolio which approximates reflects both the equity allocation and the diversification benefit among the asset class in which the portfolio invests for non pension plan the targeted investment portfolio varies based on the duration of pension liability and local government rule and regulation although significant percentage of plan asset are invested in equity concentration risk is mitigated through the use of strategy that are diversified within management guideline actuarial assumption are based upon management best estimate and judgment reasonably possible change of plus minus basis point in the discount rate assumption with other assumption held constant would have had an estimated million favorable unfavorable impact on the company net periodic benefit cost in reasonably possible change of plus minus basis point in the expected rate of return assumption with other assumption held constant would have had an estimated million favorable unfavorable impact on merck net periodic benefit cost in required funding obligation for relating to the company pension and other postretirement benefit plan are not expected to be material the preceding hypothetical change in the discount rate and expected rate of return assumption would not impact the company funding requirement net loss amount which reflect experience differential primarily relating to difference between expected and actual return on plan asset well the effect of change in actuarial assumption are recorded component of aoci expected return for pension plan are based on calculated market related value of asset under this methodology asset gain loss resulting from actual return that differ from the company expected return are recognized in the market related value of asset ratably over five year period also net loss amount in aoci in excess of certain threshold are amortized into net periodic benefit cost over the average remaining service life of employee restructuring costsrestructuring cost have been recorded in connection with restructuring program designed to streamline the company cost structure result the company ha made estimate and judgment regarding it future plan including future termination benefit and other exit cost to be incurred when the restructuring action take place when accruing termination cost the company will recognize the amount within range of cost that is the best estimate within the range when no amount within the range is better estimate than any other amount the company recognizes the minimum amount within the range in connection with these action management also ass the recoverability of long lived asset employed in the business in certain instance asset life have been shortened based on change in the expected useful life of the affected asset severance and other related cost are reflected within restructuring cost asset related charge are reflected within cost of sale selling general and administrative expense and research and development expense depending upon the nature of the asset impairment of long lived assetsthe company ass change in economic regulatory and legal condition and make assumption regarding estimated future cash flow in evaluating the value of the company property plant and equipment goodwill and other intangible asset the company periodically evaluates whether current fact or circumstance indicate that the carrying value of it long lived asset to be held and used may not be recoverable if such circumstance are determined to exist an estimate of the undiscounted future cash flow of these asset or appropriate asset grouping is compared to the carrying value to determine whether an impairment exists if the asset is determined to be impaired the loss is measured based on the difference between the asset fair value and it carrying value if quoted market price are not available the company will estimate fair value using discounted value of estimated future cash flow approach goodwill represents the excess of the consideration transferred over the fair value of net asset of business acquired goodwill is assigned to reporting unit and evaluated for impairment on at least an annual basis or more frequently if impairment indicator exist by first assessing qualitative factor to determine whether it is more likely than not that the fair value of reporting unit is le than it carrying amount some of the factor considered in the assessment include general macroeconomic condition condition specific to the industry and market cost factor which could have significant effect on earnings or cash flow the overall financial performance of the reporting unit and whether there have been sustained decline in the company share price if the company concludes it is more of contentslikely than not that the fair value of reporting unit is le than it carrying amount quantitative fair value test is performed if the carrying value of reporting unit is greater than it fair value goodwill impairment charge will be recorded for the difference up to the carrying value of goodwill other acquired intangible asset excluding ipr are initially recorded at fair value assigned an estimated useful life and amortized primarily on straight line basis over their estimated useful life when event or circumstance warrant review the company will ass recoverability from future operation using pretax undiscounted cash flow derived from the lowest appropriate asset grouping impairment are recognized in operating result to the extent that the carrying value of the intangible asset exceeds it fair value which is determined based on the net present value of estimated future cash flow ipr that the company acquires in conjunction with the acquisition of business represents the fair value assigned to incomplete research project which at the time of acquisition have not reached technological feasibility the amount are capitalized and accounted for indefinite lived intangible asset subject to impairment testing until completion or abandonment of the project the company evaluates ipr for impairment at least annually or more frequently if impairment indicator exist by performing quantitative test that compare the fair value of the ipr intangible asset with it carrying value for impairment testing purpose the company may combine separately recorded ipr intangible asset into one unit of account based on the relevant fact and circumstance generally the company will combine ipr intangible asset for testing purpose if they operate single asset and are essentially inseparable if the fair value is le than the carrying amount an impairment loss is recognized in operating result the judgment made in evaluating impairment of long lived intangible can materially affect the company result of operation impairment of investmentsthe company review it investment in marketable debt security for impairment based on the determination of whether the decline in market value of the investment below the carrying value is other than temporary the company considers available evidence in evaluating potential impairment of it investment in marketable debt security including the duration and extent to which fair value is le than cost change in fair value that are considered temporary are reported net of tax in oci an other than temporary impairment ha occurred if the company doe not expect to recover the entire amortized cost basis of the marketable debt security if the company doe not intend to sell the impaired debt security and it is not more likely than not it will be required to sell the debt security before the recovery of it amortized cost basis the amount of the other than temporary impairment recognized in earnings recorded in other income expense net is limited to the portion attributed to credit loss the remaining portion of the other than temporary impairment related to other factor is recognized in oci investment in publicly traded equity security are reported at fair value determined using quoted market price in active market for identical asset or quoted price for similar asset or other input that are observable or can be corroborated by observable market data change in fair value are included in other income expense net investment in equity security without readily determinable fair value are recorded at cost plus or minus subsequent observable price change in orderly transaction for identical or similar investment minus impairment such adjustment are recognized in other income expense net realized gain and loss for equity security are included in other income expense net tax on incomethe company effective tax rate is based on pretax income statutory tax rate and tax planning opportunity available in the various jurisdiction in which the company operates an estimated effective tax rate for year is applied to the company quarterly operating result in the event that there is significant unusual or one time item recognized or expected to be recognized in the company quarterly operating result the tax attributable to that item would be separately calculated and recorded at the same time the unusual or one time item the company considers the resolution of prior year tax matter to be such item significant judgment is required in determining the company tax provision and in evaluating it tax position the recognition and measurement of tax position is based on management best judgment given the fact circumstance and information available at the reporting date the company evaluates tax position to determine whether the benefit of tax position are more likely than not of being sustained upon audit based on the technical merit of the tax position for tax position that are more likely than not of being sustained upon audit the company recognizes the largest amount of the benefit that is greater than likely of contentsof being realized upon ultimate settlement in the financial statement for tax position that are not more likely than not of being sustained upon audit the company doe not recognize any portion of the benefit in the financial statement if the more likely than not threshold is not met in the period for which tax position is taken the company may subsequently recognize the benefit of that tax position if the tax matter is effectively settled the statute of limitation expires or if the more likely than not threshold is met in subsequent period see note to the consolidated financial statement tax regulation require item to be included in the tax return at different time than the item are reflected in the financial statement timing difference create deferred tax asset and liability deferred tax asset generally represent item that can be used tax deduction or credit in the tax return in future year for which the company ha already recorded the tax benefit in the financial statement the company establishes valuation allowance for it deferred tax asset when the amount of expected future taxable income is not likely to support the use of the deduction or credit deferred tax liability generally represent tax expense recognized in the financial statement for which payment ha been deferred or expense for which the company ha already taken deduction on the tax return but ha not yet recognized expense in the financial statement recently issued accounting standardsfor discussion of recently issued accounting standard see note to the consolidated financial statement cautionary factor that may affect future resultsthis report and other written report and oral statement made from time to time by the company may contain so called forward looking statement all of which are based on management current expectation and are subject to risk and uncertainty which may cause result to differ materially from those set forth in the statement one can identify these forward looking statement by their use of word such anticipates expects plan will estimate forecast project and other word of similar meaning or negative variation of any of the foregoing one can also identify them by the fact that they do not relate strictly to historical or current fact these statement are likely to address the company growth strategy financial result product development product approval product potential and development program one must carefully consider any such statement and should understand that many factor could cause actual result to differ materially from the company forward looking statement these factor include inaccurate assumption and broad variety of other risk and uncertainty including some that are known and some that are not no forward looking statement can be guaranteed and actual future result may vary materially the company doe not assume the obligation to update any forward looking statement one should carefully evaluate such statement in light of factor including risk factor described in the company filing with the security and exchange commission especially on this form and form and in item risk factor of this annual report on form the company discus in more detail various important risk factor that could cause actual result to differ from expected or historic result the company note these factor for investor permitted by the private security litigation reform act of one should understand that it is not possible to predict or identify all such factor consequently the reader should not consider any such list to be complete statement of all potential risk or uncertainty item quantitative and qualitative disclosure about market risk the information required by this item is incorporated by reference to the discussion under financial instrument market risk disclosure in item management discussion and analysis of financial condition and result of operation of contentsitem financial statement and supplementary data financial statementsthe consolidated balance sheet of merck co inc and subsidiary of december and and the related consolidated statement of income of comprehensive income of equity and of cash flow for each of the three year in the period ended december the note to consolidated financial statement and the report dated february of pricewaterhousecoopers llp independent registered public accounting firm are follows consolidated statement of incomemerck co inc and subsidiariesyears ended december in million except per share amount expense and other cost of general and and income expense before on net loss income attributable to noncontrolling interest income attributable to merck co inc earnings per common share attributable to merck co inc common shareholder per common share assuming dilution attributable to merck co inc common shareholder statement of comprehensive incomemerck co inc and subsidiariesyears ended december in million income attributable to merck co inc comprehensive loss income net of tax net unrealized loss gain on derivative net of reclassification net unrealized gain loss on investment net of benefit plan net loss gain and prior service cost credit net of amortization translation income attributable to merck co inc accompanying note are an integral part of these consolidated financial statement of contentsconsolidated balance sheetmerck co inc and subsidiariesdecember in million except per share amount current asset cash and cash equivalent term receivable net of allowance for doubtful account of in in excludes inventory of in and in in other asset see note current current plant and equipment at cost equipment and office in accumulated intangible and equity current liability loan payable and current portion of long term debt account and other current tax current term income noncurrent co inc stockholder equity common stock par valueauthorized sharesissued share in and paid in other comprehensive loss treasury stock at cost share in and share in merck co inc stockholder accompanying note are an integral part of this consolidated financial statement of contentsconsolidated statement of equitymerck co inc and subsidiariesyears ended december in million except per share amount commonstock otherpaid incapital retainedearnings accumulatedothercomprehensiveloss treasurystock non controllinginterests totalbalance january income attributable to merck co inc comprehensive income net of tax dividend declared on common stock per share treasury stock share purchased acquisition of valle income attributable to noncontrolling interest attributable to noncontrolling interest share based compensation plan and other december income attributable to merck co inc of new accounting standard comprehensive loss net of tax cash dividend declared on common stock per share treasury stock share purchased net loss attributable to noncontrolling interest distribution attributable to noncontrolling interest share based compensation plan and other december income attributable to merck co inc comprehensive loss net of tax cash dividend declared on common stock per share treasury stock share purchased net loss attributable to noncontrolling interest distribution attributable to noncontrolling interest share based compensation plan and other december accompanying note are an integral part of this consolidated financial statement of contentsconsolidated statement of cash flowsmerck co inc and subsidiariesyears ended december in million flow from operating activity net income to reconcile net income to net cash provided by operating activity depreciation and asset impairment for the acquisition of peloton therapeutic inc charge for future payment related to collaboration license option charge for one time transition tax related to the enactment of tax legislation income tax share based change in asset and liability account trade account and other current income tax payable noncurrent liability other net cash provided by operating flow from investing activity capital expenditure purchase of security and other investment proceeds from sale of security and other of antelliq corporation net of cash acquired acquisition of peloton therapeutic inc net of cash acquired other acquisition net of cash acquired cash used in provided by investing activity flow from financing activity net change in short term borrowing payment on debt proceeds from issuance of purchase of treasury stock dividend paid to stockholder proceeds from exercise of stock net cash used in financing activity effect of exchange rate change on cash cash equivalent and restricted increase decrease in cash cash equivalent and restricted cash cash equivalent and restricted cash at beginning of year includes million of restricted cash at january included in other asset cash equivalent and restricted cash at end of year includes million of restricted cash at december included in other asset see note accompanying note are an integral part of this consolidated financial statement of contentsnotes to consolidated financial statementsmerck co inc and subsidiary in million except per share amount nature of operationsmerck co inc merck or the company is global health care company that delivers innovative health solution through it prescription medicine vaccine biologic therapy and animal health product the company operation are principally managed on product basis and include four operating segment which are the pharmaceutical animal health healthcare service and alliance segment the pharmaceutical and animal health segment are the only reportable segment the pharmaceutical segment includes human health pharmaceutical and vaccine product human health pharmaceutical product consist of therapeutic and preventive agent generally sold by prescription for the treatment of human disorder the company sell these human health pharmaceutical product primarily to drug wholesaler and retailer hospital government agency and managed health care provider such health maintenance organization pharmacy benefit manager and other institution human health vaccine product consist of preventive pediatric adolescent and adult vaccine primarily administered at physician office the company sell these human health vaccine primarily to physician wholesaler physician distributor and government entity the animal health segment discovers develops manufacture and market wide range of veterinary pharmaceutical and vaccine product well health management solution and service for the prevention treatment and control of disease in all major livestock and companion animal specie the company also offer an extensive suite of digitally connected identification traceability and monitoring product the company sell it product to veterinarian distributor and animal producer the healthcare service segment provides service and solution that focus on engagement health analytics and clinical service to improve the value of care delivered to patient the company ha recently sold certain business in the healthcare service segment and is in the process of divesting the remaining business the alliance segment primarily includes activity from the company relationship with astrazeneca lp related to sale of nexium and prilosec which concluded in planned spin off of woman health legacy brand and biosimilars into new company in february merck announced it intention to spin off product from it woman health trusted legacy brand and biosimilars business into new yet to be named independent publicly traded company newco through distribution of newco publicly traded stock to company shareholder the distribution is expected to qualify tax free to the company and it shareholder for federal income tax purpose the legacy brand included in the transaction consist of dermatology pain respiratory and select cardiovascular product including zetia and vytorin well the rest of merck diversified brand franchise merck existing research pipeline program will continue to be owned and developed within merck planned newco will have development capability initially focused on late stage development and life cycle management and is expected over time to develop research capability in selected therapeutic area the spin off is expected to be completed in the first half of subject to market and certain other condition subsequent to the spin off the historical result of the woman health legacy brand and biosimilars business will be reflected discontinued operation in the company consolidated financial statement summary of accounting policiesprinciples of consolidation the consolidated financial statement include the account of the company and all of it subsidiary in which controlling interest is maintained intercompany balance and transaction are eliminated controlling interest is determined by majority ownership interest and the absence of substantive third party participating right or in the case of variable interest entity by majority exposure to expected loss residual return or both for those consolidated subsidiary where merck ownership is le than the outside shareholder interest are shown noncontrolling interest in equity investment in affiliate over which the company ha significant influence but not controlling interest such interest in entity owned equally by the company and third party that are under shared control are carried on the equity basis of contentsacquisitions in business combination the acquisition method of accounting requires that the asset acquired and liability assumed be recorded of the date of the acquisition at their respective fair value with limited exception asset acquired and liability assumed in business combination that arise from contingency are generally recognized at fair value if fair value can not be determined the asset or liability is recognized if probable and reasonably estimable if these criterion are not met no asset or liability is recognized fair value is defined the exchange price that would be received for an asset or paid to transfer liability an exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between market participant on the measurement date accordingly the company may be required to value asset at fair value measure that do not reflect the company intended use of those asset any excess of the purchase price consideration transferred over the estimated fair value of net asset acquired is recorded goodwill transaction cost and cost to restructure the acquired company are expensed incurred the operating result of the acquired business are reflected in the company consolidated financial statement after the date of the acquisition if the company determines the asset acquired do not meet the definition of business under the acquisition method of accounting the transaction will be accounted for an acquisition of asset rather than business combination and therefore no goodwill will be recorded in an asset acquisition acquired in process research and development ipr with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date foreign currency translation the net asset of international subsidiary where the local currency have been determined to be the functional currency are translated into dollar using current exchange rate the dollar effect that arise from translating the net asset of these subsidiary at changing rate are recorded in the foreign currency translation account which is included in accumulated other comprehensive income loss aoci and reflected separate component of equity for those subsidiary that operate in highly inflationary economy and for those subsidiary where the dollar ha been determined to be the functional currency non monetary foreign currency asset and liability are translated using historical rate while monetary asset and liability are translated at current rate with the dollar effect of rate change included in other income expense net cash equivalent cash equivalent are comprised of certain highly liquid investment with original maturity of le than three month inventory inventory are valued at the lower of cost or net realizable value the cost of substantial majority of pharmaceutical and vaccine inventory is determined using the last in first out lifo method for both financial reporting and tax purpose the cost of all other inventory is determined using the first in first out fifo method inventory consist of currently marketed product well certain inventory produced in preparation for product launch that are considered to have high probability of regulatory approval in evaluating the recoverability of inventory produced in preparation for product launch the company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process investment investment in marketable debt security classified available for sale are reported at fair value fair value of the company investment in marketable debt security are determined using quoted market price in active market for identical asset or liability or quoted price for similar asset or liability or other input that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability change in fair value that are considered temporary are reported net of tax in other comprehensive income oci the company considers available evidence in evaluating potential impairment of it investment in marketable debt security including the duration and extent to which fair value is le than cost an other than temporary impairment ha occurred if the company doe not expect to recover the entire amortized cost basis of the marketable debt security if the company doe not intend to sell the impaired debt security and it is not more likely than not it will be required to sell the debt security before the recovery of it amortized cost basis the amount of the other than temporary impairment recognized in earnings recorded in other income expense net is limited to the portion attributed to credit loss the remaining portion of the other than temporary impairment related to other factor is recognized in oci realized gain and loss for debt security are included in other income expense net investment in publicly traded equity security are reported at fair value determined using quoted market price in active market for identical asset or quoted price for similar asset or other input that are observable or can be corroborated by observable market data change in fair value are included in other income expense net of contentsinvestments in equity security without readily determinable fair value are recorded at cost plus or minus subsequent observable price change in orderly transaction for identical or similar investment minus impairment such adjustment are recognized in other income expense net realized gain and loss for equity security are included in other income expense net revenue recognition on january the company adopted asu revenue from contract with customer and subsequent amendment asc or new guidance using the modified retrospective method comparative information for prior period ha not been restated and continues to be reported under the accounting standard in effect for those period recognition of revenue requires evidence of contract probable collection of sale proceeds and completion of substantially all performance obligation merck act the principal in substantially all of it customer arrangement and therefore record revenue on gross basis the majority of the company contract related to the pharmaceutical and animal health segment have single performance obligation the promise to transfer good shipping is considered immaterial in the context of the overall customer arrangement and damage or loss of good in transit are rare therefore shipping is not deemed separately recognized performance obligation the vast majority of revenue from sale of product are recognized at point in time when control of the good is transferred to the customer which the company ha determined is when title and risk and reward of ownership transfer to the customer and the company is entitled to payment the company recognizes revenue from the sale of vaccine to the federal government for placement into vaccine stockpile in accordance with security and exchange commission sec interpretation commission guidance regarding accounting for sale of vaccine and bioterror countermeasure to the federal government for placement into the pediatric vaccine stockpile or the strategic national stockpile this interpretation allows company to recognize revenue for sale of vaccine into government stockpile even though these sale might not meet the criterion for revenue recognition under other accounting guidance for business within the company healthcare service segment and certain service in the animal health segment revenue is recognized over time generally ratably over the contract term service are provided these service revenue are not material the nature of the company business give rise to several type of variable consideration including discount and return which are estimated at the time of sale generally using the expected value method although the most likely amount method is used for prompt pay discount in the united state sale discount are issued to customer at the point of sale through an intermediary wholesaler known chargebacks or in the form of rebate additionally sale are generally made with limited right of return under certain condition revenue are recorded net of provision for sale discount and return which are established at the time of sale in addition revenue are recorded net of time value of money discount if collection of account receivable is expected to be in excess of one year the provision for aggregate customer discount covering chargebacks and rebate wa billion in billion in and billion in chargebacks are discount that occur when contracted customer purchase through an intermediary wholesaler the contracted customer generally purchase product from the wholesaler at it contracted price plus mark up the wholesaler in turn charge the company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer the provision for chargebacks is based on expected sell through level by the company wholesale customer to contracted customer well estimated wholesaler inventory level rebate are amount owed based upon definitive contractual agreement or legal requirement with private sector and public sector medicaid and medicare part benefit provider after the final dispensing of the product by pharmacy to benefit plan participant the provision for rebate is based on expected patient usage well inventory level in the distribution channel to determine the contractual obligation to the benefit provider the company us historical customer segment utilization mix sale forecast change to product mix and price inventory level in the distribution channel government pricing calculation and prior payment history in order to estimate the expected provision amount accrued for aggregate customer discount are evaluated on quarterly basis through comparison of information provided by the wholesaler health maintenance organization pharmacy benefit manager federal and state agency and other customer to the amount accrued the accrued balance relative to the provision for chargebacks and rebate included in account of contentsreceivable and accrued and other current liability were million and billion respectively at december and were million and billion respectively at december outside of the united state variable consideration in the form of discount and rebate are combination of commercially driven discount in highly competitive product class discount required to gain or maintain reimbursement or legislatively mandated rebate in certain european country legislatively mandated rebate are calculated based on an estimate of the government total unbudgeted spending and the company specific payback obligation rebate may also be required based on specific product sale threshold the company applies an estimated factor against it actual invoiced sale to represent the expected level of future discount or rebate obligation associated with the sale the company maintains return policy that allows it pharmaceutical customer to return product within specified period prior to and subsequent to the expiration date generally three to six month before and month after product expiration the estimate of the provision for return is based upon historical experience with actual return additionally the company considers factor such level of inventory in the distribution channel product dating and expiration period whether product have been discontinued entrance in the market of generic competition change in formulary or launch of over the counter product among others outside of the united state return are only allowed in certain country on limited basis merck payment term for pharmaceutical customer are typically day from receipt of invoice and for animal health customer are typically day from receipt of invoice however certain product including keytruda have longer payment term up to day outside of the united state payment term are typically day to day although certain market have longer payment term depreciation depreciation is provided over the estimated useful life of the asset principally using the straight line method for tax purpose accelerated tax method are used the estimated useful life primarily range from to year for building and from to year for machinery equipment and office furnishing depreciation expense wa billion in billion in and billion in advertising and promotion cost advertising and promotion cost are expensed incurred the company recorded advertising and promotion expense of billion billion and billion in and respectively software capitalization the company capitalizes certain cost incurred in connection with obtaining or developing internal use software including external direct cost of material and service and payroll cost for employee directly involved with the software development these cost are included in property plant and equipment in addition the company capitalizes certain cost incurred to implement cloud computing arrangement that is considered service agreement which are included in other asset capitalized software cost are amortized beginning when the software project is substantially complete and the asset is ready for it intended use capitalized software cost associated with project that are being amortized over to year including the company on going multi year implementation of an enterprise wide resource planning system were million and million net of accumulated amortization at december and respectively all other capitalized software cost are being amortized over period ranging from to year cost incurred during the preliminary project stage and post implementation stage well maintenance and training cost are expensed incurred goodwill goodwill represents the excess of the consideration transferred over the fair value of net asset of business acquired goodwill is assigned to reporting unit and evaluated for impairment on at least an annual basis or more frequently if impairment indicator exist by first assessing qualitative factor to determine whether it is more likely than not that the fair value of reporting unit is le than it carrying amount if the company concludes it is more likely than not that the fair value of reporting unit is le than it carrying amount quantitative fair value test is performed if the carrying value of reporting unit is greater than it fair value goodwill impairment charge will be recorded for the difference up to the carrying value of goodwill acquired intangible acquired intangible include product and product right license trade name and patent which are initially recorded at fair value assigned an estimated useful life and amortized primarily on straight line basis over their estimated useful life ranging from to year see note the company periodically evaluates whether current fact or circumstance indicate that the carrying value of it acquired intangible may not of contentsbe recoverable if such circumstance are determined to exist an estimate of the undiscounted future cash flow of these asset or appropriate asset grouping is compared to the carrying value to determine whether an impairment exists if the asset is determined to be impaired the loss is measured based on the difference between the carrying value of the intangible asset and it fair value which is determined based on the net present value of estimated future cash flow acquired in process research and development ipr that the company acquires in conjunction with the acquisition of business represents the fair value assigned to incomplete research project which at the time of acquisition have not reached technological feasibility the amount are capitalized and are accounted for indefinite lived intangible asset subject to impairment testing until completion or abandonment of the project upon successful completion of each project merck will make determination to the then useful life of the intangible asset generally determined by the period in which the substantial majority of the cash flow are expected to be generated and begin amortization the company evaluates ipr for impairment at least annually or more frequently if impairment indicator exist by performing quantitative test that compare the fair value of the ipr intangible asset with it carrying value if the fair value is le than the carrying amount an impairment loss is recognized in operating result contingent consideration certain of the company acquisition involve the potential for future payment of consideration that is contingent upon the achievement of performance milestone including product development milestone and royalty payment on future product sale if the transaction is accounted for an acquisition of business the fair value of contingent consideration liability is determined at the acquisition date using unobservable input these input include the estimated amount and timing of projected cash flow the probability of success achievement of the contingent event and the risk adjusted discount rate used to present value the probability weighted cash flow subsequent to the acquisition date at each reporting period until the contingency is resolved the contingent consideration liability is remeasured at current fair value with change either expense or income recorded in earnings significant event that increase or decrease the probability of achieving development and regulatory milestone or that increase or decrease projected cash flow will result in corresponding increase or decrease in the fair value of the related contingent consideration obligation if the transaction is accounted for an acquisition of an asset rather than business contingent consideration is not recognized at the acquisition date in these instance product development milestone are recognized upon achievement and sale based milestone are recognized when the milestone is deemed probable by the company of being achieved research and development research and development is expensed incurred nonrefundable advance payment for good and service that will be used in future research and development activity are expensed when the activity ha been performed or when the good have been received rather than when the payment is made research and development expense include restructuring cost and ipr impairment charge in addition research and development expense include expense or income related to change in the estimated fair value measurement of liability for contingent consideration research and development expense also include upfront and milestone payment related to asset acquisition and licensing transaction involving clinical development program that have not yet received regulatory approval collaborative arrangement merck ha entered into collaborative arrangement that provide the company with varying right to develop produce and market product together with it collaborative partner when merck is the principal on sale transaction with third party the company recognizes sale cost of sale and selling general and administrative expense on gross basis profit sharing amount it pay to it collaborative partner are recorded within cost of sale when the collaborative partner is the principal on sale transaction with third party the company record profit sharing amount received from it collaborative partner alliance revenue within sale alliance revenue is recorded net of cost of sale and includes an adjustment to share commercialization cost between the partner in accordance with the collaboration agreement the adjustment is determined by comparing the commercialization cost merck ha incurred directly and reported within selling general and administrative expense with the cost the collaborative partner ha incurred research and development cost merck incurs related to collaboration are recorded within research and development expense cost reimbursement to the collaborative partner or payment received from the collaborative partner to share these cost pursuant to the term of the collaboration agreement are recorded increase or decrease to research and development expense of contentsin addition the term of the collaboration agreement may require the company to make payment based upon the achievement of certain developmental regulatory approval or commercial milestone upfront and milestone payment payable by merck to collaborative partner prior to regulatory approval are expensed incurred and included in research and development expense payment due to collaborative partner upon or subsequent to regulatory approval are capitalized and amortized over the estimated useful life of the corresponding intangible asset to cost of sale provided that future cash flow support the amount capitalized sale based milestone payable by merck to collaborative partner are accrued and capitalized subject to cumulative amortization catch up when probable of being achieved the amortization catch up is calculated either from the time of the first regulatory approval for indication that were unapproved at the time the collaboration wa formed or from time of the formation of the collaboration for approved product the related intangible asset that is recognized is amortized to cost of sale over it remaining useful life subject to impairment testing share based compensation the company expense all share based payment to employee over the requisite service period based on the grant date fair value of the award restructuring cost the company record liability for cost associated with exit or disposal activity in the period in which the liability is incurred in accordance with existing benefit arrangement employee termination cost are accrued when the restructuring action are probable and estimable when accruing these cost the company will recognize the amount within range of cost that is the best estimate within the range when no amount within the range is better estimate than any other amount the company recognizes the minimum amount within the range cost for one time termination benefit in which the employee is required to render service until termination in order to receive the benefit are recognized ratably over the future service period contingency and legal defense cost the company record accrual for contingency and legal defense cost expected to be incurred in connection with loss contingency when it is probable that liability ha been incurred and the amount can be reasonably estimated tax on income deferred tax are recognized for the future tax effect of temporary difference between financial and income tax reporting based on enacted tax law and rate the company evaluates tax position to determine whether the benefit of tax position are more likely than not of being sustained upon audit based on the technical merit of the tax position for tax position that are more likely than not of being sustained upon audit the company recognizes the largest amount of the benefit that is greater than likely of being realized upon ultimate settlement in the financial statement for tax position that are not more likely than not of being sustained upon audit the company doe not recognize any portion of the benefit in the financial statement the company recognizes interest and penalty associated with uncertain tax position component of tax on income in the consolidated statement of income the company account for the tax effect of the tax on global intangible low taxed income gilti of certain foreign subsidiary in the income tax provision in the period the tax arises use of estimate the consolidated financial statement are prepared in conformity with accounting principle generally accepted in the united state gaap and accordingly include certain amount that are based on management best estimate and judgment estimate are used when accounting for amount recorded in connection with acquisition including initial fair value determination of asset and liability primarily ipr other intangible asset and contingent consideration well subsequent fair value measurement additionally estimate are used in determining such item provision for sale discount and return depreciable and amortizable life recoverability of inventory including those produced in preparation for product launch amount recorded for contingency environmental liability accrual for contingent sale based milestone payment and other reserve pension and other postretirement benefit plan assumption share based compensation assumption restructuring cost impairment of long lived asset including intangible asset and goodwill and investment and tax on income because of the uncertainty inherent in such estimate actual result may differ from these estimate reclassification certain reclassification have been made to prior year amount to conform to the current year presentation recently adopted accounting standard in february the financial accounting standard board fasb issued new accounting guidance for the accounting and reporting of lease asu and subsequently issued several update to the new guidance asc or new leasing guidance the new leasing guidance requires of contentsthat lessee recognize right of use asset and lease liability for each of it lease other than lease that meet the definition of short term lease lease are classified either operating or finance operating lease result in straight line expense in the income statement similar to previous operating lease while finance lease result in more expense being recognized in the earlier year of the lease term similar to previous capital lease the company adopted the new standard on january using modified retrospective approach merck elected the transition method that allows for application of the standard at the adoption date rather than at the beginning of the earliest comparative period presented in the financial statement the company also elected available practical expedient upon adoption the company recognized billion of additional asset and related liability on it consolidated balance sheet see note the adoption of the new leasing guidance did not impact the company consolidated statement of income or of cash flow in april the fasb issued new guidance on the accounting for cost incurred to implement cloud computing arrangement that is considered service arrangement the new guidance requires the capitalization of such cost aligning it with the accounting for cost associated with developing or obtaining internal use software the company adopted the new standard in the third quarter of using prospective application for eligible cost which were immaterial in august the fasb issued new guidance modifying the disclosure requirement for employer that sponsor defined benefit pension or other postretirement plan the new guidance remove disclosure that no longer are considered cost beneficial clarifies the specific requirement of certain disclosure and add disclosure requirement identified relevant the company elected to early adopt the new guidance in on retrospective basis resulting in minor change to it employee benefit plan disclosure see note also in august the fasb issued new guidance on fair value measurement that add remove and modifies certain disclosure requirement the company elected to early adopt the new guidance in resulting in minor change to it fair value disclosure see note recently issued accounting standard not yet adopted in june the fasb issued new guidance on the accounting for credit loss on financial instrument the new guidance introduces an expected loss model for estimating credit loss replacing the incurred loss model the new guidance also change the impairment model for available for sale debt security requiring the use of an allowance to record estimated credit loss and subsequent recovery the company adopted the new guidance effective january there wa no impact to the company consolidated financial statement upon adoption in november the fasb issued new guidance for collaborative arrangement intended to reduce diversity in practice by clarifying whether certain transaction between collaborative arrangement participant should be accounted for under revenue recognition guidance asc the company adopted the new guidance effective january which will result in minor change to the footnote presentation of information related to the company collaborative arrangement in december the fasb issued amended guidance on the accounting and reporting of income tax the guidance is intended to simplify the accounting for income tax by removing exception related to certain intraperiod tax allocation and deferred tax liability clarifying guidance primarily related to evaluating the step up tax basis for goodwill in business combination and reflecting enacted change in tax law or rate in the annual effective tax rate the amended guidance is effective for interim and annual period in early adoption is permitted the application of the amendment in the new guidance are to be applied on retrospective basis on modified retrospective basis through cumulative effect adjustment to retained earnings or prospectively depending on the amendment the company is currently evaluating the impact of adoption on it consolidated financial statement in january the fasb issued new guidance intended to clarify certain interaction between accounting standard related to equity security equity method investment and certain derivative the guidance address accounting for the transition into and out of the equity method of accounting and measuring certain purchased option and forward contract to acquire investment the new guidance is effective for interim and annual period in and is to be applied prospectively early adoption is permitted the company is currently evaluating the impact of adoption on it consolidated financial statement of acquisition divestiture research collaboration and license agreementsthe company continues to pursue the acquisition of business and establishment of external alliance such research collaboration and licensing agreement to complement it internal research capability these arrangement often include upfront payment well expense reimbursement or payment to the third party and milestone royalty or profit share arrangement contingent upon the occurrence of certain future event linked to the success of the asset in development the company also review it marketed product and pipeline to examine candidate which may provide more value through out licensing and part of it portfolio assessment process may also divest certain asset pro forma financial information for acquired business is not presented if the historical financial result of the acquired entity are not significant when compared with the company financial result recently completed transactionin january merck acquired arqule inc arqule publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patient with cancer and other disease for billion arqule lead investigational candidate mk formerly arq is novel oral bruton tyrosine kinase btk inhibitor currently in phase dose expansion study for the treatment of cell malignancy the company is in the process of determining the preliminary fair value of asset acquired liability assumed and total consideration transferred in this transaction which will be accounted for an acquisition of business transactionsin july merck acquired peloton therapeutic inc peloton clinical stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidate targeting hypoxia inducible factor hif for the treatment of patient with cancer and other non oncology disease peloton lead candidate mk formerly is novel oral hif inhibitor in late stage development for renal cell carcinoma merck made an upfront payment of billion in cash additionally former peloton shareholder will be eligible to receive million upon regulatory approval million upon first commercial sale in the united state and up to billion of sale based milestone the transaction wa accounted for an acquisition of an asset merck recorded cash of million deferred tax liability of million and other net liability of million at the acquisition date and research and development expense of million in related to the transaction on april merck acquired antelliq corporation antelliq leader in digital animal identification traceability and monitoring solution these solution help veterinarian farmer and pet owner gather critical data to improve management health and well being of livestock and pet merck paid billion to acquire all outstanding share of antelliq and spent billion to repay antelliq debt the transaction wa accounted for an acquisition of business the estimated fair value of asset acquired and liability assumed from antelliq is follows in million april and cash equivalent plant and intangible asset useful life ranging from year income tax liability other asset and liability net total identifiable net transferred the estimated fair value of identifiable intangible asset relate primarily to trade name and were determined using an income approach the future net cash flow were discounted to present value utilizing discount rate of actual cash flow are likely to be different than those assumed the goodwill recognized is largely attributable to anticipated synergy expected to arise after the acquisition and wa allocated to the animal health segment the goodwill is not deductible for tax purpose of contentsthe company result for include eight month of activity for antelliq the company incurred million of transaction cost directly related to the acquisition of antelliq consisting largely of advisory fee which are reflected in selling general and administrative expense in also in april merck acquired immune design late stage immunotherapy company employing next generation in vivo approach to enable the body immune system to fight disease for million in cash the transaction wa accounted for an acquisition of business merck recognized intangible asset for ipr of million cash of million and other net asset of million the excess of the consideration transferred over the fair value of net asset acquired of million wa recorded goodwill that wa allocated to the pharmaceutical segment and is not deductible for tax purpose the fair value of the identifiable intangible asset related to ipr were determined using an income approach actual cash flow are likely to be different than those assumed transactionsin the company recorded an aggregate charge of million within cost of sale in conjunction with the termination of collaboration agreement entered into in with samsung bioepis co ltd samsung for insulin glargine the charge reflects termination payment of million which represents the reimbursement of all fee previously paid by samsung to merck under the agreement plus interest well the release of merck ongoing obligation under the agreement the charge also included fixed asset abandonment charge of million inventory write offs of million well other related cost of million the termination of this agreement ha no impact on the company other collaboration with samsung in june merck acquired viralytics limited viralytics an australian publicly traded company focused on oncolytic immunotherapy treatment for range of cancer for aud million million the transaction provided merck with full right to formerly viralytics investigational oncolytic immunotherapy is based on viralytics proprietary formulation of an oncolytic virus coxsackievirus type that ha been shown to preferentially infect and kill cancer cell is currently being evaluated in multiple clinical trial both an intratumoral and intravenous agent including in combination with keytruda under previous agreement between merck and viralytics study is investigating the use of the keytruda and combination in melanoma prostate lung and bladder cancer the transaction wa accounted for an acquisition of an asset merck recorded net asset of million primarily cash at the acquisition date and research and development expense of million in related to the transaction there are no future contingent payment associated with the acquisition in march merck and eisai co ltd eisai entered into strategic collaboration for the worldwide co development and co commercialization of lenvima an orally available tyrosine kinase inhibitor discovered by eisai see note transactionsin october merck acquired rigontec gmbh rigontec leader in accessing the retinoic acid inducible gene pathway part of the innate immune system novel and distinct approach in cancer immunotherapy to induce both immediate and long term anti tumor immunity rigontec lead candidate mk formerly is in development for the treatment in patient with various tumor under the term of the agreement merck made an upfront cash payment of million million and may make additional contingent payment of up to million of which million are related to the achievement of research milestone and regulatory approval and million are related to the achievement of commercial target the transaction wa accounted for an acquisition of an asset and the upfront payment is reflected within research and development expense in in july merck and astrazeneca plc astrazeneca entered into global strategic oncology collaboration to co develop and co commercialize astrazeneca lynparza for multiple cancer type see note in march merck acquired controlling interest in valle valle leading privately held producer of animal health product in brazil valle ha an extensive portfolio of product spanning parasiticides anti infectives and vaccine that include product for livestock horse and companion animal under the term of the agreement merck acquired of the share of valle for million of the total purchase price million wa placed into escrow pending resolution of certain contingent item the transaction wa accounted for an acquisition of business merck recognized intangible asset of million related to currently marketed product net deferred tax liability of million other net asset of million and noncontrolling interest of million in addition the company recorded liability of million for contingency identified at the acquisition date and corresponding of contentsindemnification asset of million representing the amount to be reimbursed to merck if and when the contingent liability are paid the excess of the consideration transferred over the fair value of net asset acquired of million wa recorded goodwill the goodwill wa allocated to the animal health segment and is not deductible for tax purpose the estimated fair value of identifiable intangible asset related to currently marketed product were determined using an income approach actual cash flow are likely to be different than those assumed the intangible asset related to currently marketed product are being amortized over their estimated useful life of year in the fourth quarter of merck acquired an additional interest in valle for million which reduced the noncontrolling interest related to valle remicade simponiin subsidiary of schering plough entered into licensing agreement with centocor ortho biotech inc centocor johnson johnson company to market remicade which is prescribed for the treatment of inflammatory disease in schering plough subsidiary exercised an option under it contract with centocor for license right to develop and commercialize simponi fully human monoclonal antibody the company ha marketing right to both product throughout europe russia and turkey remicade lost market exclusivity in major european market in and the company no longer ha market exclusivity in any of it marketing territory the company continues to have market exclusivity for simponi in all of it marketing territory all profit derived from merck distribution of the two product in these country are equally divided between merck and collaborative arrangementsmerck ha entered into collaborative arrangement that provide the company with varying right to develop produce and market product together with it collaborative partner both party in these arrangement are active participant and exposed to significant risk and reward dependent on the commercial success of the activity of the collaboration merck more significant collaborative arrangement are discussed below astrazenecain july merck and astrazeneca plc astrazeneca entered into global strategic oncology collaboration to co develop and co commercialize astrazeneca lynparza for multiple cancer type lynparza is an oral poly adp ribose polymerase parp inhibitor currently approved for certain type of ovarian and breast cancer the company are jointly developing and commercializing lynparza both monotherapy and in combination trial with other potential medicine independently merck and astrazeneca will develop and commercialize lynparza in combination with their respective pd and pd medicine keytruda and imfinzi the company will also jointly develop and commercialize astrazeneca selumetinib an oral potent selective inhibitor of mek part of the mitogen activated protein kinase mapk pathway currently being developed for multiple indication under the term of the agreement astrazeneca and merck will share the development and commercialization cost for lynparza and selumetinib monotherapy and non pd pd combination therapy opportunity gross profit from lynparza and selumetinib product sale generated through monotherapies or combination therapy are shared equally merck will fund all development and commercialization cost of keytruda in combination with lynparza or selumetinib astrazeneca will fund all development and commercialization cost of imfinzi in combination with lynparza or selumetinib astrazeneca is the principal on lynparza sale transaction merck record it share of lynparza product sale net of cost of sale and commercialization cost alliance revenue and it share of development cost associated with the collaboration part of research and development expense reimbursement received from astrazeneca for research and development expense are recognized reduction to research and development cost part of the agreement merck made an upfront payment to astrazeneca of billion in and made payment of million over multi year period for certain license option of which million wa paid in december million wa paid in december and million wa paid in december the company recorded an aggregate charge of billion in research and development expense in related to the upfront payment and license option payment in addition the agreement provides for additional contingent payment from merck to astrazeneca related to the successful achievement of sale based and regulatory milestone in merck determined it wa probable that annual sale of lynparza in the future would trigger million sale based milestone payment from merck to astrazeneca accordingly in merck recorded of contentsmillion liability and corresponding increase to the intangible asset related to lynparza prior to merck accrued sale based milestone payment aggregating million of which million and million wa paid to astrazeneca in and respectively and the remainder of million wa paid in january potential future sale based milestone payment of billion have not yet been accrued they are not deemed by the company to be probable at this time in lynparza received regulatory approval in the european union eu both monotherapy for the treatment of certain adult patient with advanced breast cancer and monotherapy for the maintenance treatment of certain adult patient with brca mutated advanced ovarian cancer each of these approval triggered million capitalized milestone payment from merck to astrazeneca in lynparza received regulatory approval triggering capitalized milestone payment of million in the aggregate from merck to astrazeneca potential future regulatory milestone payment of billion remain under the agreement the intangible asset balance related to lynparza which includes capitalized sale based and regulatory milestone payment wa million at december and is included in other intangible net on the consolidated balance sheet the amount is being amortized over it estimated useful life through supported by projected future cash flow subject to impairment testing summarized financial information related to this collaboration is follows year ended december revenue cost of sale general and and development december receivables from astrazeneca included in other current asset payable to astrazeneca included in accrued and other current liability payable to astrazeneca included other noncurrent liability represents amortization of capitalized milestone payment amount for includes billion related to the upfront payment and license option payment includes accrued milestone payment eisaiin march merck and eisai announced strategic collaboration for the worldwide co development and co commercialization of lenvima an orally available tyrosine kinase inhibitor discovered by eisai under the agreement merck and eisai will develop and commercialize lenvima jointly both monotherapy and in combination with merck keytruda eisai record lenvima product sale globally eisai is the principal on lenvima sale transaction and merck and eisai share gross profit equally merck record it share of lenvima product sale net of cost of sale and commercialization cost alliance revenue expense incurred during co development including for study evaluating lenvima monotherapy are shared equally by the two company and reflected in research and development expense under the agreement merck made an upfront payment to eisai of million and will make payment of up to million for certain option right through of which million wa paid in march million is expected to be paid in march and million is expected to be paid in march the company recorded an aggregate charge of billion in research and development expense in related to the upfront payment and future option payment in addition the agreement provides for additional contingent payment from merck to eisai related to the successful achievement of sale based and regulatory milestone in merck determined it wa probable that annual sale of lenvima in the future would trigger sale based milestone payment from merck to eisai aggregating million accordingly in merck recorded million of liability and corresponding increase to the intangible asset related to lenvima in merck accrued sale based milestone payment aggregating million related to lenvima of these amount million wa paid of contentsto eisai in and an additional million wa paid in january potential future sale based milestone payment of billion have not yet been accrued they are not deemed by the company to be probable at this time in lenvima received regulatory approval triggering capitalized milestone payment of million in the aggregate from merck to eisai potential future regulatory milestone payment of million remain under the agreement the intangible asset balance related to lenvima which includes capitalized sale based and regulatory milestone payment wa million at december and is included in other intangible net on the consolidated balance sheet the amount is being amortized over it estimated useful life through supported by projected future cash flow subject to impairment testing summarized financial information related to this collaboration is follows year ended december revenue cost of sale general and and development december from eisai included in other current asset to eisai included in accrued and other current liability to eisai included in other noncurrent liability represents amortization of capitalized milestone payment amount for includes billion related to the upfront payment and option payment includes accrued milestone and future option payment bayer ag in the company entered into worldwide clinical development collaboration with bayer ag bayer to market and develop soluble guanylate cyclase sgc modulators including bayer adempas which is approved to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension the two company have implemented joint development and commercialization strategy the collaboration also includes clinical development of bayer vericiguat which is in phase trial for worsening heart failure well opt in right for other early stage sgc compound in development by bayer merck in turn made available it early stage sgc compound under similar term under the agreement bayer lead commercialization of adempas in the america while merck lead commercialization in the rest of the world for vericiguat and other potential opt in product bayer will lead commercialization in the rest of world and merck will lead in the america for all product and candidate included in the agreement both company will share in development cost and profit on sale and will have the right to co promote in territory where they are not the lead revenue from adempas includes sale in merck marketing territory well merck share of profit from the sale of adempas in bayer marketing territory in addition the agreement provides for additional contingent payment from merck to bayer related to the successful achievement of sale based milestone in merck determined it wa probable that annual worldwide sale of adempas in the future would trigger million sale based milestone payment from merck to bayer accordingly merck recorded million liability and corresponding increase to the intangible asset related to adempas in the company made million milestone payment to bayer which wa accrued for in when merck deemed the payment to be probable there is an additional million potential future sale based milestone payment that ha not yet been accrued it is not deemed by the company to be probable at this time the intangible asset balance related to adempas which includes the acquired intangible asset balance well capitalized sale based milestone payment wa million at december and is included in other intangible net on the consolidated balance sheet the amount is being amortized over it estimated useful life through supported by projected future cash flow subject to impairment testing of contentssummarized financial information related to this collaboration is follows year ended december product sale recorded by merck profit share from sale in bayer marketing cost of sale general and and december receivables from bayer included in other current asset payable to bayer included in other noncurrent liability includes amortization of intangible asset represents accrued milestone payment restructuringin early merck approved new global restructuring program restructuring program part of worldwide initiative focused on further optimizing the company manufacturing and supply network well reducing it global real estate footprint this program is continuation of the company plant rationalization build on prior restructuring program and doe not include any action associated with the planned spin off of newco the company continues to evaluate it global footprint and overall operating model it ha subsequently identified additional action under the restructuring program and could identify further action over time the action currently contemplated under the restructuring program are expected to be substantially completed by the end of with the cumulative pretax cost to be incurred by the company to implement the program now estimated to be approximately billion the company estimate that approximately of the cumulative pretax cost will result in cash outlay primarily related to employee separation expense and facility shut down cost approximately of the cumulative pretax cost will be non cash relating primarily to the accelerated depreciation of facility to be closed or divested the company expects to record charge of approximately million in related to the restructuring program action under previous global restructuring program have been substantially completed the company recorded total pretax cost of million in million in and million in related to restructuring program activity for segment reporting restructuring charge are unallocated expense of contentsthe following table summarizes the charge related to restructuring program activity by type of cost separationcosts accelerateddepreciation other totalyear ended december cost of sale general and administrative and development ended december cost of sale general and administrative and development ended december cost of sale general and administrative and development cost are associated with actual headcount reduction well those headcount reduction which were probable and could be reasonably estimated accelerated depreciation cost primarily relate to manufacturing research and administrative facility and equipment to be sold or closed part of the program accelerated depreciation cost represent the difference between the depreciation expense to be recognized over the revised useful life of the asset based upon the anticipated date the site will be closed or divested or the equipment disposed of and depreciation expense determined utilizing the useful life prior to the restructuring action all the site have and will continue to operate up through the respective closure date and since future undiscounted cash flow are sufficient to recover the respective book value merck is recording accelerated depreciation over the revised useful life of the site asset anticipated site closure date particularly related to manufacturing location have been and may continue to be adjusted to reflect change resulting from regulatory or other factor other activity in and includes asset abandonment facility shut down and other related cost well pretax gain and loss resulting from the sale of facility and related asset additionally other activity includes certain employee related cost associated with pension and other postretirement benefit plan see note and share based compensation the following table summarizes the charge and spending relating to restructuring program activity separationcosts accelerateddepreciation other totalrestructuring reserve january payment receipt net non cash activity reserve december payment receipt net non cash activity restructuring reserve december the remaining cash outlay are expected to be substantially completed by the end of of financial instrumentsderivative instrument and hedging activitiesthe company manages the impact of foreign exchange rate movement and interest rate movement on it earnings cash flow and fair value of asset and liability through operational mean and through the use of various financial instrument including derivative instrument significant portion of the company revenue and earnings in foreign affiliate is exposed to change in foreign exchange rate the objective and accounting related to the company foreign currency risk management program well it interest rate risk management activity are discussed below foreign currency risk managementthe company ha established revenue hedging balance sheet risk management and net investment hedging program to protect against volatility of future foreign currency cash flow and change in fair value caused by change in foreign exchange rate the objective of the revenue hedging program is to reduce the variability caused by change in foreign exchange rate that would affect the dollar value of future cash flow derived from foreign currency denominated sale primarily the euro japanese yen and chinese renminbi to achieve this objective the company will hedge portion of it forecasted foreign currency denominated third party and intercompany distributor entity sale forecasted sale that are expected to occur over it planning cycle typically no more than two year into the future the company will layer in hedge over time increasing the portion of forecasted sale hedged it get closer to the expected date of the forecasted sale the portion of forecasted sale hedged is based on assessment of cost benefit profile that consider natural offsetting exposure revenue and exchange rate volatility and correlation and the cost of hedging instrument the company manages it anticipated transaction exposure principally with purchased local currency put option forward contract and purchased collar option the fair value of these derivative contract are recorded either asset gain position or liability loss position in the consolidated balance sheet change in the fair value of derivative contract are recorded each period in either current earnings or oci depending on whether the derivative is designated part of hedge transaction and if so the type of hedge transaction for derivative that are designated cash flow hedge the unrealized gain or loss on these contract is recorded in aoci and reclassified into sale when the hedged anticipated revenue is recognized for those derivative which are not designated cash flow hedge but serve economic hedge of forecasted sale unrealized gain or loss are recorded in sale each period the cash flow from both designated and non designated contract are reported operating activity in the consolidated statement of cash flow the company doe not enter into derivative for trading or speculative purpose the company manages operating activity and net asset position at each local subsidiary in order to mitigate the effect of exchange on monetary asset and liability the company also us balance sheet risk management program to mitigate the exposure of net monetary asset that are denominated in currency other than subsidiary functional currency from the effect of volatility in foreign exchange in these instance merck principally utilizes forward exchange contract to offset the effect of exchange on exposure denominated in developed country currency primarily the euro and japanese yen for exposure in developing country currency the company will enter into forward contract to partially offset the effect of exchange on exposure when it is deemed economical to do so based on cost benefit analysis that considers the magnitude of the exposure the volatility of the exchange rate and the cost of the hedging instrument the cash flow from these contract are reported operating activity in the consolidated statement of cash flow monetary asset and liability denominated in currency other than the functional currency of given subsidiary are remeasured at spot rate in effect on the balance sheet date with the effect of change in spot rate reported in other income expense net the forward contract are not designated hedge and are marked to market through other income expense net accordingly fair value change in the forward contract help mitigate the change in the value of the remeasured asset and liability attributable to change in foreign currency exchange rate except to the extent of the spot forward difference these difference are not significant due to the short term nature of the contract which typically have average maturity at inception of le than one year of contentsthe company also us forward exchange contract to hedge portion of it net investment in foreign operation against movement in exchange rate the forward contract are designated hedge of the net investment in foreign operation the unrealized gain or loss on these contract are recorded in foreign currency translation adjustment within oci and remain in aoci until either the sale or complete or substantially complete liquidation of the subsidiary the company excludes certain portion of the change in fair value of it derivative instrument from the assessment of hedge effectiveness excluded component change in fair value of the excluded component are recognized in oci the company recognizes in earnings the initial value of the excluded component on straight line basis over the life of the derivative instrument rather than using the mark to market approach the cash flow from these contract are reported investing activity in the consolidated statement of cash flow foreign exchange risk is also managed through the use of foreign currency debt the company senior unsecured euro denominated note have been designated and are effective economic hedge of the net investment in foreign operation accordingly foreign currency transaction gain or loss due to spot rate fluctuation on the euro denominated debt instrument are included in foreign currency translation adjustment within oci the effect of the company net investment hedge on oci and the consolidated statement of income are shown below amount of pretax gain loss recognized in other comprehensive income amount of pretax gain loss recognized in other income expense net for amount excluded from effectiveness testingyears ended december investment hedging relationship foreign exchange contract euro denominated note no amount were reclassified from aoci into income related to the sale of subsidiary interest rate risk managementthe company may use interest rate swap contract on certain investing and borrowing transaction to manage it net exposure to interest rate change and to reduce it overall cost of borrowing the company doe not use leveraged swap and in general doe not leverage any of it investment activity that would put principal capital at risk at december the company wa party to pay floating receive fixed interest rate swap contract designated fair value hedge of fixed rate note in which the notional amount match the amount of the hedged fixed rate note detailed in the table below instrumentpar value of debt number of interest rate swap held total swap notional note due note due note due note due interest rate swap contract are designated hedge of the fair value change in the note attributable to change in the benchmark london interbank offered rate libor swap rate the fair value change in the note attributable to change in the libor swap rate are recorded in interest expense along with the offsetting fair value change in the swap contract the cash flow from these contract are reported operating activity in the consolidated statement of cash flow of contentsthe table below present the location of amount recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedge of december carrying amount of hedged liability cumulative amount of fair value hedging adjustment increase decrease included in the carrying amount sheet line item in which hedged item is included loan payable and current portion of long term debt long term presented in the table below is the fair value of derivative on gross basis segregated between those derivative that are designated hedging instrument and those that are not designated hedging instrument of december fair value ofderivative dollarnotional fair value ofderivative dollarnotional balance sheet caption asset liability asset liability derivative designated hedging instrument interest rate swap contractsother asset interest rate swap contractsaccrued and other current liability interest rate swap contractsother noncurrent liability exchange contractsother current asset exchange contractsother asset exchange contractsaccrued and other current liability exchange contractsother noncurrent liability not designated hedging instrument foreign exchange contractsother current asset exchange contractsaccrued and other current liability noted above the company record it derivative on gross basis in the consolidated balance sheet the company ha master netting agreement with several of it financial institution counterparties see concentration of credit risk below the following table provides information on the company derivative position subject to these master netting arrangement if they were presented on net basis allowing for the right of offset by counterparty and cash collateral exchanged per the master agreement and related credit support annex at december asset liability asset liabilitygross amount recognized in the consolidated balance sheet amount subject to offset in master netting arrangement not offset in the consolidated balance sheet cash collateral received net amount of contentsthe table below provides information regarding the location and amount of pretax gain loss of derivative designated in fair value or cash flow hedging relationship sale other income expense net other comprehensive income loss year ended december statement line item in which effect of fair value or cash flow hedge are recorded gain loss on fair value hedging relationship interest rate swap contract hedged item derivative designated hedging instrument impact of cash flow hedging relationship foreign exchange contract amount of gain loss recognized in oci on derivative decrease increase in sale result of aoci interest rate contract amount of gain recognized in other income expense net on derivative amount of loss recognized in oci on derivative interest expense is component of other income expense net the table below provides information regarding the income statement effect of derivative not designated hedging instrument amount of derivative pretax gain loss recognized in incomeyears ended december statement caption not designated hedging instrument foreign exchange contract other income expense net exchange contract sale these derivative contract mitigate change in the value of remeasured foreign currency denominated monetary asset and liability attributable to change in foreign currency exchange rate these derivative contract serve economic hedge of forecasted transaction at december the company estimate million of pretax net unrealized gain on derivative maturing within the next month that hedge foreign currency denominated sale over that same period will be reclassified from aoci to sale the amount ultimately reclassified to sale may differ foreign exchange rate change realized gain and loss are ultimately determined by actual exchange rate at maturity of contentsinvestments in debt and equity securitiesinformation on investment in debt and equity security at december is follows amortizedcost gross unrealized fairvalue amortizedcost gross unrealized fairvalue gain loss gain loss commercial paper corporate note and government and agency backed government bond backed security debt traded equity security debt and publicly traded equity security unrealized net gain recognized in other income expense net on equity security still held at december were million during unrealized net loss recognized in other income expense net on equity security still held at december were million during at december and the company also had million and million respectively of equity investment without readily determinable fair value included in other asset during and the company recognized unrealized gain of million and million respectively in other income expense net on certain of these equity investment based on favorable observable price change from transaction involving similar investment of the same investee in addition during and the company recognized unrealized loss of million and million respectively in other income expense net related to certain of these investment based on unfavorable observable price change cumulative unrealized gain and cumulative unrealized loss based on observable price change for investment in equity investment without readily determinable fair value were million and million respectively available for sale debt security included in short term investment totaled million at december of the remaining debt security million mature within five year at december and there were no debt security pledged collateral fair value measurementsfair value is defined the exchange price that would be received for an asset or paid to transfer liability an exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between market participant on the measurement date the company us fair value hierarchy which maximizes the use of observable input and minimizes the use of unobservable input when measuring fair value there are three level of input used to measure fair value with level having the highest priority and level having the lowest level quoted price unadjusted in active market for identical asset or liability level observable input other than level price such quoted price for similar asset or liability or other input that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability level unobservable input that are supported by little or no market activity level asset or liability are those whose value are determined using pricing model discounted cash flow methodology or similar technique with significant unobservable input well asset or liability for which the determination of fair value requires significant judgment or estimation if the input used to measure the financial asset and liability fall within more than one level described above the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument of contentsfinancial asset and liability measured at fair value on recurring basisfinancial asset and liability measured at fair value on recurring basis at december are summarized below fair value measurement using fair value measurement using level level level total level level level total investment commercial paper corporate note and bond backed security government and agency security government bond traded equity asset government and agency note and bond backed security backed security traded equity asset forward exchange contract currency option rate swap asset other liability contingent consideration liability forward exchange contract rate swap currency option liability primarily all of the asset backed security are highly rated standard poor rating of aaa and moody investor service rating of aaa secured primarily by auto loan credit card and student loan receivables with weighted average life of primarily year or le investment included in other asset are restricted to use including for the payment of benefit under employee benefit plan the fair value determination of derivative includes the impact of the credit risk of counterparties to the derivative and the company own credit risk the effect of which were not significant of december cash and cash equivalent of billion include billion of cash equivalent which would be considered level in the fair value hierarchy of contentscontingent considerationsummarized information about the change in liability for contingent consideration associated with business acquisition is follows value january in estimated fair value fair value december recorded in cost of sale research and development expense and other income expense net includes cumulative translation adjustment balance at december includes million recorded current liability for amount expected to be paid within the next month at december and million and million respectively of the liability relate to the termination of the spmsd joint venture in part of the termination merck recorded liability for contingent future royalty payment of on net sale of all merck product that were previously sold by the joint venture through december the fair value of this liability is determined utilizing the estimated amount and timing of projected cash flow and risk adjusted discount rate of is used to present value the cash flow the change in the estimated fair value of liability for contingent consideration in and were largely attributable to increase in the liability recorded in connection with the termination of the sanofi pasteur msd spmsd joint venture in in these increase were partially offset by the reversal of liability related to the discontinuation of program obtained in connection with the acquisition of smartcells see note the payment of contingent consideration in both year relate to the spmsd termination liability described above the payment of contingent consideration in also include million related to the achievement of clinical development milestone for mk gefapixant program obtained in connection with the acquisition of afferent pharmaceutical other fair value measurementssome of the company financial instrument such cash and cash equivalent receivables and payable are reflected in the balance sheet at carrying value which approximates fair value due to their short term nature the estimated fair value of loan payable and long term debt including current portion at december wa billion compared with carrying value of billion and at december wa billion compared with carrying value of billion fair value wa estimated using recent observable market price and would be considered level in the fair value hierarchy concentration of credit riskon an ongoing basis the company monitor concentration of credit risk associated with corporate and government issuer of security and financial institution with which it conduct business credit exposure limit are established to limit concentration with any single issuer or institution cash and investment are placed in instrument that meet high credit quality standard specified in the company investment policy guideline the majority of the company account receivable arise from product sale in the united state europe and china and are primarily due from drug wholesaler and retailer hospital government agency managed health care provider and pharmacy benefit manager the company monitor the financial performance and creditworthiness of it customer so that it can properly ass and respond to change in their credit profile the company also continues to monitor global economic condition including the volatility associated with international sovereign economy and associated impact on the financial market and it business the company customer with the largest account receivable balance are mckesson corporation amerisourcebergen corporation and cardinal health inc which represented in aggregate approximately of total account receivable at december the company monitor the creditworthiness of it customer to which it grant credit term in the normal course of business bad debt have been minimal the company doe not normally require collateral or other security to support credit sale the company ha account receivable factoring agreement with financial institution in certain country to sell account receivable in the company expanded it factoring arrangement in china and entered into factoring agreement to sell account receivable from the company major distributor the company factored of content billion and billion of account receivable in the fourth quarter of and respectively under these factoring arrangement which reduced outstanding account receivable the cash received from the financial institution is reported within operating activity in the consolidated statement of cash flow in certain of these factoring arrangement for ease of administration the company will collect customer payment related to the factored receivables which it then remit to the financial institution at december the company had collected million on behalf of the financial institution which is reflected restricted cash in other current asset and the related obligation to remit the cash within accrued and other current liability the company remitted the cash to the financial institution in january the net cash flow relating to these collection are reported financing activity in the consolidated statement of cash flow the cost of factoring such account receivable were de minimis derivative financial instrument are executed under international swap and derivative association master agreement the master agreement with several of the company financial institution counterparties also include credit support annex these annex contain provision that require collateral to be exchanged depending on the value of the derivative asset and liability the company credit rating and the credit rating of the counterparty cash collateral received by the company from various counterparties wa million and million at december and respectively the obligation to return such collateral is recorded in accrued and other current liability no cash collateral wa advanced by the company to counterparties of december or inventoriesinventories at december consisted of good material and work in approximates current cost decrease increase to lifo cost inventory valued under the lifo method comprised approximately billion and billion at december and respectively amount recognized other asset are comprised almost entirely of raw material and work in process inventory at december and these amount included billion and billion respectively of inventory not expected to be sold within one year in addition these amount included million and million at december and respectively of inventory produced in preparation for product launch of goodwill and other intangiblesthe following table summarizes goodwill activity by segment pharmaceutical animal health all other totalbalance january other december other balance december other includes cumulative translation adjustment on goodwill balance and certain other adjustment accumulated goodwill impairment loss at december and were million and million respectively the addition to goodwill within the animal health segment in primarily relate to the acquisition of antelliq see note the impairment of goodwill within other non reportable segment in and relate to certain business within the healthcare service segment other intangible at december consisted of grosscarryingamount accumulatedamortization net grosscarryingamount accumulatedamortization netproducts and product right intangible include product and product right license trade name and patent which are initially recorded at fair value assigned an estimated useful life and amortized primarily on straight line basis over their estimated useful life some of the company more significant acquired intangible on net basis related to human health marketed product included in product and product right above at december include zerbaxa billion implanon nexplanon million gardasil gardasil million dificid million bridion million sivextro million and simponi million additionally the company had billion of acquired intangible related to animal health marketed product at december some of the company more significant intangible asset included in license above at december include lenvima million and lynparza million result of collaboration with eisai and astrazeneca see note the increase in trade name in reflects billion of intangible acquired in the antelliq acquisition in see note the company ha an intangible asset related to adempas result of collaboration with bayer see note that had carrying value of million at december reflected in other in the table above in the company recorded impairment charge related to marketed product and other intangible of million within cost of sale of this amount million related to sivextro product for the treatment of acute bacterial skin and skin structure infection caused by designated susceptible gram positive organism part of reorganization and reprioritization of it internal sale force the company made the decision to cease promotion of sivextro in the market by the end of this decision resulted in reduced cash flow projection for sivextro which indicated that the sivextro intangible asset value wa not fully recoverable on an undiscounted cash flow basis the company utilized market participant assumption to determine it best estimate of the fair value of the intangible of contentsasset related to sivextro that when compared with it related carrying value resulted in the impairment charge noted above in the company recorded impairment charge related to marketed product and other intangible of million of this amount million related to intron treatment for certain type of cancer sale of intron were being adversely affected by the availability of new therapeutic option in sale of intron in the united state eroded more rapidly than previously anticipated by the company which led to change in the cash flow assumption for intron these revision to cash flow indicated that the intron intangible asset value wa not fully recoverable on an undiscounted cash flow basis the company utilized market participant assumption to determine it best estimate of the fair value of the intangible asset related to intron that when compared with it related carrying value resulted in the impairment charge noted above the remaining charge in relate to the impairment of customer relationship tradename and developed technology intangible for certain business in the healthcare service segment ipr that the company acquires through business combination represents the fair value assigned to incomplete research project which at the time of acquisition have not reached technological feasibility amount capitalized ipr are accounted for indefinite lived intangible asset subject to impairment testing until completion or abandonment of the project upon successful completion of each project the company will make separate determination to the then useful life of the asset and begin amortization in the company recorded million of ipr impairment charge within research and development expense of this amount million relates to the write off of the intangible asset balance for program obtained in connection with the acquisition of iomet pharma ltd following review of clinical trial result conducted by merck along with external clinical trial result for similar compound the discontinuation of this clinical development program resulted in reversal of the related liability for contingent consideration of million in the company recorded million of ipr impairment charge of this amount million relates to the write off of the remaining intangible asset balance for program obtained in connection with the smartcells acquisition following decision to terminate the program due to product development issue the discontinuation of this clinical development program resulted in reversal of the related liability for contingent consideration of million see note in the company recorded million of ipr impairment charge of this amount million resulted from strategic decision to discontinue the development of the investigational combination regimen mk grazoprevir ruzasvir uprifosbuvir and mk ruzasvir uprifosbuvir for the treatment of chronic hepatitis virus hcv infection this decision wa made based on review of available phase efficacy data and in consideration of the evolving marketplace and the growing number of treatment option available for patient with chronic hcv infection including zepatier which is marketed by the company for the treatment of adult patient with chronic hcv infection result of this decision the company recorded an ipr impairment charge to write off the remaining intangible asset related to uprifosbuvir the ipr impairment charge in also include charge of million to write off the intangible asset related to verubecestat an investigational small molecule inhibitor of the beta site amyloid precursor protein cleaving enzyme resulting from decision in february to stop phase study evaluating verubecestat in people with prodromal alzheimer disease the decision to stop the study followed recommendation by the external data monitoring committee edmc which assessed overall benefit risk during an interim safety analysis the edmc concluded that it wa unlikely that positive benefit risk could be established if the trial continued the ipr project that remain in development are subject to the inherent risk and uncertainty in drug development and it is possible that the company will not be able to successfully develop and complete the ipr program and profitably commercialize the underlying product candidate the company may recognize additional non cash impairment charge in the future related to other marketed product or pipeline program and such charge could be material aggregate amortization expense recorded within cost of sale wa billion in billion in and billion in the estimated aggregate amortization expense for each of the next five year is follows billion billion billion billion billion of loan payable long term debt and leasesloans payableloans payable at december included billion of note due in billion of commercial paper and million of long dated note that are subject to repayment at the option of the holder loan payable at december included billion of commercial paper and million of long dated note that are subject to repayment at the option of the holder the weighted average interest rate of commercial paper borrowing wa and for the year ended december and respectively long term debtlong term debt at december consisted of note due note due note due note due note due note due note due note due euro denominated note due euro denominated note due note due note due note due note due euro denominated note due euro denominated note due euro denominated note due note due note due note due debenture due note due debenture due debenture due note due rate note due presented in the table above includes million and million at december and respectively of borrowing at variable rate that resulted in effective interest rate of and for and respectively with the exception of the debenture due the note listed in the table above are redeemable in whole or in part at merck option at any time at varying redemption price in march the company issued billion principal amount of senior unsecured note consisting of million of note due billion of note due billion of note due and billion of note due the company used the net proceeds from the offering of billion for general corporate purpose including the repayment of outstanding commercial paper borrowing of contentseffective of november the company executed full and unconditional guarantee of the then existing debt of it subsidiary merck sharp dohme corp msd and msd executed full and unconditional guarantee of the then existing debt of the company excluding commercial paper including for payment of principal and interest these guarantee do not extend to debt issued subsequent to that date certain of the company borrowing require that merck comply with covenant and at december the company wa in compliance with these covenant the aggregate maturity of long term debt for each of the next five year are follows billion billion billion billion billion the company ha billion credit facility that matures in june the facility provides backup liquidity for the company commercial paper borrowing facility and is to be used for general corporate purpose the company ha not drawn funding from this facility leasesas discussed in note on january merck adopted new guidance for the accounting and reporting of lease the company ha operating lease primarily for manufacturing facility research and development facility corporate office employee housing vehicle and certain equipment permitted under the transition guidance in asc the company elected package of practical expedient which among other provision allowed the company to carry forward historical lease classification the company determines if an arrangement is lease at inception when evaluating contract for embedded lease the company exercise judgment to determine if there is an explicit or implicit identified asset in the contract and if merck control the use of that asset embedded lease primarily associated with contract manufacturing organization are immaterial under asc transition guidance merck elected the hindsight practical expedient to determine the lease term for existing lease which permit company to consider available information prior to the effective date of the new guidance to the actual or likely exercise of option to extend or terminate the lease the lease term includes option to extend or terminate the lease when it is reasonably certain that merck will exercise that option real estate lease for facility have an average remaining lease term of eight year which include option to extend the lease for up to four year where applicable vehicle lease are generally in effect for four year the company ha made an accounting policy election not to record short term lease lease with an initial term of month or le on the balance sheet however merck currently ha no short term lease lease expense for operating lease payment is recognized on straight line basis over the term of the lease operating lease asset and liability are recognized based on the present value of lease payment over the lease term since the company lease do not have readily determinable implicit discount rate the company us it incremental borrowing rate to calculate the present value of lease payment by asset class on quarterly basis an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the company pretax cost of debt for that same term the updated rate for each asset class are applied prospectively to new lease practical expedient the company ha made an accounting policy election for all asset class not to separate lease component payment for rent real estate tax and insurance cost from non lease component common area maintenance cost in the event that the agreement contains both merck includes both the lease and non lease component for purpose of calculating the right of use asset and related lease liability if the non lease component are fixed for vehicle lease and employee housing the company applies portfolio approach to effectively account for the operating lease asset and liability certain of the company lease agreement contain variable lease payment that are adjusted periodically for inflation or for actual operating expense true ups compared with estimated amount however these amount are immaterial sublease income and activity related to sale and leaseback transaction are immaterial merck lease agreement do not contain any material residual value guarantee or material restrictive covenant operating lease cost wa million in cash paid for amount included in the measurement of operating lease liability wa million in operating lease asset obtained in exchange for lease obligation wa million in of contentssupplemental balance sheet information related to operating lease is follows december other asset accrued and other current noncurrent average remaining lease term year average discount includes prepaid lease that have no related lease liability maturity of operating lease liability are follows lease imputed december the company had entered into additional real estate operating lease that had not yet commenced the obligation associated with these lease total million of which million relates to lease that will commence in april and ha lease term of year of december prior to the adoption of asc the minimum aggregate rental commitment under noncancellable lease were follows million million million million million and thereafter million contingency and environmental liability the company is involved in various claim and legal proceeding of nature considered normal to it business including product liability intellectual property and commercial litigation well certain additional matter including governmental and environmental matter in the opinion of the company it is unlikely that the resolution of these matter will be material to the company financial condition result of operation or cash flow given the nature of the litigation discussed below and the complexity involved in these matter the company is unable to reasonably estimate possible loss or range of possible loss for such matter until the company know among other factor what claim if any will survive dispositive motion practice ii the extent of the claim including the size of any potential class particularly when damage are not specified or are indeterminate iii how the discovery process will affect the litigation iv the settlement posture of the other party to the litigation and any other factor that may have material effect on the litigation the company record accrual for contingency when it is probable that liability ha been incurred and the amount can be reasonably estimated these accrual are adjusted periodically assessment change or additional information becomes available for product liability claim portion of the overall accrual is actuarially determined and considers such factor past experience number of claim reported and estimate of claim incurred but not yet reported individually significant contingent loss are accrued when probable and reasonably estimable legal defense cost expected to be incurred in connection with loss contingency are accrued when probable and reasonably estimable of contentsthe company decision to obtain insurance coverage is dependent on market condition including cost and availability existing at the time such decision are made the company ha evaluated it risk and ha determined that the cost of obtaining product liability insurance outweighs the likely benefit of the coverage that is available and such ha no insurance for most product liability product liability litigationfosamaxas previously disclosed merck is defendant in product liability lawsuit in the united state involving fosamax fosamax litigation of december approximately case are pending against merck in either federal or state court plaintiff in the vast majority of these case generally allege that they sustained femur fracture and or other bone injury femur fracture in association with the use of fosamax all federal case involving allegation of femur fracture have been or will be transferred to multidistrict litigation in the district of new jersey femur fracture mdl in the only bellwether case tried to date in the femur fracture mdl glynn merck the jury returned verdict in merck favor in addition in june the femur fracture mdl court granted merck motion for judgment matter of law in the glynn case and held that the plaintiff failure to warn claim wa preempted by federal law in august the femur fracture mdl court entered an order requiring plaintiff in the femur fracture mdl to show cause those case asserting claim for femur fracture injury that took place prior to september should not be dismissed based on the court preemption decision in the glynn case pursuant to the show cause order in march the femur fracture mdl court dismissed with prejudice approximately case on preemption ground plaintiff in approximately of those case appealed that decision to the court of appeal for the third circuit third circuit in march the third circuit issued decision reversing the femur fracture mdl court preemption ruling and remanding the appealed case back to the femur fracture mdl court merck filed petition for writ of certiorari to the supreme court in august seeking review of the third circuit decision the supreme court granted merck petition in june and in may the supreme court issued it opinion and decided that the third circuit had incorrectly concluded that the issue of preemption should be resolved by jury and accordingly vacated the judgment of the third circuit and remanded the proceeding back to the third circuit to address the issue in manner consistent with the supreme court opinion on november the third circuit remanded the case back to the district court in order to allow that court to determine in the first instance whether the plaintiff state law claim are preempted by federal law under the standard described by the supreme court in it opinion on december the district court ordered merck to serve it opening brief on or before february and plaintiff to file their responsive brief on or before april merck may then file reply on or before may accordingly of december approximately case were actively pending in the femur fracture mdl of december approximately case alleging femur fracture have been filed in new jersey state court and are pending before judge james hyland in middlesex county the party selected an initial group of case to be reviewed through fact discovery and merck ha continued to select additional case to be reviewed of december approximately case alleging femur fracture have been filed and are pending in california state court all of the femur fracture case filed in california state court have been coordinated before single judge in orange county california additionally there are four femur fracture case pending in other state court discovery is presently stayed in the femur fracture mdl and in the state court in california merck intends to defend against these lawsuit januvia janumetas previously disclosed merck is defendant in product liability lawsuit in the united state involving januvia and or janumet of december merck is aware of approximately product user alleging that januvia and or janumet caused the development of pancreatic cancer and other injury of contentsmost claim have been filed in multidistrict litigation before the district court for the southern district of california mdl outside of the mdl the majority of claim have been filed in coordinated proceeding before the superior court of california county of los angeles california state court in november the mdl and california state court in separate opinion granted summary judgment to defendant on ground of federal preemption plaintiff appealed in both forum in november the court of appeal for the ninth circuit vacated the judgment and remanded for further discovery in november the california state appellate court reversed and remanded on similar ground in march the party in the mdl and the california coordinated proceeding agreed to coordinate and adopt schedule for completing discovery on general causation and preemption issue and for renewing summary judgment and daubert motion under the stipulated case management schedule the hearing for daubert and summary judgment motion are expected to take place in june of december six product user have claim pending against merck in state court other than california including illinois in june the illinois trial court denied merck motion for summary judgment based on federal preemption merck appealed and the illinois appellate court affirmed in december merck filed petition for leave to appeal to the illinois supreme court in february in april the illinois supreme court stayed consideration of the pending petition to appeal until the supreme court issued it opinion in merck sharp dohme corp albrecht relating to the fosamax matter discussed above merck filed the opinion in albrecht with the illinois supreme court in june the petition for leave to appeal wa decided on september in which the illinois supreme court directed the intermediate appellate court to reconsider it earlier ruling the illinois appellate court issued favorable decision concluding consistent with albrecht that preemption present legal question to be resolved by the court in addition to the claim noted above the company ha agreed to toll the statute of limitation for approximately additional claim the company intends to continue defending against these lawsuit vioxxas previously disclosed merck is defendant in lawsuit brought by the attorney general of utah alleging that merck misrepresented the safety of vioxx the lawsuit is pending in utah state court utah seek damage and penalty under the utah false claim act bench trial in this matter is currently scheduled for april governmental proceedingsas previously disclosed in the fall of the company received record subpoena from the attorney office for the district of vermont vt usao pursuant to section of the health insurance portability and accountability act of hipaa relating to an investigation of potential health care offense the subpoena sought information relating to any actual or potential business relationship or arrangement merck ha had with practice fusion inc pfi cloud based electronic health record ehr company that wa acquired by allscripts in january the company cooperated with the government and responded to that subpoena subsequently on may merck received second record subpoena from the vt usao that broadened the government information request by seeking information relating to merck relationship with any ehr company shortly thereafter the vt usao served civil investigation demand cid upon merck similarly seeking information on the company relationship with ehr vendor the cid explains that the government is conducting false claim act investigation concerning whether merck and or pfi submitted claim to federal healthcare program that violate the federal anti kickback statute merck is cooperating with the government investigation previously disclosed on april merck received set of investigative interrogatory from the california attorney general office pursuant to it investigation of conduct and agreement that allegedly affected or delayed competition to lantus in the insulin market the interrogatory seek information concerning merck development of an insulin glargine product and it subsequent termination well merck patent litigation against sanofi concerning lantus and the resolution of that litigation merck is cooperating with the california attorney general investigation previously disclosed the company subsidiary in china have received and may continue to receive inquiry regarding their operation from various chinese governmental agency some of these inquiry may be of contentsrelated to matter involving other multinational pharmaceutical company well chinese entity doing business with such company the company policy is to cooperate with these authority and to provide response appropriate previously disclosed from time to time the company receives inquiry and is the subject of preliminary investigation activity from competition and other governmental authority in market outside the united state these authority may include regulator administrative authority and law enforcement and other similar official and these preliminary investigation activity may include site visit formal or informal request or demand for document or material inquiry or interview and similar matter certain of these preliminary inquiry or activity may lead to the commencement of formal proceeding should those proceeding be determined adversely to the company monetary fine and or remedial undertaking may be required commercial and other litigationzetia antitrust litigationas previously disclosed merck msd schering corporation and msp singapore company llc collectively the merck defendant are defendant in putative class action and opt out lawsuit filed in on behalf of direct and indirect purchaser of zetia alleging violation of federal and state antitrust law well other state statutory and common law cause of action the case have been consolidated for pretrial purpose in federal multidistrict litigation before judge rebecca beach smith in the eastern district of virginia in december the court denied the merck defendant motion to dismiss or stay the direct purchaser putative class action pending bilateral arbitration on august the district court adopted in full the report and recommendation of the magistrate judge with respect to the merck defendant motion to dismiss on non arbitration issue thereby granting in part and denying in part merck defendant motion to dismiss in addition on june the representative of the putative direct purchaser class filed an amended complaint and on august retailer opt out plaintiff filed an amended complaint the merck defendant moved to dismiss the new allegation in both complaint on october the magistrate judge issued report and recommendation recommending that the district judge grant the motion in their entirety on december the district court adopted this report and recommendation in part the district court granted the merck defendant motion to dismiss to the extent the motion sought dismissal of claim for overcharge paid by entity that purchased generic ezetimibe from par pharmaceutical inc par pharmaceutical and dismissed any claim for such overcharge trial is currently scheduled to begin on october rotavirus vaccine antitrust litigationas previously disclosed msd is defendant in putative class action lawsuit filed in on behalf of direct purchaser of rotateq alleging violation of federal antitrust law the case were consolidated in the eastern district of pennsylvania on january the court denied msd motion to compel arbitration and to dismiss the consolidated complaint on february msd appealed the court order on arbitration to the third circuit on october the third circuit vacated the district court order and remanded for limited discovery on the issue of arbitrability after which msd may file renewed motion to compel arbitration sale force litigationas previously disclosed in may kelli smith filed complaint against the company in the district court for the district of new jersey on behalf of and putative class of female sale representative and putative sub class of female sale representative with child claiming discriminatory policy and practice in selection promotion and advancement disparate pay differential treatment hostile work environment and retaliation under federal and state discrimination law in april the magistrate judge granted plaintiff request to amend the complaint to add the following company subsidiary corporate defendant ii an erisa claim and iii an individual constructive discharge claim for one of the named plaintiff approximately individual opted in to this action the opt in period ha closed in august plaintiff filed their motion to certify title vii pay discrimination class and also sought final collective action certification of plaintiff equal pay act claim on october the party entered into an agreement to fully resolve the smith sale force litigation part of the settlement and in exchange for full and general release of all individual and class claim the company agreed to pay million on december the court approved the settlement of contentsqui tam litigationas previously disclosed in june the district court for the eastern district of pennsylvania unsealed complaint that ha been filed against the company under the federal false claim act by two former employee alleging among other thing that the company defrauded the government by falsifying data in connection with clinical study conducted on the mumps component of the company ii vaccine the complaint alleges the fraud took place between and the government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right the two former employee are pursuing the lawsuit without the involvement of the government in addition previously disclosed two putative class action lawsuit on behalf of direct purchaser of the ii vaccine which charge that the company misrepresented the efficacy of the ii vaccine in violation of federal antitrust law and various state consumer protection law are pending in the eastern district of pennsylvania in september the court denied merck motion to dismiss the false claim act suit and granted in part and denied in part it motion to dismiss the then pending antitrust suit result both the false claim act suit and the antitrust suit have proceeded into discovery which is now complete and the party have filed and briefed cross motion for summary judgment which are currently pending before the court the company continues to defend against these lawsuit merck kgaa litigationas previously disclosed in january to protect it long established brand right in the united state the company filed lawsuit against merck kgaa darmstadt germany kgaa historically operating the emd group in the united state alleging it improperly us the name merck in the united state kgaa ha filed suit against the company in france the uk germany switzerland mexico india australia singapore hong kong and china alleging among other thing unfair competition trademark infringement and or corporate name infringement in the uk australia singapore hong kong and india kgaa also alleges breach of the party coexistence agreement the litigation is ongoing in the united state with no trial date set and also ongoing in numerous jurisdiction outside of the united state the company is defending those suit in each jurisdiction patent litigationfrom time to time generic manufacturer of pharmaceutical product file abbreviated new drug application ndas with the food and drug administration fda seeking to market generic form of the company product prior to the expiration of relevant patent owned by the company to protect it patent right the company may file patent infringement lawsuit against such generic company similar lawsuit defending the company patent right may exist in other country the company intends to vigorously defend it patent which it belief are valid against infringement by company attempting to market product prior to the expiration of such patent with any litigation there can be no assurance of the outcome which if adverse could result in significantly shortened period of exclusivity for these product and with respect to product acquired through acquisition potentially significant intangible asset impairment charge januvia janumet janumet xr in february par pharmaceutical filed suit against the company in the district court for the district of new jersey seeking declaratory judgment of invalidity of patent owned by the company covering certain salt and polymorphic form of sitagliptin that expires in in response the company filed patent infringement lawsuit in the district court for the district of delaware against par pharmaceutical and additional company that also indicated an intent to market generic version of januvia janumet and janumet xr following expiration of key patent protection in but prior to the expiration of the later granted patent owned by the company covering certain salt and polymorphic form of sitagliptin that expires in and later granted patent owned by the company covering the janumet formulation which expires in par pharmaceutical dismissed it case in the district court for the district of new jersey against the company and will litigate the action in the district court for the district of delaware the company filed patent infringement lawsuit against mylan pharmaceutical inc and mylan inc mylan in the northern district of west virginia the judicial panel of multidistrict litigation entered an order transferring the company lawsuit against mylan to the district court for the district of delaware for coordinated and consolidated pretrial proceeding with the other case pending in that district the district court for the district of delaware ha scheduled the lawsuit for single day trial on invalidity issue in october the court will schedule separate day trial on infringement issue if necessary in october mylan filed petition for inter partes review ipr at the united state patent and trademark office of content uspto seeking invalidity of the patent the uspto ha six month from filing to determine whether it will institute the requested ipr proceeding other litigationthere are various other pending legal proceeding involving the company principally product liability and intellectual property lawsuit while it is not feasible to predict the outcome of such proceeding in the opinion of the company either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceeding is not expected to be material to the company financial condition result of operation or cash flow either individually or in the aggregate legal defense reserveslegal defense cost expected to be incurred in connection with loss contingency are accrued when probable and reasonably estimable some of the significant factor considered in the review of these legal defense reserve are follows the actual cost incurred by the company the development of the company legal defense strategy and structure in light of the scope of it litigation the number of case being brought against the company the cost and outcome of completed trial and the most current information regarding anticipated timing progression and related cost of pre trial activity and trial in the associated litigation the amount of legal defense reserve of december and of approximately million and million respectively represents the company best estimate of the minimum amount of defense cost to be incurred in connection with it outstanding litigation however event such additional trial and other event that could arise in the course of it litigation could affect the ultimate amount of legal defense cost to be incurred by the company the company will continue to monitor it legal defense cost and review the adequacy of the associated reserve and may determine to increase the reserve at any time in the future if based upon the factor set forth it belief it would be appropriate to do so environmental matter the company and it subsidiary are party to number of proceeding brought under the comprehensive environmental response compensation and liability act commonly known superfund and other federal and state equivalent these proceeding seek to require the operator of hazardous waste disposal facility transporter of waste to the site and generator of hazardous waste disposed of at the site to clean up the site or to reimburse the government for cleanup cost the company ha been made party to these proceeding an alleged generator of waste disposed of at the site in each case the government alleges that the defendant are jointly and severally liable for the cleanup cost although joint and several liability is alleged these proceeding are frequently resolved so that the allocation of cleanup cost among the party more nearly reflects the relative contribution of the party to the site situation the company potential liability varies greatly from site to site for some site the potential liability is de minimis and for others the final cost of cleanup have not yet been determined while it is not feasible to predict the outcome of many of these proceeding brought by federal or state agency or private litigant in the opinion of the company such proceeding should not ultimately result in any liability which would have material adverse effect on the financial condition result of operation or liquidity of the company the company ha taken an active role in identifying and accruing for these cost and such amount do not include any reduction for anticipated recovery of cleanup cost from former site owner or operator or other recalcitrant potentially responsible party in management opinion the liability for all environmental matter that are probable and reasonably estimable have been accrued and totaled million and million at december and respectively these liability are undiscounted do not consider potential recovery from other party and will be paid out over the period of remediation for the applicable site which are expected to occur primarily over the next year although it is not possible to predict with certainty the outcome of these matter or the ultimate cost of remediation management doe not believe that any reasonably possible expenditure that may be incurred in excess of the liability accrued should exceed million in the aggregate management also doe not believe that these expenditure should result in material adverse effect on the company financial condition result of operation or liquidity for any year of equitythe merck certificate of incorporation authorizes share of common stock and share of preferred stock capital stocka summary of common stock and treasury stock transaction share in million is follows commonstock treasurystock commonstock treasurystock commonstock treasurystockbalance january of treasury stock balance december issuance primarily reflect activity under share based compensation plan on october the company entered into accelerated share repurchase asr agreement with two third party financial institution dealer under the asr agreement merck agreed to purchase billion of merck common stock in total with an initial delivery of million share of merck common stock based on the then current market price made by the dealer to merck and payment of billion made by merck to the dealer on october which were funded with existing cash and investment well short term borrowing the payment to the dealer were recorded reduction to shareholder equity consisting of billion increase in treasury stock which reflected the value of the initial million share received on october and billion decrease in other paid in capital which reflected the value of the stock held back by the dealer pending final settlement upon settlement of the asr agreement in april merck received an additional million share determined by the average daily volume weighted average price of merck common stock during the term of the asr program le negotiated discount bringing the total share received by merck under this program to million share based compensation plansthe company ha share based compensation plan under which the company grant restricted stock unit rsus and performance share unit psus to certain management level employee in addition employee and non employee director may be granted option to purchase share of company common stock at the fair market value at the time of grant these plan were approved by the company shareholder at december million share collectively were authorized for future grant under the company share based compensation plan these award are settled with treasury share employee stock option are granted to purchase share of company stock at the fair market value at the time of grant these award generally vest one third each year over three year period with contractual term of year rsus are stock award that are granted to employee and entitle the holder to share of common stock the award vest the fair value of the stock option and rsu award is determined and fixed on the grant date based on the company stock price psus are stock award where the ultimate number of share issued will be contingent on the company performance against pre set objective or set of objective the fair value of each psu is determined on the date of grant based on the company stock price for rsus and psus dividend declared during the vesting period are payable to the employee only upon vesting over the psu performance period the number of share of stock that are expected to be issued will be adjusted based on the probability of achievement of performance target and final compensation expense will be recognized based on the ultimate number of share issued rsu and psu distribution will be in share of company stock after the end of the vesting or performance period subject to the term applicable to such award psu award generally vest after three year prior to rsu award generally vested after three year beginning with award granted in rsu award generally vest one third each year over three year period total pretax share based compensation cost recorded in and wa million million and million respectively with related income tax benefit of million million and million respectively of contentsthe company us the black scholes option pricing model for determining the fair value of option grant in applying this model the company us both historical data and current market data to estimate the fair value of it option the black scholes model requires several assumption including expected dividend yield risk free interest rate volatility and term of the option the expected dividend yield is based on historical pattern of dividend payment the risk free interest rate is based on the rate at grant date of zero coupon treasury note with term equal to the expected term of the option expected volatility is estimated using blend of historical and implied volatility the historical component is based on historical monthly price change the implied volatility is obtained from market data on the company traded option the expected life represents the amount of time that option granted are expected to be outstanding based on historical and forecasted exercise behavior the weighted average exercise price of option granted in and wa and per option respectively the weighted average fair value of option granted in and wa and per option respectively and were determined using the following assumption year ended december dividend risk free interest expected expected life year information relative to stock option plan activity option in thousand is follows numberof option weightedaverageexerciseprice weightedaverageremainingcontractualterm year aggregateintrinsicvalueoutstanding january exercised forfeited outstanding december december information pertaining to stock option plan is provided in the table below year ended december intrinsic value of stock option exercised value of stock option received from the exercise of stock summary of nonvested rsu and psu activity share in thousand is follows rsus psus numberof share weightedaveragegrant datefair value numberof share weightedaveragegrant datefair valuenonvested january december of contentsat december there wa million of total pretax unrecognized compensation expense related to nonvested stock option rsu and psu award which will be recognized over weighted average period of year for segment reporting share based compensation cost are unallocated expense pension and other postretirement benefit plansthe company ha defined benefit pension plan covering eligible employee in the united state and in certain of it international subsidiary in addition the company provides medical benefit principally to it eligible retiree and their dependent through it other postretirement benefit plan the company us december the year end measurement date for all of it pension plan and other postretirement benefit plan net periodic benefit costthe net periodic benefit cost credit for pension and other postretirement benefit plan consisted of the following component pension benefit international other postretirement benefitsyears ended december cost return on plan asset amortization of unrecognized prior service cost net loss settlement net periodic benefit cost credit the change in net periodic benefit cost credit year over year for pension plan are largely attributable to change in the discount rate affecting net loss amortization in connection with restructuring action see note termination charge were recorded in and on pension and other postretirement benefit plan related to expanded eligibility for certain employee exiting merck also in connection with these restructuring activity curtailment were recorded on pension and other postretirement benefit plan and settlement were recorded on certain and international pension plan reflected in the table above the component of net periodic benefit cost credit other than the service cost component are included in other income expense net see note with the exception of certain amount for termination benefit curtailment and settlement which are recorded in restructuring cost if the event giving rise to the termination benefit curtailment or settlement is related to restructuring action noted above of contentsobligations and funded statussummarized information about the change in plan asset and benefit obligation the funded status and the amount recorded at december is follows pension benefit otherpostretirementbenefits international value of plan asset january return on plan company of exchange rate change benefit paid settlement other fair value of plan asset december obligation january loss gain benefit paid effect of exchange rate change plan amendment termination other benefit obligation december status december recognized other asset accrued and other current liability other noncurrent liability actuarial loss gain primarily reflect change in discount rate at december and the accumulated benefit obligation wa billion and billion respectively for all pension plan of which billion and billion respectively related to pension plan of contentsinformation related to the funded status of selected pension plan at december is follows international plan with projected benefit obligation in excess of plan asset projected benefit obligation value of plan plan with an accumulated benefit obligation in excess of plan asset accumulated benefit obligation value of plan assetsentities are required to use fair value hierarchy which maximizes the use of observable input and minimizes the use of unobservable input when measuring fair value there are three level of input used to measure fair value with level having the highest priority and level having the lowest level quoted price unadjusted in active market for identical asset or liability level observable input other than level price such quoted price for similar asset or liability or other input that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability level unobservable input that are supported by little or no market activity the level asset are those whose value are determined using pricing model discounted cash flow methodology or similar technique with significant unobservable input well instrument for which the determination of fair value requires significant judgment or estimation at december and million and million respectively or approximately and respectively of the company pension investment were categorized level asset if the input used to measure the financial asset fall within more than one level described above the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument of contentsthe fair value of the company pension plan asset at december by asset category are follows fair value measurement using fair value measurement using level level level nav total level level level nav total pension plan asset cash and cash equivalent fund developed market market and agency obligation obligation security developed income security government and agency obligation obligation and asset backed security investment asset at fair value pension plan asset cash and cash equivalent fund developed market and agency market income estate security developed income security government and agency and asset backed security investment insurance contract asset at fair value certain investment that were measured at net asset value nav per share or it equivalent have not been classified in the fair value hierarchy the nav amount presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan asset at december and the plan level investment in insurance contract are generally valued using crediting rate that approximates market return and invest in underlying security whose market value are unobservable and determined using pricing model discounted cash flow methodology or similar technique of contentsthe table below provides summary of the change in fair value including transfer in and or out of all financial asset measured at fair value using significant unobservable input level for the company pension plan asset insurancecontracts realestate other total insurancecontracts realestate other totalu pension plan balance january return on plan asset relating to asset still held at december relating to asset sold during the year and sale net balance december pension plan balance january return on plan asset relating to asset still held at december purchase and sale net out of level balance december fair value of the company other postretirement benefit plan asset at december by asset category are follows fair value measurement using fair value measurement using level level level nav total level level level nav total asset cash and cash equivalent fund developed market market and agency obligation security developed income security government and agency obligation obligation and asset backed security asset at fair value certain investment that were measured at net asset value nav per share or it equivalent have not been classified in the fair value hierarchy the nav amount presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan asset at december and the company ha established investment guideline for it pension and other postretirement plan to create an asset allocation that is expected to deliver rate of return sufficient to meet the long term obligation of each plan given an acceptable level of risk the target investment portfolio of the company pension and other postretirement benefit plan is allocated to in equity to in international equity to in fixed income investment and up to in cash and other investment the portfolio equity weighting is consistent with the long term nature of the plan benefit obligation the expected annual standard deviation of return of contentsof the target portfolio which approximates reflects both the equity allocation and the diversification benefit among the asset class in which the portfolio invests for international pension plan the targeted investment portfolio varies based on the duration of pension liability and local government rule and regulation although significant percentage of plan asset are invested in equity concentration risk is mitigated through the use of strategy that are diversified within management guideline expected contributionsexpected contribution during are approximately million for pension plan approximately million for international pension plan and approximately million for other postretirement benefit plan expected benefit paymentsexpected benefit payment are follows pension benefit international pensionbenefits benefit payment are based on the same assumption used to measure the benefit obligation and include estimated future employee service amount recognized in other comprehensive incomenet loss amount reflect experience differential primarily relating to difference between expected and actual return on plan asset well the effect of change in actuarial assumption net loss amount in excess of certain threshold are amortized into net periodic benefit cost over the average remaining service life of employee the following amount were reflected component of oci pension plan other postretirementbenefit plan international year ended december loss gain arising during the period service cost credit arising during the period loss amortization included in benefit cost service credit amortization included in benefit cost of contentsactuarial assumptionsthe company reassesses it benefit plan assumption on regular basis the weighted average assumption used in determining pension and other postretirement benefit plan and international pension plan information are follows pension and otherpostretirement benefit plan international pension plansdecember periodic benefit cost discount expected rate of return on plan salary growth interest crediting benefit obligation discount salary growth interest crediting for both the pension and other postretirement benefit plan the discount rate is evaluated on measurement date and modified to reflect the prevailing market rate of portfolio of high quality fixed income debt instrument that would provide the future cash flow needed to pay the benefit included in the benefit obligation they come due the expected rate of return for both the pension and other postretirement benefit plan represents the average rate of return to be earned on plan asset over the period the benefit included in the benefit obligation are to be paid and is determined on plan basis the expected rate of return for each plan is developed considering long term historical return data current market condition and actual return on the plan asset using this reference information the long term return expectation for each asset category and weighted average expected return for each plan target portfolio is developed according to the allocation among those investment category the expected portfolio performance reflects the contribution of active management appropriate for the expected rate of return for the company pension and other postretirement benefit plan will range from to compared to range of to in the decrease reflects lower expected asset return and modest shift in asset allocation the change in the weighted average expected return on pension and other postretirement benefit plan asset from to is due to the relative weighting of the referenced plan asset the health care cost trend rate assumption for other postretirement benefit plan are follows december care cost trend rate assumed for next rate to which the cost trend rate is assumed to year that the trend rate reach the ultimate trend plansthe company also maintains defined contribution saving plan in the united state the company match percentage of each employee contribution consistent with the provision of the plan for which the employee is eligible total employer contribution to these plan in and were million million and million respectively of other income expense netother income expense net consisted of year ended december income interest loss gain income from investment in equity security net net periodic defined benefit plan credit cost other than service cost other includes net realized and unrealized gain and loss from investment in equity security either owned directly or through ownership interest in investment fund other net presented in the table above in includes million of goodwill impairment charge related to certain business in the healthcare service segment see note other net in includes gain of million related to the settlement of certain patent litigation income of million related to astrazeneca option exercise in in connection with the termination of the company relationship with astrazeneca lp azlp and gain of million resulting from the receipt of milestone payment for an out licensed migraine clinical development program other net in also includes million of goodwill impairment charge related to certain business in the healthcare service segment see note well million of charge related to the write down of asset held for sale to fair value in anticipation of the dissolution of the company joint venture with supera farma laboratorios in brazil other net in includes income of million related to astrazeneca option exercise and million loss on extinguishment of debt interest paid wa million in million in and million in tax on incomea reconciliation between the effective tax rate and the statutory rate is follows amount tax rate amount tax rate amount tax rateu statutory rate applied to income before tax differential arising from foreign earnings gilti and the foreign derived intangible income tax settlement tax credit state tax of related cost including other includes the tax effect of loss on foreign subsidiary and miscellaneous item of contentsthe tax cut and job act tcja wa enacted in december among other provision the tcja reduced the federal corporate statutory tax rate from to effective january required company to pay one time transition tax on undistributed earnings of certain foreign subsidiary and created new tax on certain foreign sourced earnings the company reflected the impact of the tcja in it financial statement however since application of certain provision of the tcja remained subject to further interpretation in certain instance the company made reasonable estimate of the effect of the tcja which were since finalized described below the one time transition tax is based on the company post undistributed earnings and profit for substantial portion of these undistributed the company had not previously provided deferred tax these earnings were deemed by merck to be retained indefinitely by subsidiary company for reinvestment the company recorded provisional amount in for it one time transition tax liability of billion this provisional amount wa reduced by the reversal of billion of deferred tax that were previously recorded in connection with the merger of schering plough corporation in for certain undistributed foreign on the basis of revised calculation of post undistributed foreign and finalization of the amount held in cash or other specified asset the company recognized measurement period adjustment of million in related to the transition tax obligation with corresponding adjustment to income tax expense during the period resulting in revised transition tax obligation of billion in the company recorded additional charge of million related to the finalization of treasury regulation associated with the tcja permitted under the tcja the company ha elected to pay the one time transition tax over period of eight year through the company remaining transition tax liability which ha been reduced by payment and the utilization of foreign tax credit wa billion at december of which million is included in income tax payable and the remainder of billion is included in other noncurrent liability in the company remeasured it deferred tax asset and liability at the new federal statutory tax rate of which resulted in provisional deferred tax benefit of million on the basis of clarification to the deferred tax benefit calculation the company recorded measurement period adjustment in of million related to deferred income tax the foreign earnings tax rate differential in the tax rate reconciliation above primarily reflect the impact of operation in jurisdiction with different tax rate than the united state particularly ireland and switzerland well singapore and puerto rico which operate under tax incentive grant which begin to expire in where the earnings had been indefinitely reinvested thereby yielding favorable impact on the effective tax rate compared with the statutory rate of in and and in the foreign earnings tax rate differential do not include the impact of intangible asset impairment charge amortization of purchase accounting adjustment or restructuring cost these item are presented separately they each represent significant separately disclosed pretax cost or charge and substantial portion of each of these item relates to jurisdiction with lower tax rate than the united state therefore the impact of recording these expense item in lower tax rate jurisdiction is an unfavorable impact on the effective tax rate compared to the statutory rate income before tax consisted of year ended december of contentstaxes on income consisted of year ended december provision federal provision federal foreign income tax at december consisted of asset liability asset liabilitiesproduct intangible and license depreciation and other postretirement unrecognized tax net operating loss and other tax credit allowance total deferred tax deferred income tax other asset deferred income tax company ha net operating loss nol carryforwards in several jurisdiction of december million of deferred tax on nol carryforwards relate to foreign jurisdiction valuation allowance of billion have been established on these foreign nol carryforwards and other foreign deferred tax asset in addition the company ha million of deferred tax asset relating to various tax credit carryforwards and nol carryforwards all of which are expected to be fully utilized prior to expiry income tax paid in and were billion billion and billion respectively tax benefit relating to stock option exercise were million in million in and million in reconciliation of the beginning and ending amount of unrecognized tax benefit is follows january related to current year related to prior year for tax position of prior year settlement lapse of statute of limitation balance december amount reflect the settlement with the irs discussed below amount in includes million related to the divestiture of merck consumer care business in of contentsif the company were to recognize the unrecognized tax benefit of billion at december the income tax provision would reflect favorable net impact of billion the company is under examination by numerous tax authority in various jurisdiction globally the company belief that it is reasonably possible that the total amount of unrecognized tax benefit of december could decrease by up to approximately million in the next month result of various audit closure settlement or the expiration of the statute of limitation the ultimate finalization of the company examination with relevant taxing authority can include formal administrative and legal proceeding which could have significant impact on the timing of the reversal of unrecognized tax benefit the company belief that it reserve for uncertain tax position are adequate to cover existing risk or exposure interest and penalty associated with uncertain tax position amounted to benefit expense of million in million in and million in these amount reflect the beneficial impact of various tax settlement including those discussed below liability for accrued interest and penalty were million and million of december and respectively in the internal revenue service irs concluded it examination of merck federal income tax return result the company wa required to make payment of million the company reserve for unrecognized tax benefit for the year under examination exceeded the adjustment relating to this examination period and therefore the company recorded million net tax benefit in this net benefit reflects reduction in reserve for unrecognized tax benefit for tax position relating to the year that were under examination partially offset by additional reserve for tax position not previously reserved for in the irs concluded it examination of merck federal income tax return result the company wa required to make payment of approximately billion the company reserve for unrecognized tax benefit for the year under examination exceeded the adjustment relating to this examination period and therefore the company recorded net million tax benefit in this net benefit reflects reduction in reserve for unrecognized tax benefit for tax position relating to the year that were under examination partially offset by additional reserve for tax position not previously reserved for well adjustment to reserve for unrecognized tax benefit relating to year which remain open to examination that are affected by this settlement the irs is currently conducting examination of the company tax return for the year and in addition various state and foreign tax examination are in progress and for these jurisdiction the company income tax return are open for examination for the period through earnings per sharethe calculation of earnings per share share in million are follows year ended december income attributable to merck co inc common share share issuable common share outstanding assuming earnings per common share attributable to merck co inc common shareholder per common share assuming dilution attributable to merck co inc common shareholder issuable primarily under share based compensation plan in and million million and million respectively of common share issuable under share based compensation plan were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive of other comprehensive income loss change in aoci by component are follows derivative investment employeebenefitplans cumulativetranslationadjustment accumulated othercomprehensiveincome loss balance january net of tax other comprehensive income loss before reclassification adjustment pretax comprehensive income loss before reclassification adjustment net of tax adjustment pretax adjustment net of tax other comprehensive income loss net of tax at december net of tax other comprehensive income loss before reclassification adjustment tax other comprehensive income loss before reclassification adjustment net of reclassification adjustment reclassification adjustment net of comprehensive income loss net of adoption of asu adoption of asu balance at december net of other comprehensive income loss before reclassification adjustment tax comprehensive income loss before reclassification adjustment net of reclassification adjustment pretax adjustment net of tax other comprehensive income loss net of tax balance at december net of tax relates to foreign currency cash flow hedge that were reclassified from aoci to sale represents net realized gain loss on the sale of available for sale investment that were reclassified from aoci to other income expense net in these amount included both investment in debt and equity security however result of the adoption of asu in these amount relate only to investment in available for sale debt security includes net amortization of prior service cost and actuarial gain and loss included in net periodic benefit cost see note includes pension plan net loss of billion and billion at december and respectively and other postretirement benefit plan net gain of million and million at december and respectively well pension plan prior service credit of million and million at december and respectively and other postretirement benefit plan prior service credit of million and million at december and respectively of segment reportingthe company operation are principally managed on product basis and include four operating segment which are the pharmaceutical animal health healthcare service and alliance segment the pharmaceutical and animal health segment are the only reportable segment the pharmaceutical segment includes human health pharmaceutical and vaccine product human health pharmaceutical product consist of therapeutic and preventive agent generally sold by prescription for the treatment of human disorder the company sell these human health pharmaceutical product primarily to drug wholesaler and retailer hospital government agency and managed health care provider such health maintenance organization pharmacy benefit manager and other institution human health vaccine product consist of preventive pediatric adolescent and adult vaccine primarily administered at physician office the company sell these human health vaccine primarily to physician wholesaler physician distributor and government entity large component of pediatric and adolescent vaccine sale are made to the center for disease control and prevention vaccine for child program which is funded by the government additionally the company sell vaccine to the federal government for placement into vaccine stockpile during result of change to the company internal reporting structure certain cost that were previously included in the pharmaceutical segment are now being included part of non segment expense within merck research laboratory prior period pharmaceutical segment profit have been recast to reflect these change on comparable basis the animal health segment discovers develops manufacture and market wide range of veterinary pharmaceutical and vaccine product well health management solution and service for the prevention treatment and control of disease in all major livestock and companion animal specie the company also offer an extensive suite of digitally connected identification traceability and monitoring product the company sell it product to veterinarian distributor and animal producer the healthcare service segment provides service and solution that focus on engagement health analytics and clinical service to improve the value of care delivered to patient the company ha recently sold certain business in the healthcare service segment and is in the process of divesting the remaining business the alliance segment primarily includes activity from the company relationship with astrazeneca lp related to sale of nexium and prilosec which concluded in of contentssales of the company product were follows year ended december int total int total int totalpharmaceutical oncology keytruda revenue lynparza revenue lenvima gardasil gardasil ii acute care simponi isentress isentress health brand pharmaceutical pharmaceutical segment health animal health segment segment sale segment plus international may not equal total due to rounding alliance revenue represents merck share of profit which are product sale net of cost of sale and commercialization cost see note other pharmaceutical primarily reflects sale of other human health pharmaceutical product including product within the franchise not listed separately represents the non reportable segment of healthcare service and alliance other is primarily comprised of miscellaneous corporate revenue including revenue hedging activity well third party manufacturing sale other in and also includes approximately million million and million respectively related to the sale of the marketing right to certain product of contentsconsolidated sale by geographic area where derived are follows year ended december state middle east and pacific other than japan and china reconciliation of segment profit to income before tax is follows year ended december profit pharmaceutical segment health segment segment interest expense depreciation and amortization research and development amortization of purchase accounting adjustment restructuring cost charge related to the termination of collaboration with samsung loss on extinguishment of debt other unallocated net income before tax segment profit are comprised of segment sale le standard cost well selling general and administrative expense directly incurred by the segment animal health segment profit are comprised of segment sale le all cost of sale well selling general and administrative expense and research and development cost directly incurred by the segment for internal management reporting presented to the chief operating decision maker merck doe not allocate the remaining cost of sale not included in segment profit described above research and development expense incurred in merck research laboratory the company research and development division that focus on human health related activity or general and administrative expense nor the cost of financing these activity separate division maintain responsibility for monitoring and managing these cost including depreciation related to fixed asset utilized by these division and therefore they are not included in segment profit in addition cost related to restructuring activity well the amortization of purchase accounting adjustment are not allocated to segment other profit are primarily comprised of miscellaneous corporate profit well operating profit related to third party manufacturing sale other unallocated net includes expense from corporate and manufacturing cost center goodwill and other intangible asset impairment charge gain or loss on sale of business expense or income related to change in the estimated fair value of liability for contingent consideration and other miscellaneous income or expense item of contentsequity income loss from affiliate and depreciation and amortization included in segment profit is follows pharmaceutical animal health all other totalyear ended december included in segment profit equity income loss from affiliate depreciation and ended december included in segment profit equity income loss from affiliate and ended december included in segment profit equity income loss from affiliate and plant and equipment net by geographic area where located is follows december state middle east and pacific other than japan and china company doe not disaggregate asset on product and service basis for internal management reporting and therefore such information is not presented of contentsreport of independent registered public accounting firm to the board of director and stockholder of merck co inc opinion on the financial statement and internal control over financial reportingwe have audited the accompanying consolidated balance sheet of merck co inc and it subsidiary the company of december and and the related consolidated statement of income of comprehensive income of equity and of cash flow for each of the three year in the period ended december including the related note collectively referred to the consolidated financial statement also have audited the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission coso in opinion the consolidated financial statement referred to above present fairly in all material respect the financial position of the company of december and and the result of it operation and it cash flow for each of the three year in the period ended december in conformity with accounting principle generally accepted in the united state of america also in our opinion the company maintained in all material respect effective internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the coso basis for opinionsthe company management is responsible for these consolidated financial statement for maintaining effective internal control over financial reporting and for it assessment of the effectiveness of internal control over financial reporting included in management report on internal control over financial reporting appearing under item our responsibility is to express opinion on the company consolidated financial statement and on the company internal control over financial reporting based on our audit we are public accounting firm registered with the public company accounting oversight board united state pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statement are free of material misstatement whether due to error or fraud and whether effective internal control over financial reporting wa maintained in all material respect our audit of the consolidated financial statement included performing procedure to ass the risk of material misstatement of the consolidated financial statement whether due to error or fraud and performing procedure that respond to those risk such procedure included examining on test basis evidence regarding the amount and disclosure in the consolidated financial statement our audit also included evaluating the accounting principle used and significant estimate made by management well evaluating the overall presentation of the consolidated financial statement our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting assessing the risk that material weakness exists and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk our audit also included performing such other procedure we considered necessary in the circumstance we believe that our audit provide reasonable basis for our opinion definition and limitation of internal control over financial reportinga company internal control over financial reporting is process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle company internal control over financial reporting includes those policy and procedure that pertain to the maintenance of record that in reasonable detail accurately and fairly reflect the transaction and disposition of the asset of the company ii provide reasonable assurance that transaction are recorded necessary to permit preparation of financial statement in accordance with generally accepted accounting principle and that receipt and expenditure of the company are being made only in accordance with authorization of management and director of the company and iii provide reasonable of contentsassurance regarding prevention or timely detection of unauthorized acquisition use or disposition of the company asset that could have material effect on the financial statement because of it inherent limitation internal control over financial reporting may not prevent or detect misstatement also projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate critical audit mattersthe critical audit matter communicated below is matter arising from the current period audit of the consolidated financial statement that wa communicated or required to be communicated to the audit committee and that relates to account or disclosure that are material to the consolidated financial statement and ii involved our especially challenging subjective or complex judgment the communication of critical audit matter doe not alter in any way our opinion on the consolidated financial statement taken whole and we are not by communicating the critical audit matter below providing separate opinion on the critical audit matter or on the account or disclosure to which it relates customer discount accrual in the medicaid managed care and medicare part rebatesas described in note to the consolidated financial statement the company record certain variable consideration including discount which are estimated at the time of sale generally using the expected value method amount accrued for aggregate customer discount of december in the are billion and are evaluated on quarterly basis through comparison of information provided by the wholesaler health maintenance organization pharmacy benefit manager federal and state agency and other customer to the amount accrued certain of these discount take the form of rebate which are amount owed based upon definitive contractual agreement or legal requirement with private sector managed care and public sector medicaid and medicare part benefit provider after the final dispensing of the product by pharmacy to benefit plan participant the provision for rebate is based on expected patient usage well inventory level in the distribution channel to determine the contractual obligation to the benefit provider management us historical customer segment utilization mix sale forecast change to product mix and price inventory level in the distribution channel government pricing calculation and prior payment history in order to estimate the expected provision the principal consideration for our determination that performing procedure relating to customer discount accrual in the medicaid managed care and medicare part rebate is critical audit matter are that there wa significant judgment required by management with significant measurement uncertainty the calculation of the rebate accrual includes assumption related to price and customer segment utilization pertaining to forecasted customer claim that may not be fully paid until subsequent period this in turn led to high degree of auditor judgment subjectivity and effort in applying the procedure related to those assumption addressing the matter involved performing procedure and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statement these procedure included testing the effectiveness of control relating to customer discount accrual in the medicaid managed care and medicare part rebate including management control over the assumption used to estimate the corresponding rebate accrual these procedure also included among others developing an independent estimate of the rebate accrual by utilizing third party data on customer segment utilization change to price the term of the specific rebate program and the historical trend of actual rebate claim paid the independent estimate wa compared to the rebate accrual recorded by management to evaluate the reasonableness of the estimate additionally these procedure included testing actual rebate claim paid and evaluating the contractual term of the company rebate agreement pricewaterhousecoopers llpflorham park new jerseyfebruary have served the company auditor since of content supplementary dataselected quarterly financial data for and are contained in the condensed interim financial data table below condensed interim financial data unaudited in million except per share amount sale of general and and income expense net before income attributable to merck co inc earnings per common share attributable to merck co inc common shareholder per common share assuming dilution attributable to merck co inc common shareholder sale of general and and income expense income before income attributable to merck co inc earnings per common share attributable to merck co inc common shareholder per common share assuming dilution attributable to merck co inc common shareholder amount for include charge related to the acquisition of peloton therapeutic inc see note amount for include charge related to the formation of collaboration with eisai see note amount for and reflect acquisition and divestiture related cost see note and the impact of restructuring action see note of contentsitem change in and disagreement with accountant on accounting and financial disclosure not applicable item control and procedure management of the company with the participation of it chief executive officer and chief financial officer ha evaluated the effectiveness of the company disclosure control and procedure based on their evaluation of the end of the period covered by this form the company chief executive officer and chief financial officer have concluded that the company disclosure control and procedure defined in rule or under the security exchange act of amended the act are effective for the fourth quarter of there have been no change in internal control over financial reporting that materially affected or are reasonably likely to materially affect the company internal control over financial reporting management is responsible for establishing and maintaining adequate internal control over financial reporting such term is defined in rule of the act management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in internal control integrated framework issued in by the committee of sponsoring organization of the treadway commission based on this evaluation management concluded that internal control over financial reporting wa effective of december pricewaterhousecoopers llp an independent registered public accounting firm ha performed it own assessment of the effectiveness of the company internal control over financial reporting and it attestation report is included in this form filing management reportmanagement responsibility for financial statementsresponsibility for the integrity and objectivity of the company financial statement rest with management the financial statement report on management stewardship of company asset these statement are prepared in conformity with generally accepted accounting principle and accordingly include amount that are based on management best estimate and judgment nonfinancial information included in the annual report on form ha also been prepared by management and is consistent with the financial statement to assure that financial information is reliable and asset are safeguarded management maintains an effective system of internal control and procedure important element of which include careful selection training and development of operating and financial manager an organization that provides appropriate division of responsibility and communication aimed at assuring that company policy and procedure are understood throughout the organization staff of internal auditor regularly monitor the adequacy and application of internal control on worldwide basis to ensure that personnel continue to understand the system of internal control and procedure and policy concerning good and prudent business practice annually all employee of the company are required to complete code of conduct training this training reinforces the importance and understanding of internal control by reviewing key corporate policy procedure and system in addition the company ha compliance program including an ethical business practice program to reinforce the company long standing commitment to high ethical standard in the conduct of it business the financial statement and other financial information included in the annual report on form fairly present in all material respect the company financial condition result of operation and cash flow our formal certification to the security and exchange commission is included in this form filing management report on internal control over financial reportingmanagement is responsible for establishing and maintaining adequate internal control over financial reporting such term is defined in rule under the security exchange act of the company internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle in the united state of america management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in internal control integrated framework issued of contentsin by the committee of sponsoring organization of the treadway commission based on this evaluation management concluded that internal control over financial reporting wa effective of december because of it inherent limitation internal control over financial reporting may not prevent or detect misstatement projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate the effectiveness of the company internal control over financial reporting of december ha been audited by pricewaterhousecoopers llp an independent registered public accounting firm stated in their report which appears herein kenneth frazier robert davischairman presidentand chief executive officer executive vice president global service and chief financial officeritem other information none of contentspart iii item director executive officer and corporate governance the required information on director and nominee is incorporated by reference from the discussion under proposal election of director of the company proxy statement for the annual meeting of shareholder to be held may information on executive officer is set forth in part of this document on page the required information on compliance with section of the security exchange act of if applicable is incorporated by reference from the discussion under the heading stock ownership information of the company proxy statement for the annual meeting of shareholder to be held may the company ha code of conduct our value and standard applicable to all employee including the principal executive officer principal financial officer principal accounting officer and controller the code of conduct is available on the company website at http www msd com about how we operate code of conduct value and standard html the company intends to disclose future amendment to certain provision of the code of conduct and waiver of the code of conduct granted to executive officer and director if any on the website within four business day following the date of any amendment or waiver every merck employee is responsible for adhering to business practice that are in accordance with the law and with ethical principle that reflect the highest standard of corporate and individual behavior the required information on the identification of the audit committee and the audit committee financial expert is incorporated by reference from the discussion under the heading board meeting and committee of the company proxy statement for the annual meeting of shareholder to be held may item executive compensation the information required on executive compensation is incorporated by reference from the discussion under the heading compensation discussion and analysis summary compensation table all other compensation table grant of plan based award table outstanding equity award table option exercise and stock vested table pension benefit table nonqualified deferred compensation table potential payment upon termination or change in control including the discussion under the subheading separation and change in control well all footnote information to the various table of the company proxy statement for the annual meeting of shareholder to be held may the required information on director compensation is incorporated by reference from the discussion under the heading director compensation and related director compensation table and schedule of director fee table of the company proxy statement for the annual meeting of shareholder to be held may the required information under the heading compensation and benefit committee interlock and insider participation and compensation and benefit committee report is incorporated by reference from the company proxy statement for the annual meeting of shareholder to be held may of contentsitem security ownership of certain beneficial owner and management and related stockholder matter information with respect to security ownership of certain beneficial owner and management is incorporated by reference from the discussion under the heading stock ownership information of the company proxy statement for the annual meeting of shareholder to be held may equity compensation plan informationthe following table summarizes information about the option warrant and right and other equity compensation under the company equity compensation plan of the close of business on december the table doe not include information about tax qualified plan such the merck saving plan plan category number ofsecurities to beissued uponexercise ofoutstandingoptions warrantsand right weighted averageexercise price ofoutstandingoptions warrantsand right number ofsecurities remainingavailable for futureissuance under equitycompensation plan excludingsecuritiesreflected in column equity compensation plan approved by security holder compensation plan not approved by security holder total includes option to purchase share of company common stock and other right under the following shareholder approved plan the merck co inc and incentive stock plan and the merck co inc non employee director stock option plan excludes approximately share of restricted stock unit and performance share unit assuming maximum payouts under the merck sharp dohme and incentive stock plan also excludes share of phantom stock deferred under the msd employee deferral program and share of phantom stock deferred under the merck co inc plan for deferred payment of director compensation item certain relationship and related transaction and director independence the required information on transaction with related person is incorporated by reference from the discussion under the heading related person transaction of the company proxy statement for the annual meeting of shareholder to be held may the required information on director independence is incorporated by reference from the discussion under the heading independence of director of the company proxy statement for the annual meeting of shareholder to be held may item principal accountant fee and service the information required for this item is incorporated by reference from the discussion under proposal ratification of appointment of independent registered public accounting firm for beginning with the caption pre approval policy for service of independent registered public accounting firm through fee for service provided by the independent registered public accounting firm of the company proxy statement for the annual meeting of shareholder to be held may of contentspart iv item exhibit and financial statement schedule the following document are filed part of this form financial statementsconsolidated statement of income for the year ended december and consolidated statement of comprehensive income for the year ended december and consolidated balance sheet of december and consolidated statement of equity for the year ended december and consolidated statement of cash flow for the year ended december and note to consolidated financial statementsreport of pricewaterhousecoopers llp independent registered public accounting financial statement schedulesschedules are omitted because they are either not required or not applicable financial statement of affiliate carried on the equity basis have been omitted because considered individually or in the aggregate such affiliate do not constitute significant subsidiary of exhibitsexhibitnumber restated certificate of incorporation of merck co inc november incorporated by reference to merck co inc current report on form filed november no by law of merck co inc effective july incorporated by reference to merck co inc current report on form filed july no indenture dated of april between merck sharp dohme corp schering corporation and bank trust national association successor to morgan guaranty trust company of new york trustee the indenture incorporated by reference to exhibit to msd registration statement on form no first supplemental indenture to the indenture dated of october incorporated by reference to exhibit to msd registration statement on form filed september no second supplemental indenture to the indenture dated november incorporated by reference to exhibit to merck co inc current report on form filed november no third supplemental indenture to the indenture dated may incorporated by reference to exhibit to merck co inc form quarterly report for the period ended march no indenture dated november between merck co inc schering plough corporation and the bank of new york trustee the indenture incorporated by reference to exhibit to schering plough current report on form filed november no second supplemental indenture to the indenture including form of note dated november incorporated by reference to exhibit to schering plough current report on form filed november no third supplemental indenture to the indenture including form of note dated september incorporated by reference to exhibit to schering plough current report on form filed september no of contentsexhibitnumber fifth supplemental indenture to the indenture dated november incorporated by reference to exhibit to merck co inc current report on form filed november no indenture dated of january between merck co inc and bank trust national association trustee incorporated by reference to exhibit to merck co inc current report on form filed december no note due officer certificate of the company dated march including form of the note incorporated by reference to exhibit to merck co inc current report on form filed march no note due officer certificate of the company dated march including form of the note incorporated by reference to exhibit to merck co inc current report on form filed march no note due officer certificate of the company dated march including form of the note incorporated by reference to exhibit to merck co inc current report on form filed march no note due officer certificate of the company dated march including form of the note incorporated by reference to exhibit to merck co inc current report on form filed march no merck co inc executive incentive plan amended and restated effective june incorporated by reference to merck co inc schedule filed april no merck co inc deferral program including the base salary deferral plan amended and restated effective december merck co inc incentive stock plan amended and restated june incorporated by reference to merck co inc schedule filed april no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form quarterly report for the period ended march filed may no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by referent to exhibit to merck co inc form annual report for the fiscal year ended december filed february no of contentsexhibitnumber description form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of restricted stock unit term for quarterly and annual grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed on february no performance share unit award term under the merck co inc stock incentive plan incorporated by reference to exhibit to merck co inc current report on form quarterly report for the period ended march filed may no merck co inc incentive stock plan incorporated by reference to appendix to merck co inc schedule filed april no merck co inc change in control separation benefit plan effective amended and restated of january incorporated by reference to exhibit to merck co inc current report on form filed november no merck co inc separation benefit plan amended and restated of january incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no merck co inc non employee director stock option plan amended and restated of december incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no retirement plan for the director of merck co inc amended and restated june incorporated by reference to exhibit to msd form quarterly report for the period ended june filed august no merck co inc plan for deferred payment of director compensation amended and restated effective of january distribution agreement between schering plough and centocor inc dated april incorporated by reference to exhibit to schering plough amended for the year ended december filed may no amendment agreement to the distribution agreement between centocor inc can development llc and schering plough ireland company incorporated by reference to exhibit to schering plough current report on form filed december no severance agreement and general release between merck co inc and adam schechter dated december incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no offer letter between merck co inc and jennifer zachary dated march incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no subsidiary of merck co inc consent of independent registered public accounting power of certified resolution of board of rule certification of chief executive rule certification of chief financial section certification of chief executive section certification of chief financial officer of contentsexhibitnumber in xbrl instance document the instance document doe not appear in the interactive data file because it xbrl tag are embedded within the inline xbrl document sch xbrl taxonomy extension schema document cal xbrl taxonomy extension calculation linkbase document def xbrl taxonomy extension definition linkbase document lab xbrl taxonomy extension label linkbase document pre xbrl taxonomy extension presentation linkbase document cover page interactive data file formatted inline xbrl and contained in exhibit management contract or compensatory plan or arrangement certain portion of the exhibit have been omitted pursuant to request for confidential treatment the non public information ha been filed separately with the security and exchange commission pursuant to rule under the security exchange act of amended long term debt instrument under which the total amount of security authorized doe not exceed of merck co inc total consolidated asset are not filed exhibit to this report merck co inc will furnish copy of these agreement to the security and exchange commission on request item form summarynot applicable of contentssignaturespursuant to the requirement of section or of the security exchange act of the registrant ha duly caused this report to be signed on it behalf by the undersigned thereunto duly authorized dated february merck co inc by kenneth frazier chairman president and chief executive officer by jennifer zachary jennifer zachary attorney in fact pursuant to the requirement of the security exchange act of this report ha been signed below by the following person on behalf of the registrant and in the capacity and on the date indicated signature title date kenneth frazier chairman president and chief executive officer principal executive officer director february davis executive vice president global service and chief financial officer principal financial officer february karachun senior vice president finance global controller principal accounting officer february brun director february cech director february ellen coe director february craig director february glocer director february lazarus director february rothman director february russo director february thulin director february week director february wendell director february zachary by signing name hereto doe hereby sign this document pursuant to power of attorney duly executed by the person named filed with the security and exchange commission an exhibit to this document on behalf of such person all in the capacity and on the date stated such person including majority of the director of the company by jennifer zachary jennifer zachary attorney in fact copy and paste below content previous next setting hover over fact for quick information on off auto scrolling position top center selecting fact from the section menu or the fact menu will automatically scroll that element to the top or middle of the viewer window this setting will have no use on ie or safari tagged data savereset search result savereset selected fact savereset tag shading hover savereset copy and paste below content previous next nested fact previous next copy and paste below content previous next